var title_f30_11_30896="Differential dx rabies";
var content_f30_11_30896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Algorithm for differential diagnosis of rabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 638px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     JEV: Japanese encephalitis virus; LM: Listeria monocytogenes; HSV: Herpes simplex virus; EV 71: Enterovirus; VZV: Varicella zoster virus; CMV: Cytomegalovirus; EBV: Epstein-Barr virus.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rupprecht, CE, Hanlon, CA, Hemachudha, T. Rabies re-examined. Lancet Infect Dis 2002; 2:327. Copyright &copy; 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30896=[""].join("\n");
var outline_f30_11_30896=null;
var title_f30_11_30897="Spitz nevi in nevus spilus";
var content_f30_11_30897=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple Spitz nevi arising in a nevus spilus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30897=[""].join("\n");
var outline_f30_11_30897=null;
var title_f30_11_30898="Global incidence of gastric cancer in men";
var content_f30_11_30898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Global incidence of gastric cancer in men*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 340px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFUAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6F8c+LrXwfYWVzd2V9em7uRaRRWYjLl/LeTJ8x0UDbG3f0rk/+Fx2f/Qq+JP/ACT/APkij49/8g3wr/2Gf/bO6rzY9c88itadNSV2RKVmek/8Lis8Z/4RXxJ/5J//ACRR/wALis8/8ir4k/8AJP8A+SK82PXg0vGB61p7GJPOz0j/AIXFZ/8AQq+JP/JP/wCSKP8AhcVn/wBCr4k/8k//AJIrzjOeT0pcBhzR7GIc7PRv+FxWf/Qq+JP/ACT/APkij/hcVnjP/CK+JP8AyT/+SK83x82ego4HQ5o9jEPaM9I/4XFZ/wDQq+JP/JP/AOSKX/hcNp/0KviT/wAk/wD5IrzYZHXFODc+1P2ERe0Z6N/wuG0/6FXxJ/5J/wDyRSn4w2Y/5lXxJ+dn/wDJFeblsDn8KQkkcdPpR7CIe0Z6QPjFZn/mVfEnH/Xn/wDJFL/wuG0/6FXxJ+dn/wDJFecL1/xoGeccUewiHtGej/8AC4bTOP8AhFfEmfrZf/JFH/C4LT/oVPEv/kn/APJFedfNxzS84zR7CIe0Z6J/wuC0xn/hFfEn/kn/APJFH/C4bT/oVfEn/kn/APJFedk/KcdvWjn15o9hEPaM9FHxftT/AMyp4k/Oy/8Akik/4XBaH/mVPEv/AJJ//JFeeAnrQc85Io9hEPaM9D/4XDaZx/wiviX/AMk//kij/hcFp/0KviT/AMk//kivPOuc0YI+tHsIh7RnoY+MFoeP+EV8SfnZf/JFL/wuC1/6FTxJ+dn/APJFed4yDRt9+KPYRD2jPRP+Fv2uM/8ACKeJMfWy/wDkikHxgtSMjwp4kx/25/8AyRXnynkDjFKFPJz3o9hEPaM9B/4XBa/9Cp4l9P8Alz/+SKD8X7XOP+EU8SZ+tl/8kV5+wzx29qQKAc+1HsIi9oz0L/hb1r/0KniT87L/AOSKT/hb1rj/AJFTxJ+dl/8AJFefFD1pAT3zR7CI/aM9C/4W9a5P/FKeJfzsv/kil/4W7bf9Cp4k/Oy/+Sa8+UYNPA5o9hEXtGd9/wALdtv+hU8S/nZf/JNJ/wALftf+hU8SfnZf/JFcEe/PWmMx6c0ewiP2jPQf+FvW2P8AkVPEv52X/wAkUf8AC3bb/oU/Ev52X/yRXnw9COlKGzgDsaPYRF7RnoH/AAt61/6FTxJ+dl/8kU0/GG0H/Mq+JP8AyT/+SK4JhimgBuho9hEPas9AHxftT/zKniX/AMk//kigfF+1PTwp4k/Oz/8AkivP9oySM0uOMc5o9hEPas7/AP4W9a/9Cp4k/Oy/+SKP+Fv2uP8AkVPEv52X/wAkVwAGFxnFKAAMZ4HpR7CIe0Z3/wDwt62/6FTxJ+dl/wDJNA+LtsenhTxJ+dl/8k1wO0EYHBo2kHmj2EQ9ozvv+FvW2cf8Ip4k/Oy/+SKP+FvWuf8AkVPEn52X/wAk1wHpnqaAvPWj2ER+0Z3/APwt22x/yKniT87L/wCSaP8Ahb1rn/kVPEn52X/yTXBbeuTmggKMEnPWj2ERe1Z3v/C3bYjP/CKeJcfWy/8AkmlHxct/+hT8SfnZf/JNefHOOpx3pS3GKPYRD2jO/wD+FvW2cf8ACKeJPzsv/kij/hb1qP8AmVPEn52X/wAkVwDZyNtIAeD1o9hEPas9AHxetj/zKniX87L/AOSKP+Fu23/QqeJPzsv/AJJrgVJGMjij1o9hEPaM7/8A4W7bf9Cp4k/Oy/8Akmk/4W9bf9Cp4k/Oy/8AkiuBwcU0g59KPYRD2rPQP+Fu23/QqeJfzsv/AJJpf+FuW/8A0KfiT87L/wCSa4D6ZxTgT24zxR7CIe1Z3n/C3bb/AKFPxL+dl/8AJFH/AAt62z/yKniT87L/AOSa4IrzTdvXNHsIh7Rnf/8AC3bb/oVPEn52X/yRSf8AC37XGf8AhFPEmPrZf/JFcDyCck0hGB1pexiP2jO+/wCFwWn/AEKviT87P/5IrX8IfEay8Ta//ZEej6vp9ybaS7VrwQbGRHjVgDHK5zmVeoHevJX4HNbvws/5Kpa/9ga9/wDR9pUTpqKuVGbbse60UUViaHl/x7GdN8K/9hr/ANs7qvNz09q9I+PX/IO8K/8AYa/9s7qvN2xjuK6aOxlPcaPUg044GOM0DPJzwKMDOc4rUgAeaUHtwaTHJJNICBjng0AOyPx+tNDE9CKCOB6mmlfpTEO6cdT7UE+lAU45oKnPUUwD3pT7cD1oI5x3pQAPpQITBUUK3OT0px6AZNIBx3zQAu4c460uSR7U0A5PNOHCnHFACc5pwPHrSDOOacBnPPH0oAUngYppIyCSadjpg80wjnk/hQA4NjvgUjHI6n8qbjjOeadggcdKAFRh68UqE4P9KbjuKcOB7n1oAVuWFHbHXHvSFRkUdD1oAXkHH40o6kdKTgmlweT3oAC2FPWkLZGehFLjI9qbjnk4PtQIehyTxxUpOenFQgc5FPB46YoAUjJ96aSccnmlJ549Ka3Kkd/rQAbhwBkUZwc8UzGccUuNuT3pgSkgimN8p45pE9fXr7UpHfk0gDcQQB3pQ3c0gXIzxTtvHJFAArEnpgUgznn8qcKCME4PvzQA4HAHPNGOevIqM88Z5qRVGCc80DGZUYNCn5hxg0pHHvSDORg0ASZyKjdsnrxTgCAxJxTG+UAdKYgB54PSjB7CgDnk4FOAz0xQAjZAPpS84zzTmA4A6U0DAHtSAVj7flR69DQMjpzRnBoAQnjIPP0oPTvmk5wMd6MEmgAzkdacrc44pB17UmMnAwPSmA4Pk5P8qTdwT3+lLjBPpTc5DfXrSAcBkc4qNienT3pxHFN2gc5570mMjYHPUGt74WD/AIupbf8AYGvf/R9pWG/Wt34W/wDJU7X1/sa9/wDR9pWVX4S4bnulFFFcpueX/Hv/AJBvhXH/AEGv/bO6rzYnByelekfHz/kGeFf+w1/7Z3VeblTmumj8JlU3FyCOlN59RgdqNpJpCOR3GK1Mx65I4pMnJ9KVRj2FORCXG5GKHrgUpSUVdlJXdhhPzdaT19vWttbGAADywR1yTyad9ghx/q1Br5uXFWEi7csvuX+Z6iyes1e6MPOMf5xRuB9TW59ggwP3a0yTT4WGFXafUU48VYNuzUl8l/mJ5PWSumjFzjOOT704dBmr39lvg/vF9uKrTW0kG3eM5HOOgr1qGa4SvJQp1E2cVTB16a5px0Ig3PynmhW65ppI3AgZNCk9MCvQOYk/Kmg5PfGe1IRS4IXj+dADwRjp0pdw6d6YFIHPNLgg4HpQA7JJHajgjvmmr0z3p44+tADG6YzRkADn2oYcmj8fyoAUNz1JpQcj6U1F608LjpQAgb5jgUZ4zmlC4JJ60hXHvQIdu7Dk0uOOTimYJxjgU7GevSmAcYPJ4pWxkGmBT1J5NBUsxyelAEi4Lcfyp+cetRpkZyBTxnGaQBkUhYZpCABwKRQP/r0AKWA69qOM5pSBzikxTAVVxSggHHbpisqHX7CfVBYQSNLOM7iillU+hNaZ5ORnFSpKWzLnTlC3MrDtwxilBA7np2pj/KuSQAOpPavPPFnjSTzza6NIUETfNOMEP7D2qKtaNJXkb4XCVMVPkpo9G+XoTmq1zf2dtt+0XEMe7ON7gZrxK+1bUL+QyXN1IzFdpw2Mj0wKoksTliW9MnNcMsxX2YnsU8gf25/cj3T+2NNxxf2p/wC2gqa2vrS4BFvcwybeuxwcV4JjHIFPRmX7pI+lSsxfWJo8gjbSb+4+gVbI4H40DIYc14bYaxqGnyCS2upVfaV5O4Y+hrXtfG2sw7g8sc2e8idPpjFbRx9N7qxy1MirL4JJ/geuE8HH60m7JyfwrygePtXPGy2/74P+NL/wn+rj+C1/74P+NX9epdzL+xcT5feerHnqT+VLu2ivGj4w1tiT9tIz2Crx+lKvi/XMf8fzfii/4VP1+n5l/wBhYjuvx/yPZSVyCKTIIryG28ba1A5Zp45gRjbIgIH5VZ/4T/V+6Wuf9w/401jqTJlkmJT0s/mer5AHcUgIwQPrXjn/AAmOuEnF9gemxeP0q5pGu+J9Vu1t7W5LHjc3lrtUep4pLHU27JMcskrQjzSkkvn/AJHq5Bpp/Kqei21/b2W3U7sXVwTksFAAHoKuFT2xXZF3VzyJx5ZNJ3AHsSaXABGKQKx9Pagq2aokkOD9ajJwCP1FPAyO9RsD2FIBd3X8qbuxmlVTx3pGGaQxGPArc+FhH/C07X1/sa9/9H2lYXIxW98LBj4qW3P/ADBr3/0faVlV+EuG57pRRRXKbnl/x6/5BvhX/sM/+2d1Xm7Nxxzg16R8exnTfCo/6jP/ALZ3VebFfeumj8JlU3DPJ9aCfkNAGCfajnbgitSAQMzgDucAVt2kLQph5CSe2eBWNDIY5FYdVOa1Le5llBdlRYl6tmvm+JI4idFRpJcnVu3ytf8ATU9TK3TjO8nr03LwOT1p+Mdaq286zsdmRj171ZwSK/PqtKpRlyVE0/M+jhOM1zRd0AORgHvSnjknApoU98dac3TFQUN3A55prBWU7uQRg5pdmaUr7Zqk7bCsY2oQRwOGj4DdsdKp5ypPpXRNGGBDAHNRRWcUabAgPHJPU19dgOJvYYfkrpyktvNf8A8bE5V7SpzU3ZMw0JPXrVuOzBtGnduMEjFTzaZhWMbEsT0zVtINtn5DHdxyRXoY7iGjKhGWGnZtq+mtupzYfLJqo1Vjpb5X6FCwtkuEclyCpxgVaj0+IA+YzHr0qG3tZ4y77xGAOAec/Wi0vZGlCSgHPGelY43EY3EVKk8DVvBJOy3Wnp+ty6FOhSjGOIhaTvv1Kt2nkTMiEkdQTUQJPPaty5iSSE+YAAB970rCwRxkGvUyPM/r1Hllfmju+/mceYYT6vO62Yu7kYHFLuGCR1puB+NHU+le4cA7Jzx3p2ACDnrTe2c0vPYD8aAA9eOKFYgcUucsM8Y9qZjr69KBDicjODTuxzTewFBIz70wFXtjnvSkkn2NNySPl4oOeB3pASIc59ae2T3qIEgHPWnevegBp5PB4PelVtuRRjnHrS465NABu6c1z3iqfVSsNno8YEk+fMl/55r6+1dAVPGOa50/2pZ+Jbq4e3nuLCZFWMRuMIeMnBNZVn7tu/Y6cN8fNpprZ7P+ty94e0a30az8uL55nOZZG6uf8Ks3Gp2lvfQ2c8wW5mH7tDn5qtAkYOO1ed+P7mfT/E2nXvlgpGmUwTzzz/OoqSWHp3itDXDUnja7jN6u/wB9tDstfvbm3015dNMElypwI3I+b1HXrXil07NcTGUASFyWA6A55rZ8S2Q/cXenvPNY3QMqhvmKN/ED/jWABxkg15eLre0lbsfS5XhY0INp3v5Wfox4x9aMgikXB3ZODjjFBGR6VyHpgxzzSjPpSFemKT9aBjielJkmk/rQAAOtMBeaAQDSd/ek6knB4oEKCDTsj1pB9KKYxSeM8UqozK7KpIUbjjsKTHPSvSfhrbQT6DeJNDE4aXY2R94Y6GtKNJ1ZciOTGYn6rS9o1c4XWNNfTZYEdldZollRgMZBHStLwfdayt7Hb6QzBWO5lcZjx3JrovEv2O98X6Xpk6ottAuH52gZGQv04Fdpp1nb2NusVnEkcPUBBxz3rsp4Vuo+WVkjycTmfLQiqkLuSvrt5F1Gfy0DFS+PmK8DPenM3C1Fn09ad1HfNeqfMsczf/WzSLjqcmmDJGCRmnYPOT7UwHkggAUFh0701vv4BxQFJAzmkAhbHHY0gyPTNGCKMHpxikMa3PQ1u/Cwf8XTtf8AsDXv/o+0rDYcDnmtz4Wj/i6dr76Le/8Ao+0rKp8LLhue6UUUVym55f8AHo/8S3wr/wBhn/2zuq83JB9a9I+PX/IN8K/9hr/2zuq83wcj2roo7GU9wyMijIA5pq59+PalYHtzWxAoPzcjj2qaWcykA4CDoo6CoFHze1BAz3NZToQqSjKau1sVGpKKaT3Jo5TG+UJU9OtaenXRkUo4JZRncTWOo5AAyataewjufm4UqQcnFeXnOApYnDTk4+8ldPrp/Wx2YHESpVYq+jN0k4zTQQOtJncowcg9Kbjnp1r8xtbRn1Y8kUbh7DNG3uTSBeDnpSdhjsgCgdfr600qcfWj7uS2MetCEOYhfmYgD1qnPdK5EdviSRuPYD1rNvLl7l8nhF4CjpUCEBhnOB128GvssBwy3TVXEPXdR/z/AOAeHiM197kprTv/AJFm5eRG8rzi6EZ4p9rZyNKpkUqnUk0y2iNzMIxlVUHHfFWITLa3WLgkhxgEn3616lWrUw1L2FDlVWzbVrN9mraX8tTkhCNWftKl+S9t9F/wDQuZIgoWQgB/lx61l3sAhbcuCh4+lT6i0bqVJG5cFPes0lmYk7mPTJNcPDuDrwSrQlZN+8mt+1v8+h0ZnXpyfJJXfRr9QJIo3YHcU3dkYJpduegr7I8MM/j9aXOeuM0gXn9aXkjOMelAC56Um5RjIJPWl2k9f51ERhiGU8Hg+tYVsVSoNKrK1+/kbUsPVrJunG9iYgMuB+QpTxjOBUcRD8jIxxinHHTGe1awnGpFSg7pmU4ShJxkrNDsjntRkAe9GQQeM+9IMt2PFUIcD34wKWWOREUuhUP0zV7SbcSSmVwQi/dyOpq1qrL5SxumS33T0wa+HzPNq+KxLwuEfu7aW1fXX/gn0+CwtHC01VxEdfyv5HnvibxUNAvY7cW3nl495Jfbjmqum/EKxmk2XlvJbA9HB3D8aX4mRINEWXylMqzKokwMgc1ymlWulahpVxfar50DQuEdoOd+R1I7fWvQyrG1p0Ur7X3+/c6sZgMKrzlDft+Gh6JN4jgi1aytsJ9muojKtwz7VHoOawdU8aSw6jcW8CWvlW+SZGcuJPQLjvXBapqlxfhIXdhaQ8QxZyEAGB+NZ4HTNehUx03pEyoZNSjaU10/p+tvkdDrPizUdTEWWFvs/wCeDFc/XmsqfULu4g8ie4lliLBsSNu5/GqnfoKTB6kVySqznq2epTw9KmkoRSsb884tPD0cEWpRSzeeJFiizmLgg8+/pWHI5di5xk9gMVH1IIBo6+tTKXNbyKp01C/mPGT0oz600euTmj+HnNSaXHD3PNLnB4pinOO1O/PNADh7UnQdaTkHmjHtTAUYxmmjP4UvI60pPQ4oEJ9a3PCWjpreqm1leSOIRly6YyMdKw+gr0X4WWQWC7vWALOwiXjkAcmtsPT9pUUWceYV3Qw8prfobdn4M0e3gZHjaZmXazSNyfcen4Vt6Zp9pp1v5NlEsUYOcDufU1YwCOMZxigDHOK9uFGENYo+MqYmrV+OTZ4z4xDf8JNqAZmb951bqRivQ/AmpvqGhR+fIJJoSUbAxgDp+lVvHmgnUrMXVrH/AKXAPugD5x/jVnwDaG08OQHcW84mU8Y254x+lclKnKniH2Z6+KxNKvgY/wAysv69TpeOuKCwDYPAoXnrSd+ntXoHgi8c0gbpgUoYDpwaQgn3+lMBf4ulOz2PP0pm0hvYilA4x1pALkE//XpAQOM0g60YwPQ0hjXYYHat34WHPxTtf+wNe/8Ao+0rAI+YZrf+Fn/JVLb/ALA17/6PtKyq/Cy4bnulFFFcpueX/HvI03wrj/oM/wDtndV5wT3z1r0f4986b4V/7DP/ALZ3VebDGRj8K6aPwmVTcAQBilPTj9aaR1zTieK1MwI9TzSDpntmkGTTsccUAO+vPenRsAwL8jPeo+QKdblVlBkGVHb3qKjtFsqOrR0YIIGMY7UpIHpVeGUSoGUcZxUzDcelfj1aLjUalo79T7eEk4poez4HNMLHJwc/WgoMHHXNOUYzWRQitk8/XmkmVZIXUgEEY5oNABJ6cVUW4u6E1dWZg3EMkR2yAAHv2NMUACt+aJJYtkijH8qxzbg3ogRsgnAOM1+jZRnkcZFwqq04q77W7nzGNy90GnDVM0tMhRIfMVslwM+1LqSB4lwjNJ0Xb2qaCHyoVTk4H504/jivjsRmEnj3iou9np006fge3Tw6+rqi1bTX1MGSKSEIZFxuPANRkEj+da2qQNJECgzt5OKx1IDc9K+9yfMPr9D2krKV3ovwPncbhvq9TlWw8kBcED3pF5HXrTCDj0+tPUd/yr1ziFVsHB/SlB60wj0pcHHTpQA/PIGcU1wpGcYPfFAB6YyaVgecisMRhaOJSjVinY1o4ipQbdOVhqKBnb3PSnE80hbAH0ppyq8jIzinKVLDU9bRivuQoxqV52WsmPU88H86VzgAcbvr2pi+uOD60SqzONvQ+orzc5WInQUMMruTs7djvyp0IVXOu9lp6m9ZOE01X7KpPFZd1cSyqHkOew44Fa1kENkoTldpHNczq1/FYWbzT3EcGflDvyNx6cV8zk2C9p7em/dmtLvpvf79j1MZiEqtOaXNFvbv2MrxksD+G737SNwVMrns3Y140OAQCcH3rb1zxJqWqrJBczobctnZGoCnHp396wvXH512YTDPDRcXK576bkrtWHZ/CjjsaQDPWgcH7tdQxfQ04896b1HFHpQIMA96CMZpMNg8DFOA4yKYAB/KkPNLgYNFABgilB560mTj2oOfegBQB2NLkg4zSLgHJoI7UAHIPal9eaaTn0oJwOnFMBxPvV3TNTu9Mn86ymaNsYPPHPtVHI9KO4pxbi7omUVJcsldHS+GdQvZb0wpdP5pYzx553OAfl+jDivUNE1WPVtPWdAY5AdskZ6xt3BrxfR3aPVLN48hhMmPzr1XTbaHSfEF3AiSEX379WwSFI+8Ce3qK9HB1JfL+rHz2cUYdFra6+W/4a/I6EkdCSfrTY0SMYUAKvAAHAoIOBRgcZ/KvUsfN3JCRtxn8qOcnjmo9w6YPXtTgPT6c0wFGcZ6e9OzjrUeMDByfalxxz1oEOJ6djQOB3IoI7AfjSD7vp70hik5P/1qavJ680oGVPXpSY54pDEY4xW78LTn4qWv/YGvf/R9pWEeTW98Lf8Akqdr/wBga9/9H2lZVfhZcNz3OiiiuU3PMPj1zp3hXt/xOf8A2zuq834Fej/Hv/kG+FcY/wCQz/7Z3VebbRg9+9dNH4TKpuKOQcUnA6UcA47U3pz2rYzHgZX2pcd/85pE6cZofjnt0pALnAJ4pIlaV/LUfMeBTCDwPx5rU0WIbnlIOQMDPvXJj8UsJh5130X49PxN8PR9tVVNdTRgjWNAqgAd8dzUmOaVsY56VGBxyDX5LVqyrTdSbu2fZRioRUYrQeDnjjigZ+gpFHJyD9KGXjrWZY7GSOtRSSpHjzGC56ZNOwR2J7VSu7eCOMuUZpCcKNxJJrqwlKnVqqFRtJ9ld/mjGtOUIOUUvmX1ZXXKkEeoqFIEjnMqjBIxxVWAta7YmjJL/MSD07VoZz+AroxFKeBm1SleErq/dde/oZU5xrpc61XTsxd3HHamGRU4ZgCfWnxqNv41R1RBj5YgzNwWAzisMHh/rNaNK9r/ANdWi69T2UHPsWmdQpYsAo5JJrDuQi3EgjwBngClt/LWUNOGODkKBxT7pIxIGg5QjGQe9fZ5VgP7NxnI23zK17Wj33vqzw8ZiPrVDmSSs++pVyRx+dOzjj8KUj3NJt59TX1p4wq5LE07oOSKaOTwCKTaMZFAh+ffikGDwQc008HoaVVO3JoGOzxgc1EG8wSI33RzmpGB4wOtRsoVOOPXivJzKjWqp2fucr07vp229T0sBVpU7ae/da+XXvv6CQscbWPzA4+tVtU1mPSImZkEkrKQikdfXmrAABD5+YdOK5PxlbTF45ymYh8uVYn9O1ePLN5+yjhp2cmmm739NU931/4J7uByalWxLqO6he6W359C3P45trezdngnQgjainIY/XtXCeKPFMuvW0UElskKxvvBDEk8YqW4hWeFkYEA81jT6eYVLGeInsM4zWsMY5Jxdlfey39T1pZLRw81Upq9trvYofjTs8e1DKccqQPpTSO1Bb0H54GaM+lNIOMkHFKB0pki9aXPPSrFrY3V2Stpbyy8EnYuRx1qttODyAV4INMXMr2HAhvakJppzg0DPWkO47PWjkdzSdz1Io7DFMBwNIc9jR9M0lAXFpRnpikAGaMHGaAF6Clxn8aYc8GnYJ70wA8ZFKOxpCpPTk0gByAc/hQI2vCNr9r8SWEe4rtk35A/u8/0r0vxpqT6Zo7NbymO8kYCLAyTzk/pVjw5pVpp+nW5toVWR4lLSEfM3Hf86i8UxRLp51B42kmssyxDPGff1FevRoypUXrqz5PE4yGKxcW17q0t3JfCepXOq6St1eQLCxYqu3+IDvWqwx2rL8M6qmsaVFcogjcHa6jorD0/nWqR1GDXZSd4J3ueXiVy1ZLl5dduwijgc8VIp6cUm3gAE0hA446CtDAVyc896cDkdiRURIHbvT0xtJHegB4Gc96b0OOcdaQe3WkbtnNIY6kzgHApMcgDOaNuPp3pAI5zjmt74W/8lTtf+wNe/wDo+zrBYcA1u/Cz/kqlt/2Br3/0faVnV+FmkPiPdKKKK5Dc8v8Aj0cab4VP/UZ/9s7qvN9w6nrXo/x9/wCQX4W5x/xOf/bO6rzRlPAANdNH4TGpuSZz07UjE445pi8A56d6Q5PWtiB+SBxjFLvx6VGuMc8CnAZoAUuSOBWrpD/uWHH3qyD3wDVvTZ1jlKN91+/vXj57QnXwM4wV3o/uZ3ZdUVPERcjc3jP1pwfrUW3n2zSgHPGa/LrH1tyQMcZIpC/JppB6k9aT09aLBcl3e9QvEJJo5WJzHnApz9qOfStKVSdKXNB2f+ehM4qatIayu0yum1SOCevy0reXbB5Xc89Sxz+ApyHaxz+lY17cNMdpG0KxyK9TLcNVx9WNGOkVu/K/mceKrQw0HN79PUt3Woksv2ZsDHORVX7W6KVj+Vm5Zs5LH+lVT700ck5B4r7vDZLhcPTVNRv3b3fr3XkfO1cdWqS5m7fp6EobceetLuA5PSoQTj6UozkY79a9ZJJWRxtkgwRnrShhioirZ9qAOeozTEShutB4HX61GvHQ0pPsfagB+fbNAbjkU1144FIDxzzQASzpDC0kjqqKMlicAVBHqlk0YkW6hwRkZYVneLZHi8N6hIpAITg4zXnVsXMCNL98jJrzcdjHh2ouN0z6LJsohmEJTc3FpnrhZCco25MZB9RWfrD3oiVLG3SUyZVi38Nc/wCFLBrxWuJbmURxttCK5GfY+1dbcmYQHyFVn4wDwOvP6V87hci9q3Xm7R3SPUxuarB1VQp2lJaNvRX/AK3POItNub15YLWSOO7jP+qccvjqB71kQ6XGshMpdpFY7lPHPcV6VqelW0t0s8U/2W+b/VkHG4/SqE2myeINNDqsNrcFz+9RSN3Y/Wu6pg5UouK+JX+a/wA0dVDOadaaq1Pgdlrpyv8AVO2/Q5C4iE0LxjgNx9K3LfwJF/Y6ZYjUidwZj8g56Ed66Kw8PWVsqIyGWWLndI3JPv2rUCkZG7I9PSuahiaOGjz4hO0lp5/5E5liKmNko4N25Xq/63X5nH+JvDN7PotnbWHkyfZzzEkYTcT3z/SuAvNOvLSR454XVk4bvivcVDDkNgenWsvXNJTUbVwmyO5I4kCjk9gfaor5phpqMqd09mmRl9GvRbp17OO6a3v6GToc/wBv8JNF4eEVtcKNkiv645PHc9q8zu7aa2maK5jdHBI+YYz716L4T8OalompxyyXEbW8gIljQnHTgms/xvoWq3+vK1ujXERj+Q4ChMfwk16Uq1Ovh1Wi9I6eRyUL4bFyo9Ja+fp5nCDpQDV3UNJ1CwLC7tZI1Xq2Mr+fStTQvB+q63pj3tiisgkEYRjtLe4J4IFccq1OMeZtWPWcktWc8fpS9RXo1v8ACLWrhlWG7tGOMvy2FP5c1ynivwpqvhm9e31O3YIuMToCY2z0wf6UqdenV+B3M1Wg5cqepiA0bqQLzQev1rY1uKfu04U0YFB607BcVsYxg8UZ4pn40oxznrRYVzsPCVrpIsrqe/voVklUQ4IIMYPX8T61r6h4NtY40v8ATJNscS+aEkUvvI5H/wCquD0ma3h1O2mvEL28bhnUDkgV7dYX1tqVss9pKrxkdux9D716OFhTrR5ZLb7z57M51sLU9pCTs9+3oZfhLXzq2lTT3aLDJbttkI4HTOcdqxvGfi2yfS3tNOljuGmBR2GcIvqPWtKXS4NC0bUXt1aYTZecvJtO3nOMexNLo/h7TJIobtrSHaV3xKF4CkcBs9T3+tdL9s4qn16nBF4WNR17Plvovl/mO+HsrP4agR43Ro2K/MuNw6g/rXSjofSmIgWMKBhVAAA4wKAfm6100ockFF9Dzq9RVakqiVru48n2/WgE+wpjKQc55oIwOvFaGI7cOmKUtjgdKYOeecUhGev1oAfnjOPypSTjp1pgYDvyKVug60AP+nWm55PNNHI+lJtzyMZpDFcg45Irc+FhB+Klrj/oDXv/AKPtKwH4YfTpXQfCz/kqdr/2Bb3/ANH2lZVfhZpD4j3SiiiuQ3PL/j3/AMg3wr/2Gv8A2zuq81b7wHOK9K+Pf/IM8K/9hn/2zuq80PBNdNH4TGpuGKO/UYpM5HPNN6nityBwxnFBXCk5poBDZpfvcfpQIeo9jxSY5700t+VKG49/alYZx7Nf6f8Aa7myuLiO5gnJkjLZBjbowFS2/jvVBcRtceQ0O4bwseCV745qbVWFt4gG8t5V9D5BK/wnoK4+8t5LS7lt5Mh42K89/evi8fgaSlfl7r+vVH6ZldWOLhask20mvR7/AHO6+491tL22vYg9pPHKuAfkYEjPrVgD8K8O8P6rLo+pRXURJUHbIn95T1r1H+0ZLuGORQyRsA4XuPTNeLRyOtiKvJSenVvocGauOXWctU9jf6A8UKewrn5LmZl2s5K+mal0+VhcKpkKqc8ds13VeFq9KlKpKauru2vT+ux40M3hOaiovUnu74klICVwfv8Ar9Ko5ZicnknJpGyJGXqckZpCeOelfXZZl9DCUY+yWrWr6s8XFYmpWm+d7dBxAxg84pQOTTVPHB96AOeuTXpnIOI4JP5UY55OPpSEkrk9aaSMjnP1pgSbucc8UcHHHFMXJJ6/hS4LDAzn60APb5TnGKQscDGQKR8d8UDnvSEKORyaGUYHp6ClODwelNzzjv8AWgCG8tor22e3uELQSDDLnHFVofBdo7JLHHhP+ebMcVtadAZZQ7DMa+vc1s/Wvk8/zSFCapU4qUlvfp5Hv5TTrRi5qbjF9na5j2OiC1iWOMJEnog61qWOix3F0kbSSbT97HGB61KOvyk1Na3EltMJEOOx75FeAs+xjkvftHskjtlgKLTdrt9W2ctqtlavdOijzY4n+R2GG4pwAReAAB0A4rfv4FvZmkYKkjd0GB+VVItMKygyENGOvPJr6rDZ/gpwcpO0l33f6HkVcvxCaitV+CMcqQ2VUc9eelKU5IHX0rp7HQIb+4ZVkMIAzgAGrcnhGGMMWvXAAyTtHFTHE5djYKUl6Jrb7v8Aglf7XhpOMX667nO6VaxTRN5o3MvbPrXa6Dp0MVsWe2jDP03Lk4rmItPOnapfRhmkQ+Xsc9xt/wAc1rWmoz2vAbeg42tXy+Kq0I42ckvdWi+5I9eMasqEY813u/nqYni2xa31WRkg2W7gEFVwuaxjjGD0rutd1WC40t4jbySFxjb6H1/CuGkG3BBJFKpSnyOrTd4N627+aO3C4iMmqVRWmloLDb29w6xXcaSwucFGGQfrXS2ttDaQJBbRJFCgwqIMBfoK5hM4zXf6Np8U1vb3Pmb0ZM7COn1riVKdV8sS8ZNU0psuaDAY4ZJGUqWOOe4pfE9tDcaBfi4hjmVIJHVXUEBgpwRnoa0QAQRngU6VVZNpwVIwQR1r26FP2UFHseFOo5S5j4i7f/XpAMmvqXxH8OdB1Yu6abbxSvks8XyMSe/HFeeN8FriaWc2uoeWgBKLNF37DOf1rsWMhzckk0/zPahjaco3eh5BjA5pOvbmvoLwr8HdMsVeXxFIb9zwsYJRFHrkHJNec/FLRNL07UEudEia2tZGMYhySMgdRnpWixEHJR7mlPExqycYa26nB4A6UE8YFKc7fSm465roNwAJ5xXpXwuuA2m3kAXBSQOT2OR/9avNCMd69T+Gti1ro0k8kbJJO+QSMEqBxXXgr+2Vjys5cVhWn3VjrnRZFZJFVlIwQRkGnqoRVVcBV4AA6UzvknmlJJwO1e4fHEhbntSHrUZyBg09VLD/AAoELx9cU0k55XimgANz+eakYZByeKYCg5GMDPamHoM96Oh4/Sk5HWgBVGM9zS4AHcGmqv8A+ulHUjnBpAOXqM0g5J46U08txmgnB6k0hg3B/lW98LP+Sp2v/YGvf/R9pWCeWXjNb/wu/wCSp2v/AGBr3/0fZ1lV+Flw+I9zooorkOg8v+Pf/IN8K/8AYZ/9s7qvNWb16mvSvj5/yDPC3/YZ/wDbO6rzNv09K6qHwmNTcQE9aUE9sCgd/X2pu4kVsQOAycfjQQMdaAeMEYoHCnAPrigQuPWkxg+tB6ijI3YzxigZDdW0N0irMoYBgw9QR3Fc347tYxFBdg4l3bD7jrXU5Gc1S1awh1O0aGYEHqrf3TXHjMOqtKSitX+h6eVY54XE05zk+Vfk9zzWIqskZb7oYE/TNerxSLIiPG26NgGB7EV5rqGj3lg7iSJnjXnzFGVrQ0rxJPYWkUDwbwh+8SQSvp9a8fLq8cLKUK2lz63PcFLNKdOthGpWvs1szr31WxF2LVrhVn3bdhz1rSjRGXJlVW7DBrh/DNil7fHUbiSOT5i4i3ZZWzxkV2QP5V69GpVxFNy+Ht6fM+RzDD0MHWVKDcml71+/kTyxtCwEi4YjI5qPPqDUbXU6vJCIZGjC7lclTuPoO4rH0G/1K9a8+3Wv2cJLtiDLjK/1oWInRj+/Wu3upu/y3X4mCwyq3dNpJd2l/wAObhOT1wKcPpUQJwCRzjpT8nHpXanc4xSevBo4xjGTSFiOp/Glx3PpTAd9ATSjIIz3pgJ7/wA6kOSBnr3xSEIcn1x60oGB6mmYxzmlJ6daBjsEmrmnWwnkJcZRe3r7VSOR36dq7XwtY21zpiyshEhcgkN1xXnZrWqUsNJ0viei8jpwcISqrn2RbstCjaKF2kKqwzsxjGa5S01mwudSvLOOTZPBM0WyQgFsHGR9TXpKDjPXFfOfxJ/deO9U8gCMiUMNnGDtByMV8PUwMJx8+59dlUPrU5U5aaaeWp6tt5+npR09q858J+MZI9lnqzl4yQEnYgbB/tev1r1nSNMS8tkuXfMLqHTafvA968yWDqqfJY2xVN4V/vDNz8wA6088DpV/xXpKHwxqq2bCGUQFxJzlcc8H8K8S0XxXqOnyx+ZM9xbg5aOQ5Jz1weua2eXVOW6auVg6LxcJTpvboe3aB/yEV4x8prpSFA5A/GuI+H2s2uvTzTWiuhtxiRJBzz0/ka7Vxhgcc4ruwEJQptSVnc8nHRcKvLLdHG63bjTdWL7j9nnUtzkhT6CmZBGR3rp9atI7uwlWVN+1Sy+oNcLps7cwSYDD7orqzDB/WqH1mHxQsn5rv69/I58LiPZT9jLZ7f5GooyeayJLB3uXCZCH+I1qqTg81FNcRQZ3uNw7Z5rx8FjamDk5U+qtqehWw8cQkn07GJdokVwYsb0XgMOK17XX7i0sore1iij2DliMlqw5ZDNcu+3aCSeKDk59x3r7LJ8LHEUvrGIguZ9drr8jyMzrOlNUKUnZLVdmeleHtWXVLdyUCTIcMo9PWtJsNyrA844NeU29xNb5aGV4ieCVODiu98HSCXRl67ldtxJzk560sfgFQTqRenY56GI9p7r3NtU/vDmiV0ijaSVlRB1JOKa0gRSzMAqjJJ7CuE8Q642pM0EXFsrZXI5auTC4WWJnZbdWa1aqpq7Ok1fV7I6VdiG5jaTZtAHPJ7V45400r+1NHdYomkuYvmiUHHPQ/pXRAnB9MenWruiSW8WqI11D5sRIAHZSehx3rLNMBUwlSFWD93+t/I9LKcZCUJRt72//AAx4te+B9bs/Df8AbFzZTJEspR42Q7lXGRJ/u9s1kWuhaldwLPb2U0kLH5WUdfpX2Ff2FvqFjNY3SeZazoY3TOPlP8q8h1/SILG/XQbqSVFRRLbmNinmRg8cjuO4ruwdq0uST16FTzOcY3Uev3I5TSfAFtEVk1KZrhsA+WnyqD9e9dwihQAoAUDAA7Uwdhjt61PbKZbiNQcgt3r6GFOnh4NrofOVsTVxU17R37EZ+970fwnPFTXqKl3IsYwoPHFQKeoJGM1WHrKvSjVWzVzCpB05uD6APfmkzgkZNLnAAzS8EA961IF2qcE0mMDjpTe/XBFL1wDxQAm3J68U/txTO5/Skyc96YDsH1pTjtim5PG4fnRn6UAOwAcUcUgzjJxSbuo/OpGIw5IOK3vhb/yVO1/7A17/AOj7SsBjzxz71v8Awsz/AMLTtc/9Aa9/9H2lZVfhZcPiPdKKKK5DoPLvj5/yDfCv/YZ/9s7qvNSe/U16V8ff+QX4W/7DP/tndV5mcg8Diuqh8JjU3HkZNNIGMYoJPPJ5HrSD0IrYgXjceMYFDYxTWB2jHGOKCcYyelAhepzj2p2PYelN5+lGCR1xQA4Kvc9KABnOaYQOp6+1A6Z/TNADm6diPSqmoWFvfQeVPGCD0I4IPsasnlckmnYJHt/OpnTjUVpK5pSqzpSU6bs0eZ65pOpaLbzXK4kgDYVoicqPVq6zwLf3N/oCTXjFnDsinHUDGPrWxeWkd/ZTW1wMxSLtYA4rnNH0vV9Es2s7aSG4jeQlHYnMQ9cdK8+NBYSpzQvyv5ntVcfLMqHsqzSmno3pp69zqWlSNGeVlRRyWY4AqjZ63p148y29yjiJlUt/CSegB71wfjfxFeMJtImt1hII8x1Od47YHbPWsqxnjNlEke1ApLdec+/5VGJzL2TXIr/gdGX8P/WYt1ZWfS1np3PZFHI4peN3JrykX115ZUXU209t5ruPC97NdacouQoCHYr92+tVQzWlVmoPS/cyx/DlfB0vaqSkl2Oh2jGaYeGx7U35sAAjFBBYn2/WvTPnhwA6n8qkyAOuSKjxgY4oGR+NMQ/gjr+NBx2NIOmegoA6ZJJpAOxzk4r0nwvFHFolv5Z3BhvJPqa81II6/rW34Z1eSxuVhkctbOcY/un1FcGZUJ1qNodNTow01Cepzfiv4h+ILLX723tAtraxSGNEkhDHjrz3zXG+Tq/izWJ7qO3e6u5WXzWiTCqTwCccAcV9Ba9otn4g077NfRpIh5SQYJQ+oP6U/RPD+neH4pI9KthAsrbn+YsSfqa+Sd9j7Whm1ChSvTp2nt/T3PL7H4R30tuj32oQW8pPMaKXwPrxXsGn2sdlZW9pD/q4Y1jXPPAGKk3EjkdelJvI5A55pJHmYrHVsVb2r0Rg/EK9l0/wlqD2sRkldPLxtJADcEn6DNfN44H0r6D+Imqi10C7tFjMss8TAgMBtHrXz32AojK7a7H0mQRtQk2t2e3/AAX0s2WgzX8iSJNePjD9Ci9CB+Jr0NTkkmvKvg/4mMiTaTqV2DICGtvNY5b1UH+nvXqTE8/0ppHz+aRqRxU/adfyEuN5t3EGPMI4z0rgdU0m7t5WuPKYJnk+hr0AA9T27VFcQm4gaNiVDAjirp1KlCp7Wk9bWt0Z57UZx5JLQ8vNxMNyrKQjZ6GoRwck8+9dLdaEtrJmWIleuQcg1i6h5RmWOHGEBXitcrpYKeKUYQk3vray+77jXG4rE+xbbSXluysM+uPalwevamDr19uKcCccV9mlY+dvcXrkda3vCN/9j1FY5Gbypvlx2B9awFOGyTgU5XZSGQkEcjFRWpKrBwfUcJuElJHoPjN9mjMA+1mcDGcbhXAbcgZNdBLdnXre2tCfLlgjLl3P3yBXOngk81x5fSdGDpy3v/X5G2Inzy5lsBPzYHSpbZxHMrDqpB4qDOWBp8BEcofrhga7pwU4uL2ZjCTjJSXQ7C88SK+nziA+RejkfLnj2PrivI/FGvXWo+OdHWGb7XLArRyADO0Mec49ua77WrPC/a0ZZLe45I3DcpPOCK5XQdFh0dbgRMHeaQyF2XBAPRfoK8OllqdWFalLRbrzPZp4+FKlOFSF29vRmsR27ULxgjgj0pWOOlNR8EqevQ17smtu54qT3JWZ2iyw3d92Mn0qIcDPJ+tWrRoSdtxnG7OM8CoJ9nmt5X3CcrXJRqctaVHla636f8ObTheCqX/zGMF/Ojjn0oKngMQfrSZI44+ortOcUjnHHtSjpTdx6inZPb+VMAPBBprLnnNDA9c0pJ6A8UAJkZ5ocegxSHJNGMZGeaAH5BIwCPY01uucUE4wO9BJIzSAQjI61vfCz/kqVr1/5A17/wCj7SsA9eK3/hYCPina5/6A17/6PtKyq/CzSn8R7pRRRXGdB5d8ff8AkF+Fv+wz/wC2d1Xmoz9K9K+Pn/IM8Lf9hn/2zuq81YAtyTXVQ+ExqbjTkg9M5o9R0+ppTwaTH5VsZgSfbFIuCelSY6Z/OjGOnFAhh5GOtLyF9qXGCcHg0duDTGNFOYA9eCRTc44FOGRQIbjJ6Yo4z0zzTi3+zxTRgnIFAxc4/lUVxPDa27y3EiRxIMszHAFPzjPSuY+Ilw0PhqVVKASusZ3DqOvHvxUVJ8kHLsbYel7arGn3Z5z4o1FdV1u4ulRVUnYu05BA4BrOhjeWTbGpZvQVGTz61d0lC90D2UE18zVqN3mz9Ew1GMeWlHbY24fmiTKkHHQ9q6fw7ebNKvYmnjjccx7yBgke9c0KUY6V5NWCqKx706anHlZ0PhnVY7GW4+2zOUK/JyWyc9q7LS7tL6xiuUGN4yQexry3Jrds/Et3bW/lIsfB+XI4VfQCvcwGY+zXJVei+8+WzrIPrMva4Ze+3rrZWt0PQO2SM0DBGcYrmtP8V27Qj7arpN32LlT9K2tO1K21BCbWTft+8pGCPrXuUsTSq/BJM+NxOXYrC3dWDSXXp95bX7xJpw656YoAx9aU9Rn+VbnCC0oxk8nnmkJywA496CPTqaANbSNcudMVlj2yK2PlcnC/SrUvifUZGZlaNR/d25ArniG49KcQQw5965p4SjOTnKKbNVWmlZMu3GoXE8zSPPJvJzwxAH0Fa0/ieeXS/svlKHKhDKHww9TXO8Ecjmp7Vo47mN5l3RqwYgHqKivg6NWHLKO3bQulXnCXMmVWsbnWbN2gSaaGUFRLHlunHWuH1vw9d6LY2c1+yxTXJfFs3+sRV4DEehr6Q06WKe3iktFCwuNygDH6V4N8UfEMOv8AiH/RoysVorQByfv4PJr4mlh3RbTZ+gZVjqmIq8kFaO7/AEOTtJpLa4iuImKyRsHUg4OQa9l8G/EdtZ1RLLULNIC6ErJESRkc8jsMV4oOvNeg/CLTje3l9Ih2usYQMeQM89PwrSrJwi2tzuzWjRnRdSottj03UvFH2S4AitlkjYfKzNg0kHipbqYrBa4UL8xZuQaoXPhi/lt0kaVGuBx5Z6Y+tc/bTvZzSqY/3mMEHtzXJKOK9p7GOre1tvkfNRWFlQ9q9Lb3Oi1nWvMQqxUMB9xehPvXLFstk9ScmnN87Mzck8k03ac9K+0yzLVg4uUneb3f6LyPmcVinXdkrRWwYG4mlBGcYpVHHpTgpHOea9Q5BNqlun5U7Hb9KQDrg0uO45oAD75oGOaCOaQnFMBCBketXdHu0tLom4gjmicbWDDkD1FUj+tKM88VM4qacWOLs7o1Nc0Vra1+1WZM9qV3q2OR7ViwMtxEkik7WGRuGD+Vdl4OvWnjl0+bDRhCVGO3cVjaxpz6XfYZR5RbdGDzuX3ry8InRxNSE3q7P18/8ztrz9pRhZbf1b/IoQwSzyMsMUkjKOQq5I+tauraItnplvfGRxNJgNGy425Hau30uWK6s4rmKNU8xcnA5+hNYPi66E1xbaeUOC6szeoPHFefGrVxWMjKptG+nbv6nQ3Cjh3Cn9rd9zkGgkC58qQDGc7TUQH5V0HieJrW7Co8nlvk58wkHtjHtWAePavoKFT2sFPueXOPI+UGA7imZHPU1r3GmIdNiu7N5HQkK6sBlT+FI+g6kiFjaPtHPBFCxFPrK3roDpy7GXhT7UAA8ZpWB3EEFSOCPSmjOc44FbEDjgcYGPpQeg4xTvxprD17UxCMOgzzSAA/U0p4OcUHqMjrQAmM44FLjkY5pcZPXFICcmkMRk9TW78Lf+Sp2v8A2Br3/wBH2dYbZx71ufC7P/C07X/sDXv/AKPtKyq/AzSn8R7nRRRXGdB5d8fTjTPCx/6jP/tndV5mXy3tXpfx+/5BfhbP/QZ/9s7qvM2HNdVD4TGpuLnPY0bzSHgYpOlbGYpcnk0bsjHNGaO1MQZAPTFBfPQGkAJ6UvTvQAbjzQWwOQaTnaSO5pRnHJ6UANJyMY/Wkzjv+FK4BOcUgHFMBcgcVk+J9LTWdIktmZlZTvQgZ+YdK1sY46e9Hc8VE4qacX1NKdSVOSnHdHgBjInMTAqwbafY9K6G3iSGNUQDjqR3PrV/4iaDFp88V7ajZHOxDrnPzdciuYsbmVJUjDfIWGQea+XxdCUZcr6H6RlmNp1YKolv+Bvbvalzk0hB7UfzrzrHv3HA+xpQw9OaYBTsccUCbHBvQfhVvTpLhL2H7GxWcsAuO596p9q7HwbpiCIahIdzvkIMfd55rpwlCdaqow08+x5mbY2nhMNKdRXvol3bOshdgiiUjfgbsdM04uCMYFMB6+lOHQ8DdX2KPyl6gT60E5780N2A6mkPIOM0xEikY5yaC3TGc1HtyO9OCjPWgB28DnHNAcMcdTTCPSgDIPTFIZj+L5bhdOjlhmnQxPj5JCoCn6e+K4Qtnk5rsPGl20VtHbqFImyW9RgiuMye4r5fNFH6w+X5+p+kcN86wMebu7en/D3Hd69D+EGrNpWpXPmx5spwFklz/qyMkHHf0rn9E0KG5tFuLhmYSDKBeNvX863NE059OWeMMJEdgynHzfjXiVMXGF1HdHdjZU69OVKR7nDOk0ayRtuRhkEdxXnvipv+J5cn3Ht2rWsJLnS7CFEcPHIgcbhnHHI9qwNcuGu9Qd5MZCgHAxmvXyavCWJ5Etbfdt/wx8Dj6TjT5r6XKAOBnp+tAfJx1p8MbSyLGmMk4prptcgnocdK+q5483JfXc8flduboKG+oJpVbB703Hvz2o5BxmrEP3jNG/04qMAZPrS7D2/lQIcXx3p27J5GKZgZ6Hil4+lADt46CkLdwPrSEYOAKCOTnkdaAJbW6ltphLBIUdT1HeteS+TXJl/tG5jtWjGFIQndmsJcnPb2pRwcAVlUoxm+baS6lxm0rdDov7J1C0h86xuxLCBvwj4z+FYr3cr3QuJWLyBg2WP6VBufj5iPxpPQmpp0pRbc2m/Sw5TT+EuX2oS3sgabA5JAA6ZOTVRjxwTT4H8uTPlo/HRhkConG5iTgZOcCtIxUVyxWhDberLdjfzWUiSW7sCDkgng/UV3ugauNUtGdo9kqHa4HTPtXmxVh1GP0q9pupXlhuFpJtD9VIyCa48bg44iF4/F3N6FZ03Z7HX+INDtrlZLqNvIlALMQMhuO49a5CA28cPmtK7TdkC4H4n0qxbazeC9SS4nkeMH51PIK9xiq2rLa/bWaxkLQtzgjG0+lLC0qtJeyqO66f5BVlGXvxRXklDuzBAgY52r0AqMOMcClChnCkgdsnoKaQK9BaaHMxxbdj0oB7U0DBFLjPJ60wFPp60A/N7U0rkjNIMentSGObnAH51vfC3/AJKna4/6At7/AOj7SufIAwK3/hZ/yVO1/wCwNe/+j7Ssqvws0p/Ee6UUUVxnQeXfH3/kF+Fv+wz/AO2d1XmI4PJ/WvTfj9/yCvC3/YZ/9s7qvMjgEc11UPhMam4pGeDSEdcUu44xTeSD71sZjs8EUhIz9KAO5oHT1piF9OcUfjTDycUDjr2NADxn8KOnQfrTM8AUZB6GgBx756Umcfe/AUDgA0gGcZoAXOSSeacOe+KYcAcUo6HB/SgCDUrK3v7Z7e6UPG4xgjJHuPevM/FPhkaHNBc2fmy2Yx5jPg7TmvU1AJ61z3xCGPC11juU7+4rkxdCFSDk90j1MrxdWhXjGL0bWhw6/MoPbrU6QSyKWjikZfUKTVvwfpseq6fIZjIhQhVcDg+v1rttPso7GyFvESVOSSerE96+Gr4lUpOK3R+lyxcUtNzzkU4d62vEGkR2Hly25PlN8p3HJBrHjRpJFRBlicDFb05qouaJvGpGUeboNXFeh+EwV0K33KR1Iz6E1l2fhJfLja7lff1ZUxj6Zrp4Y0hhSKJdqINoHoK+iyzCVaU3UqK2h8PxFm2HxdKNGg72d2/wJVJ65pwOT6UwYAwDzTuQvHOa9s+RFAGe1GTTTkYyDmnce31oAXJOKARyO9IPbpQzn/8AVQAo5FKABznimkgDrQTnjnP0pAa1n4c0XxNarFexyx3cGT5kb4LKf0ou/hVoojLx3d9HsBJ+ZWyPyp3hJyutwgHhgwPPtXa6w7x2EjRnBOFP0r5LOKao1ZT7q59Dl2OxEYRpwm0locBJolvY2Ijs5ZpfL6GRVXI+g71Sglkt5AynB6HiulqrJYwPKZHHOcnng18f7Xmbcj3oV9LT1LlzqIis0gfBCksAOuTXPSMZZGduMnP0qxqgT7T8v3tvOKggAedA33SRX3eRYSnRw6xTu5Nfcl0X3HyeYVpVKvseiZswW8UChgvI53Ec1iSMTIx5+Yk1sahL5VthfvN8ox2rGCnpjms+HlUryqYuo276K/3/AOReZuMFGjFWtqGfUUvI6U3nnihcZGRX055I4fnSqxI4pBxSAH3oEP6nk8Uh+97Ugz+NAPPB/CgBxBJ44pcYHUUzJ7E0vUnNADunPWl6Cm9s0dx39qBgc57UZOOOM0+OKSXhELc44qzBp0jMBLlU+uTXLXxtDDr97NL8/u3NadCpV+CNxtnaS3BBKlY+7YrQg0+OObe3zY+6p5xVtV2IFUYAGBS7TnP618Njs9xGIm1TfLHa39dT6DD5fSpJcyuyDUAWhZYlDMOenSseyQvcxKR0OT7VvHj2pkUKJIzKuHbqRU5dm31OjUpct77PzHicH7epGd9jDvIjDcMGxhjuGPSoMgg4H61o6zGwlWQj5duM+9Zm35unJ9a+zyjEPEYSE5PW1n8jwsbTVOtKK2H9/WkbIAHAoAOT04pME9jivSOQX5gOgoHQg8Z6U3npz0owR1FMB3f6UmOMikDZPAP4jFKc+9IYZ9ccVv8Awux/wtS1/wCwNe/+j7SufI4963/hb/yVO1/7At7/AOj7Ssqvws0p/Ee6UUUVxnQeW/H7/kF+Fv8AsNf+2d1XmTdcc16b8fv+QV4W/wCwz/7Z3VeZH72cYNdVD4TCpuA+pNJ34xgdqXJwO1J2x1rYgdng88Un0o78g4xSZ9uaYheMcjIpvQHCg0L15o69D+tAB26Glc47YFJg+pFGeQO1MAJHQGlB9TkUYA5xz70cgdBSAO+BSDIPUH0p3TpijPHuaAEDYIH61keL4o5vDN+rjpHuGD3HIrYyM8dKp60EOkXglj8yMRMSucZGKzqq8GvI2oS5asX5oxfBFl9j8Pwbi26b96QwxjPat8DFUtAvI73R7W4iQorIAFJzjHGP0q8D1r8srScqknLe5+kGH4i1OC3t3tQolmcYKn+EHuawfC0TvrdsVXIUkk44AxU3iO1uJdXmaKCV1wvKqSOldV4dsBY6eikDzJBvc+/avpMmwnPKLXSzZzZtjqWEwbitZTVvvWr+RqH5RnPHpSZ6cUuOOBx6YpMnivsz87FHHpQef/rUckc9KcO/TjmgQgHrSjnt0oJ6Z60gwfX/AAoAcD60n4cUq8+1H8WP1oAaOSeh704kdexpAcnHGaTAGPWgCa1ne3nWWFirqcgg12t5qq3dl5YjIY4JOciuGU9etatpdQw2yKxO7vwTXzvEVCpOipUld7WSvoz08sqQjUam9PU0QQKp6k0I8ky7i8ZLoFOMnBHPqOajbUUGdqMT71nSyvM5kc5J7eleBlmQ16tW+Ii4xXyb9D0cVmUKcf3TvIQ9Rzj1oHU4z/hRjn3NOAIz9a/QErKx82KScepHc0nOeetGefWjPOOKEktEDdw4ApoPJyfwp5Hek5xyKYCcZ70owe360YxjIGKO3FAgPPakHHSnDFKeMdeaAGAEc+lKAeOfrmlPTA70A8mgB31oIJPXNIc7eaQZ54PFIZsaMGET5BAJzn1rQUdKoaV/x6nr941dBHAr82zqTnjajff8kfVYFJUIjujHB7UHOBigsaBkfWvKOsHGSOOaXGCcdcUh3fSk5zQBFdJvtZQw7Ej61zx+/wAk5rpjk9s1z10oW5l2H5c8Yr63heu1KpR+f6Hi5vT0jP5ES4x1JpFAz/nilA4pvIHPSvsjwx+OtIW/OmknkjrR1HfIoAUnIA5ozzjvSY9BSDrQAu7JznpW98LP+Sp2v/YGvf8A0faVgYG4f0roPhd/yVO1/wCwNe/+j7Ssavws0p/Ee50UUVyHQeW/H/8A5BXhb/sM/wDtndV5keoxg16b8fv+QV4W7/8AE5/9s7qvMgMc9q6qHwmFTcXp0/WmA845zSkAjr0pMdc8AVsQKM96T8qcvJx+NJwODgUxCHHPbFIBjrSnB4BGKTjgnNACFsOFweR1pSBnO3FKOg4pTzwtMQA8fd60A4xSkZX0NB6Dk8ikMPr09KQc/T0oxjtS57Y/KgA4PTisDx1cyW3hm5aLGXxG2ewJwa3lOT3zWZ4m0/8AtPRp7VWKu4BXAzyDxWdZNwaW9jfCyjGtCUtroreEoxF4csAoKgx7sHnqa1wcd6xvC7uNP+yTsDcWbGGQg5zjofpW1ENzEMOhBBr84p4OeIxbobO7PvMVio0KLrbr/PYdErbzngEd+9TbQPSjgcE/jQcYFfoOCwqwtGNFO9j4XFYh4mq6rVrgAAQfWgYoDdeaUHoK6jmHFePWjP5UAcf40cevWgA5J9RRnBzxS/y7UADrigQhA7ce9FKwGcn1xR/KgBemKTOT9KQE5zg5o7igYo9e9OB45PvwKaBx1pVwCKAH555oP3e9C8mgEEn+dABjH196ARnnrS0Dp/KgQHhfWhQM89aM5+tHXAxzQAAnnFLnPXg0nA9zS88cfrQA7PvSZ9M8UHA6mjqPagBBknrUg6VGOo5oYgDBNAAc7iScUIeQMmlzxyaPxOaAAE7skGn8k46UzpnpRuPuKANmzmhhs8GQdckdxTm1CAKSpLHsuMVihsggmgE5xXgVuHqFerKrUk2279P8j0oZlUpwUIpaGo+puz/u41A/2uatWV2bhDuCh15OOlYPzZ9KcJGXIU47H39qMRw/hZ0nClG0uj1CnmVaM+abuux0yHcD6daXkkfSmK2UXHTGeKMkHJ4r4GUOWTifRqV1cSVxFE7N/CM1zjnc5PPJzVrULtp2KJnyun1qkTznPNfdcP5dPC03Vqby/BHzuZYpVpKEdkO7dfzpOx44oHTJ/KmMTjn+VfRnmDgfbJoAyOppoAzzkn1o6Z9KBEhyDTQOp6UZ7g0hzmkMVuBit34Wf8lTtc/9Aa9/9H2lYA5I5roPhfgfFW2AOf8AiTXvPr+/tKzq/CzSn8R7nRRRXGdB5b8fv+QX4Wx/0Gf/AGzuq8z6HjGfWvTPj+M6V4W/7DX/ALZ3VeYnjrnmuqh8JhU3HHoWA+vtSHkDPfpSAjOSKGIJwDwK3MxQOeOlI2PbFAPrQTxQAADsDRjPI4NBboaQt1oEHGe5pe4Oc0ZyBwaUEUwEIPOaVRjHBoHTilPWgBGHPGcUYBHTPpS528cUHNIBFHPamzs6wO0KeZIFJVCcbj2GaX+I0ueeP1oY07HGeC9QN7f6uZLdIpjKHYoc+2PwxXYW4BZs/ermhHaaB4hnkkdIbe/XcCxwqsvUfjmujspY5ofMhZWRzkMOQfevlcHh5wzWTkul/wDhj6rMq8KmXwlDZ2/D/hiwB6GjHrj2pAOvOKdnI45Ir6o+VAqOMgUp9R1FAHfvR044oAUenfrSk8Z60gx3NJ1BNAC9wKQfdPX2oyM89KXdgEdKBDeo4pxU5z0GOmKOBkUe1AAc+vtSDv1/GnHBXoMUp7HgZPNAAAQOKUkcU0nnk0uRjGKYC5JPoKVQcfyApM0dsGkAuT09KVemfWm4J4PFLjI5zTAUnr1oPUDH60gHGehHel3emM0AOBAznikBHbrR9TRx0FIBSD978KDyOBxSHg//AF6Qlc/jQAc5xSj3ox6cUgHcmmIcenSg88c4pOCOvFCgfjQAZ+nFL070gwM/WlLYFAwx2pwxg85poPUDmk+lADhkkYHHrRjPsKQkk9aVfxxSAsQ3s0K7VYFR0yM4p9xqEsqmPAVWGDjrRZPbqJPtAB9ARVIkZOABk8V5KwmGrYmXNR1jZ83Rt/mdjrVYUlaej6dhTxx+VHPfrS4A5FJ06V6xxCDd3p3pk59qQgZ6nI9aF5JwQcc4NTUmqcXOWyLhBzkorqNU7WZepU4p3btmoQMsXHGevvUhPNc2Bqzq0IyqJp+f5m+Mpwp1pRg7od0AzS+lNA74pM859Oa6zmHMMit74W/8lTtf+wNe/wDo+0rnxz7c5zXQfC05+Klr1/5A17/6PtKyq/Cy6fxHulFFFcZ0nlvx/wD+QV4W/wCwz/7Z3VeYnnn0r074/wD/ACCvC/8A2Gf/AGzuq8wIORjGK6qHwmFTcUnrxx6Ug9h0pcHtjJpBg5zz9K3MwAG7pikwB0xS4BPAOfekHTkUAKSCeelA6k0mQO4peMj1oEBGB/8AWpcc5xSBskdcUvfOc0wAUpxjGOKTtxjFKOcegoADwOBRk8Djn0ozjnrml+vA7UAKOvI5obg470g7nFKfwxQBl69o0GtWqwXLMgVwwKYz+tM0PT5tPku45Lrz42feiHP7tceprWbp707HqM1jKhGUudaM6I4iah7Pp2E7egpenvQM88cUuecEdK2OcUHgelGenpSHAHegHOB0oAUnk8duMUDB9qQZwcY4pckD1pAKSB9cUYB5zzSE8j+tJjnsT1pgKB7An60vI6gUHuR3o6nr0oAU89ulNzntTj0OT0pucEe1ACnnnHSnEjimilx2oAf05PSkHSk56Z4pRxQAuT07UbjnngUuBnntQQOMY5oATGR1pcAHJOfrRjg96T06UCHZH40AYHFIMen4UEZ+hpDDjPsOlBHcinYHQdKQYx1oAUDnpSBgevQcUv40nfAxTEKTz6Ug/HFDYzyaB830oAUjt+NIRx1peO1Jgd+gNAAowDz9aT6Uvf8AxowCBg0AIKcOnQ0dCcUbiAOOaBiEcnPT60o4P60nbtSgcdCKBAxI6dcUhyMUueKQYH3v1qZNqLcVdlRSckpbCEnOcAU0KSckdfTrSoAOTyfWlBIA5rzcPhK1SSrYt3fSPRX/ADO6viacI+ywysur6v8AyE7Y9O1HTn+tLjDcnmjr9BXqHngDgZPA9KMgijjv1pR0yRSAAwA963/hac/FO1/7A17/AOj7SsBRkVv/AAs/5Kna/wDYGvf/AEfaVlV+FmlP4j3SiiiuM6Ty34/86V4W/wCwz/7Z3VeYY9TXp/x+/wCQX4W/7DX/ALZ3VeYn3rqofCYVNxCe/NB60HnFIemDW5mGCcijAxxS84xjFHQ0ANx6rSnHel69iB0pCOeP/wBdMQ7jaMGgYznijbuA70HjoPagA5x6GjGOhpT0xjpQCTQAd+gpepIzSd80vpQAcA8nil6DrQMZ5zQMjigAOSM8Uc+v5UhHzUvB6n8PWgABI4H50oHrS/LjpSE8e38qAF4J5z+NGRmmj6fWnKO+KAD+I0o4Pt0o29aUD2P50gDPJ9aac9SKcSoPTn0oHrj8KYCDpjpikG7NOI6cdaXnPv0oAbmgHnjmlxgckUoNACDPt+NOOKQdR3HWg5NAhRyTj86cBgUg64pcZGMUDF+vWg4xjoaQgcYx+FHGehNAgJ4GAaB6cn1pT6cmg/8A66AE7ZxTgSaTH5Uq8cEGgAH40c9Mce9Kc5PHPrS+tACdCMAenFJ/nil9x2pPXsaAEK46fnSYyc08hiKQ5zj0oAbz1p2DkHNIOeB0pfT9cUAHaj0NKe3WgjJ5AoAQnA46UZ9QMUYxn1oHHU/lQAmc45pe2OtI2PWlyeTQAnQ+ooyd2c0dT2oBAx1xQIXscik6dP5UoAIpDnHBpgNPXjNKMDGKUnjimjqfSgBenal6r14pcdPWk6jvSGAOcV0Hwt/5Kpa8f8wa9/8AR9pXPjleK6D4W8fFO1/7At7/AOj7Ssa3wM0p/Ee6UUUVxnSeW/H4Z0rwtj/oM/8AtndV5i/XHevTvj//AMgrwt/2Gf8A2zuq8xPXFddD4TCruJgCkUcZIGaX2C0Z9sGtjMdtI5BppHXk0DqO1KDxQITnOOKUDqcYoxjoMGjHPTNAAOMAc0Yycng4oByOAKQd+KYDjweopMds0DGcUvcYoAUc9TSgZGMjmm9/ajPegB2B70mAAPWkDcgkUvXOMUAavgfwTo2peDdAvr7+1Jbq6sIJpX/tW7Xc7RqWOBIAMknpxXO6NF5MF3CHldIL+8gQyyNI2xLmRVBZiScKAMknpSWulpa20VvbX+tQwRII44o9WulRFAwFAEmAAO1WbG0isoPJg8wpudyZJGkZmZizMWYkkliTknvXBhcNVpTlKpK6fqdFWrCcUoqx1/h7w9ZX1gLt7h7y4BOdPtSqzYyeSWPTj+EE8irOhy2KJe2c2mvaXFxdrHBK9mlyIOeUPmd/Xv3xXII2whlyCDkEcYq9Bq+owGVoL+7iMpy+yZl3H1ODzXY4tmKaNC7042PiKRtUhM1jBdiO4lgi2RnnJAwAAcduK2vE1vp0vhqW/thaDdfFLR7eAw7osfdYFRux6889649Ly5WIxpczCMyeaUDnBf8AvYz196W8vrq+dXvbme4ZRgGVy5HtzRyttBdFcg9O9Zeq24u9R0K0kedIJ7xkkEMzwswFvMwG5CDjKqevatT7tVNQsbe/WET+crRSeZG8M7xOrbSuQyEHozDr3rPE05VKUoQdm00n2KpSUJqUldJlfW9GttH1HQpLGS/UzXrRSLLfzyqy/Z5mwVdyOqqenat7S7WO7v4oLi6jtY3PzTScqnH+RWFDo9rHdQXDSX80kDF4/tF9PMqsVKkhXcjOGYdO5rTLcfjXNl2GrYaj7OtPmlfff8zTFVYVanNCNkdVq+l2Gj/ZA1neXNq06l78upjkQHkRhCQMjOMnNaPiC2sLzw9c3dilq+69WOxNtbmJypHMZG0FiPXnnv2rhxcTJH5aSSLGSG2hiASO+PWprnUb25limuby5lljOY3klZinOeCTxXbyPTUx5kdX4c0y3h0Gaa6iMWoPfrZZltFnMGQDkxsQOScZOT7VzGuWklhrF5bTPG8kcrKWjUKvXsBwPp2psGqX8M0s0N7dRzTHMkizMGf6kHmqzMWdmJ3MxySe5pqLTuxNpoQjPvXLaTpkWoQ3Nxc3GotK17dL8moTooCzyKoCq4AAAA4HauoXIz6Vkt4bsC8rK9/H5kjyMsV/Oi7mYsxCq4AySTwO9cOZYWtiaajQnyu++v6HZgMRSoTcqseZW8v1E8Il/wCxiJJZZSl1cxq0sjSNtWeRVBZiScAAc+lehaBoFne2Iumne7nBOdPtSqy8dyWPTj+EE81x2m2UGm2gtrRWWJWZhvdnJLMWYlmJJJJJ5NWkJjIZTtKnII7GuyEJRgot6pHLKSc3JLQ67whDaz+I7y3uNMhVTHIyxzhnaHAPHPBPuRn6U74f6ZZz3cdxeC1uXeXyktpZE4GOXKE5b0AwfXtXN2+q6hbvI8F9dRPKcuyTMpc+pweajF3ci6+1C4lFyW3ebvO/d67uuabi3cSkkaraSz+JWikiKWDXwgeWMZjQM/QMOAcHp2rW8W6cn2W9nsvJhtrO7+zmD7IkbA44IkBLOD15x646Vyj3dw0MkTTymJ38x0Lnazf3iO596ddaheXiKt5d3EyJ9xZJCwX6Anijld0xXVjifiJLOlnpiQ3FxAJL3YxglaNiPJlOMqQcZAP4VgaDJcxeKNHX7dfyJLNIjpLdyyKw8mQ4KsxHUA/hXe6xpNnrNvFDfxPIkUnmqUleMhsEZBUg9GI/GqOn+FtJsb6G8t4Z/tEJJjMl1LIFJUqThmI6Ejp3rlq0KsqyqRlaK6Hp4fGYeng50J07zd7SstNvmdDbRrNcRRyOsSuwUyNyFBPU+wrptY0S00zSnkto59SDAAXyOvkRn2CknPb5iPpXKjNSJJJGjpFI6o4w4ViAw9D611tNnlpnYXVqlr4Snm1i1s4Li4CCxhjhVJVx1Ykc4I/vE/ypNUtFtfCksmsWtlb31wyfYoYoVjkRR94sRyQR/ez/AIc22r6nJbmB9RvWhK7TG07lSPTGelE2sanLA0M2o3skTDBR52KkemM1PKyuZG1olibPRdcurizB1G2WHyo7mENsV25bYw5474qp44sray8RSx2kaxIUR2jTojFQSAO3096zv7SvluDcpe3S3JXaZRMwYj0znOKrSySSyPJM7O7HLMxyT9TVKLvcTatY8M1PUNQOsamBqmpIFvZ0VUvJVVQJWAAAbAAAHSvS/h7PNceEbOS5mmnlMk4LyuXYgTOBknJOAAKbc+B9BubmaeW0m82aRpXK3UqgsxyTgNgck9K29J0610mwis7GMx28ZYqpcvySWPJJPUk1hRozhNyk7pnbicTSq0oQhCzW7010Ox0HQLO9shdyTvdzjP8AxL7VlWXGTySx6cfwgnmpvC0Hn65cJJa29tp1uWnuUuIElMaL/BudSfbt3rlFYowKnaw5BHGD61OL662zr9qnKz/60eYcSY/vev41s4t31OJNHZ2AtLnTzqNtp1qXutWS3aMwKwjhI4ULjC59RWTNo0I8YvAsL/2UL8QM4B2Llvubux7etYdnf3VluNndTwbxhvKkK7vrjrTftU/kPD503ku/mGPedpb1I6Z96FFp6A5I67xNawNouqStZ29tLa6kbeAxxLHuTHQ4Hzcc5PNcRyfSrV5f3d6qC6up51T7ollZwPpk1W5x1yKcY2QpO4AYXBNI3HbilHHHUUo47Y4qiRBnPSl+o60nbtRjA5Oc0wGnj6UowCevFO2jI7jrRQA3bgelCjg08gE/SjBPHakMb9OK6H4W/wDJU7X/ALA17/6PtKwDx1rf+Fv/ACVS1/7A17/6PtKxrfAzSn8R7nRRRXGdJ5b8fudL8Lf9hr/2zuq8y79RXqPx6trufRfD0lnY316LfVhJKlnbSXDohtbhdxWME43MozjuK8rxfZH/ABIPEn/gjvP/AI1XTRklHVmNRNvQccc4FJ0+tIft2P8AkA+JM/8AYDvP/jVGL/8A6AHiQ8f9AO8/+NVtzx7mfK+w/AOe5pGx3PU9qbi+I50HxLz/ANQO8/8AjVBF9xjQPEn/AII7z/41Rzx7hyvsOPXtRj1OR71Hi/wf+JD4lz/2A7z/AONU4/bs/wDIB8Sn/uB3n/xqnzx7i5X2HjnP6UihiTntTQL7voPiX/wR3n/xqgC+H/MB8S/+CO8/+NUc8e4cr7EhHPtR0yO3tUe2+x/yAvEmf+wHef8AxqjF9wP7B8SY/wCwHef/ABqjnj3DlfYkOMc80men86YRf440HxJ/4I7z/wCNUD7dn/kA+JMf9gO8/wDjVHPHuHK+xJ0PB/GlA2j39BUf+ndtB8S/+CO8/wDjVH+nd9B8Sf8AgjvP/jVHPHuHK+xI2CPepLWCS5uo4IRmSRxGg9STgVB/p3fQfEn/AII7z/41T7ebUreVJYNF8URSqcq6aJeKVPsRFRzx7hyvseneKPD1hJoxttNitY7nTZIopZYyhaRWAUs4U7gQ3970NUbjwfpzf2hDBLdxz2lxb2wlldSjGRlBbaFBAG7pmuFW+1hTOy6X4sDXAImI0a9HmA9d37vnPvWtqHijWr3Szp50DxDFbsVZgujag5O3oMyK2AOuBisr20UjS1+hp6/oOkWXnQ2t/Il1bziKUTLI6Kp6MSIhtOR0G7I6E1DoGh6ZfS3EVxqUU0/yiBIpGhWZiTkbnTqMdNvJI5rAudT1u7hWG70/xdPEv3Ul0i+ZR9AY6msNS1axRhaWHi23343CLR75M/XEdVzK1uYmzvsdhfaNaQeFEgbT2F//AGmbZWEqF84OAX2cjGOOOeeOlSf8IZYMIP300ci3iWs8azCTbuAPDGNRuGfQiuNg1HU4oZIksPFiRyHc6Jo18A59SPK5NPm1vXJAu628YuVYMN2k35wR0P8Aq+oqb/3h28jp38JWM4i+yTXER/tRtPcysGBAydwwBzx0rRk0mK88N2umWEFwyDVnj2SzKHbaj5O7bgdM4wfxrgW1HVHQq2n+LCpk87adGvseZ/f/ANX97361NLrWtylDLa+MXZGDqW0m/O1sYyP3fBx3pX/vB8jsIPBmm3F7pQS5uDbXizb9jhsNH/dYouR/wEVV0bSdJPkataG+lhW/htoo3KIwfglnwD8uegH51zLa1rbOjtbeMTImdrnSb8lc9cfu+M1DZ6jqtnuFpp3iyAP94RaNfLux64jp3/vBbyO38W6bDJ9pumjlmkfVzB5cQRWYeXkAPtLde2SPaq0fhjSrjWTZQz3CSW1s892plEmHGP3asE6jPJ2n2Fcp/a2sFgTZeL8iTzs/2Pf534xu/wBX1x3p8uta3LJFJJZ+MHkiJKM2kX5KZ9D5fFCaStzBv0OjHh7SZIrq9trq5uLO3tRM0S5Vi+SCA7IMqMddtR/EUBtbtQAQptIhgnkDBrn/AO2daNz9p+x+L/tG3b5v9kX+7Hpny84qC6vNQupRJdaX4pmkAADyaLfMQB2yYqakr3bE07WsdnqHhfTItfbS7L7dNLEplmaWZI0WPaDncFJ4J/u/41oad4f0qxnuJPLa8hn0p7mMSENsIxnaSg55GGwMc8HPHA/2pq32v7V9h8W/asY87+x77fjGPveXmn/2zrRnSY2fi8zICqyHSL/coPUA+Xmle6+IfyOmh8N6T/ZtlPd3dxC98jvEFDSbSD8q4WM7j68r9Kz7Vf7O8KXVxwLjUX+zxnuIl5c/icD8KyY9Y1mJHSOz8XIkhJcLpF+AxPUkeXzmi+1S9vILSJ9D8QpHbRCKNU0G9HGSSTmLqSeafMurFZ9EbjQW8vw/M4tII7hL4RGVVO9hszySSe/QYHtW7fabZCPUbRbS3W1g0tLmKYRqHMnUNv6nJyMZxxXDjWdZ+zfZhZ+Lxb7dnlf2Pf7Nvpjy8YqNtT1V7UWraf4sNqOkJ0a+KD8PKxRddw17He6tptiketWiWtutraWUUtvMsY3lj3Ljk5ORye1Ymh6ebXQ9au57IG/gSEwpcQhgFdsFgrDB474rnW1TVXt0tpNN8VvbJ0hbRr4oP+A+XirN1r2rz6nNfrpniiC4k4zDol8mB2UYjzjgUk0la49ex2mqaZZWLeILq0tYGuYIrcpC0YdYi+N5CHI/wp+rabZ2C61dWNpbvdR/Z9sLRrIsW/G7CEEc/wD6q4GDVNTguGuItO8WJOww0i6NfBj9T5WTRHqmpw3Dzwaf4sjmf70iaNfBm+p8rJpafzBr2Og8S6Xax+N/sNuPKtpZYlKxnGzcFyB6davT+ELGWS4itZriFoL5LQvO6srhscjCjBGenNcdBqF7FfRXf9i+JXmSQS5fQ707mBzz+65qzq+u6tqty811pficgtvWIaJfbIz/ALIMZxVX2tIVvI6iHwnp9zcIscl3FHHftYyLI6lnwCdynaMdOnP1otfCmm3UtmVku4opL2S0dXkUs21WIZTtGOVxjB61zNt4g1iG/tbt9M8U3L2x3RrcaLfOo/Dy6hvta1e8uhcTad4rMisWj/4k19+7yc4X93xSv/eHbyO38JaJBZarot7G8xlkuriEq5G3aqOB268VQ0zwrb39srXby29zPFLNCVmDbgp67NnA5HV81yj61rjSI7WnjEvGSyN/ZN9lSRgkHy+Dikh1nW4IRDDZeMI4hnCJpN8F568eXRfrzBbyO4j07Trh/CkUdqYXuY2LSARtnA53AoQx9z09Kq23hayml0+OaW4abUHnCSRFQkOzPUY5/AjFchDq2swxRxQ2Hi+OKNtyIukXwCn1AEfB5NJHqusRQyRRaf4tWKQkui6PfANnrkeXzT9JB8jsbLwnp8w06Fprkz3drLN5iuuxWX0G3JB+tcRyM/L+dSx6prEZiKaf4tQxKUj26PfDYp6gfu+B7VVL3Z/5gfiX/wAEV7/8aqoyS3ZLTeyJAD04p2PTrUO66/6AfiT/AMEV5/8AGqBJd5GdD8Sf+CK8/wDjVVzx7k8r7EoUEdT17UuPmFRCS6B/5AfiT/wRXn/xqgyXXX+w/Ev/AIIrz/41Rzx7hyy7EoGDSY5qISXYP/ID8Sf+CK8/+NUeZdY/5AfiX/wRXn/xqnzx7hyy7Ex68nNAHPFQmS7/AOgF4k/8EV5/8apQ91g50PxKP+4Fef8Axqlzx7hyy7EhBzwc5oAP97rUfmXeBjQ/Emf+wFef/Gqbvu/+gH4lI/7AV5/8ao549w5X2JgO+ePSt/4Wf8lTtf8AsC3v/o+0rmi93/0AvEv/AII7z/41XUfCeC8l+JMV1Jper2ttFpN1E0t5p09sm9prYqoaRFBJCMcD+6ayqyTi0maU4tS2PcaKKK5DoCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The highest rates occur in Eastern Asia, South America, and Eastern Europe.",
"    </div>",
"    <div class=\"reference\">",
"     Stewart B, Keihues P. World Cancer Report, International Agency for Research on Cancer Press, Lyon France 2003. p.194.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30898=[""].join("\n");
var outline_f30_11_30898=null;
var title_f30_11_30899="Vitreous aspirate vitrectomy";
var content_f30_11_30899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Vitreous aspirate and vitrectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 602px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30899=[""].join("\n");
var outline_f30_11_30899=null;
var title_f30_11_30900="Cozen fracture";
var content_f30_11_30900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Cozen fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Right proximal tibial fracture. B) Healed fracture with valgus deformity in proximal tibia. C) Teleogram demonstrating right lower extremity with valgus alignment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Phillips, MD, and Scott B Rosenfeld, MD, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30900=[""].join("\n");
var outline_f30_11_30900=null;
var title_f30_11_30901="Liposomal morphine: Pediatric drug information";
var content_f30_11_30901=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liposomal morphine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?18/16/18694?source=see_link\">",
"    see \"Liposomal morphine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/37/41555?source=see_link\">",
"    see \"Liposomal morphine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8776643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DepoDur&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10512372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10512486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/16/18694?source=see_link\">",
"      see \"Liposomal morphine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Epidural: Surgical pain: Single dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cesarean section: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lower abdominal or pelvic surgery: 10-15 mg;",
"     <b>",
"      Note:",
"     </b>",
"     Some patients may benefit from a 20 mg dose; however, the incidence of adverse respiratory effects may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Major orthopedic surgery of the lower extremity: 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     For epidural use only (at the lumbar level); do not administer I.V., I.M., or by the intrathecal route; not recommended for administration into thoracic epidural space or higher (has not been studied). Do not use if suspect vial has been frozen. Gently invert vial to resuspend particles immediately before use (avoid aggressive agitation). May administer undiluted or may dilute up to 5 mL total volume in preservative free NS. Product does not contain preservative; drug must be administered within 4 hours after withdrawal from vial. Do not use in-line filter during administration. Do not administer within 15 minutes of epidural lidocaine and epinephrine; do not administer any other medication into the epidural space for at least 48 hours after DepoDur&reg;.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8776933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, extended release liposomal suspension, epidural, as sulfate [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DepoDur&reg;: 10 mg/mL (1 mL, 1.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8776649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F8776641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10512379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in carton under refrigeration, 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not freeze; do not use if product has been frozen or is suspected of having been frozen. Check freeze indicator (located on carton) before administration; do not administer if indicator bulb is pink or purple (this indicates drug may have been frozen). May store unopened vials at room temperature for up to 7 days. After withdrawal from vial, drug may be held at room temperature for &le;4 hours before use. Do not heat or gas sterilize. Discard unused portion of vial (vial does not contain preservatives). Do not mix with other medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10512373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epidural (at the lumbar level) single-dose management of surgical pain in adults; may be used in women undergoing cesarean section following clamping of the umbilical cord (FDA approved in adults) (not for use in vaginal labor and delivery)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8775522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Morphine may be confused with HYDROmorphone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Morphine sulfate may be confused with magnesium sulfate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       MSO",
"       <sub>",
"        4",
"       </sub>",
"       and MS are error-prone abbreviations (mistaken as magnesium sulfate)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8776730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypertension, hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever, headache, insomnia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, constipation, dyspepsia, flatulence, nausea, paralytic ileus, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder spasm, oliguria, urinary retention (may be prolonged)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, hematocrit decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, hypoesthesia, paresthesia, rigors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, hypercapnia, hypoxia, oxygen saturation decreased, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Sweating increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Cardiac arrest, confusion, lethargy, obtundation, respiratory arrest. Apnea and prolonged respiratory depression have occurred following subarachnoid puncture.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10512375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to morphine sulfate or any component; severe respiratory depression or respiratory depression in a setting without resuscitative equipment or appropriate monitoring; acute or severe asthma; upper airway obstruction; GI obstruction especially known or suspected paralytic ileus; suspected or known CNS injury, increased ICP, circulatory shock, or conditions that preclude an epidural injection",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10512377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone). Use with caution in patients with biliary tract disease or acute pancreatitis (morphine may cause spasm of the sphincter of Oddi).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When administered to a pregnant woman, epidural morphine readily passes into the fetal circulation and may result in respiratory depression in the newborn; resuscitative equipment and naloxone should be available for the neonate.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10512376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CNS and respiratory depression may occur. Use with extreme caution in patients with COPD, cor pulmonale, hypoxia, hypercapnia, pre-existing respiratory depression, significantly decreased respiratory reserve, head injury, increased ICP, or other intracranial lesions. Severe hypotension may occur; use with caution in patients with circulatory shock, hypovolemia, impaired myocardial function, or those receiving drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Warn patient of possible impairment of alertness or physical coordination. Interactions with other CNS drugs may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prior to administration via epidural, evaluate benefits versus risks in patients with infection at injection site, bleeding diatheses, or anticoagulation therapy. Only physicians experienced in the techniques and familiar with the clinical management of the adverse effects of epidural drug administration should administer drugs via the intraspinal route. When morphine is used via the epidural route, severe adverse effects may occur, including significant respiratory depression; facilities must be properly equipped to resuscitate patients; monitor patients for delayed sedation. Patients must be closely monitored for a minimum of 48 hours (due to prolonged effects of extended release epidural preparation). Safety and efficacy have not been established in pediatric patients. Freezing may adversely affect modified-release mechanism of DepoDur&reg;; check freeze indicator within carton prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8776766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8776771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8776708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8776709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies; however reduced growth and behavioral abnormalities in offspring have been observed. Morphine crosses the human placenta. The frequency of congenital malformations has not been reported to be greater than expected in children from mothers treated with morphine during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     DepoDur&reg; is administered as a single dose for acute, surgery-induced pain. It may be used in women undergoing cesarean section following clamping of the umbilical cord; not for use in vaginal labor and delivery.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Refer to the Morphine, Systemic monograph for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10512487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status, oxygen saturation, pain relief (if used for analgesia), level of sedation.",
"     <b>",
"      Note:",
"     </b>",
"     Resedation may occur; monitor patients closely for &ge;48 hours.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10512380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10512684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     See Table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Dosage",
"         </b>",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Form / Route",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Analgesia",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Peak",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Duration",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Epidural",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1 h",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12-20 h",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10512485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Distributes to skeletal muscle, liver, kidneys, lungs, intestinal tract, spleen, brain, and into breast milk; crosses placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 30% to 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: In the liver via glucuronide conjugation to morphine-6-glucuronide (active) and morphine-3-glucuronide (inactive)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10512488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/37/41555?source=see_link\">",
"      see \"Liposomal morphine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol. Morphine may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Morphine may cause itching, low blood pressure, or blurred vision (use caution when climbing stairs or changing position from sitting or lying to standing), loss of appetite, dry mouth, nausea, vomiting, or constipation (consult prescriber about use of stool softeners and/or laxatives). Report chest pain, slow or rapid heartbeat, acute dizziness, or persistent headache; changes in mental status; swelling of extremities or unusual weight gain; changes in urinary elimination or pain on urination; acute headache; back or flank pain; muscle spasms; blurred vision; skin rash; or shortness of breath.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10512489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     DepoDur&reg; is an extended release sterile suspension of multivesicular liposomes in NS; liposomes range in size from 17-23 micrometers (median diameter); the pharmacokinetics, safety, and efficacy of DepoDur&reg; have not been studied in patients &lt;18 years of age and use in these patients is",
"     <b>",
"      not",
"     </b>",
"     recommended",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16025 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30901=[""].join("\n");
var outline_f30_11_30901=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776643\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512372\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512486\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776933\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776649\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776641\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512379\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512373\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775522\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776730\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512375\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512377\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512376\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776766\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776771\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776708\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776709\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512487\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512380\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512684\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512485\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512488\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10512489\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16025\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16025|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/16/18694?source=related_link\">",
"      Liposomal morphine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/37/41555?source=related_link\">",
"      Liposomal morphine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_11_30902="Skin anatomy";
var content_f30_11_30902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54157&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin and common disorders. The skin is the body's largest organ. It covers the entire body and weighs approximately six pounds. The skin includes two primary layers: the outer epidermis and the inner dermis. The epidermis has important protective functions. It protects against injury and excessive water loss. It also prevents disease-causing microorganisms from entering the body. The thick dermis contains blood vessels, nerve endings, and glands that respond to heat, pressure, and pain. Beneath the dermis, the subcutaneous layer is made up of loose connective tissue and fat (adipose) tissue. This layer acts as a cushion for the skin, helps maintain body heat, and is a store of energy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30902=[""].join("\n");
var outline_f30_11_30902=null;
var title_f30_11_30903="Renal manifestations of autosomal dominant polycystic kidney disease";
var content_f30_11_30903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal manifestations of autosomal dominant polycystic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30903/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30903/contributors\">",
"     Arlene B Chapman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30903/contributors\">",
"     Frederic F Rahbari-Oskoui, MD, MSCR",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30903/contributors\">",
"     William M Bennett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30903/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30903/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30903/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30903/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/11/30903/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant polycystic kidney disease (ADPKD) often leads to progressive renal failure due in part to continued enlargement of the cysts. Kidney size typically increases to more than five times normal years prior to the loss of kidney function, and measured total kidney volume is the strongest predictor for the development of renal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/1\">",
"     1",
"    </a>",
"    ]. Other renal manifestations that can occur include hypertension, urinary tract infection, concentrating defect, hematuria, nephrolithiasis, acute or chronic flank and abdominal pain; protein excretion is generally not a prominent feature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30582?source=see_link\">",
"     \"Hypertension in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link\">",
"     \"Urinary tract infection in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEMATURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria, which is often grossly visible, occurs at some time in the course in approximately 35 to 50 percent of patients with ADPKD, usually occurs prior to loss of kidney function, and may be the presenting symptom of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. A precipitating event, such as a urinary tract infection or strenuous activity, can often be identified and recurrent episodes are not uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/4\">",
"     4",
"    </a>",
"    ]. Gross hematuria is associated with more rapid progression of kidney disease in ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rupture of a cyst into the collecting system is thought to be responsible for the development of hematuria. Although hemorrhage into a cyst is also common, the typical presentation is pain rather than hematuria since many cysts do not communicate with the collecting system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/2\">",
"     2",
"    </a>",
"    ]. The hematuria due to cyst rupture generally resolves within two to seven days with conservative therapy consisting of bed rest and hydration, analgesics that excluding nonsteroidals, and in some cases holding antihypertensive medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/4\">",
"     4",
"    </a>",
"    ]. Occasionally, bleeding can persist for several weeks. With unusual and severe bleeding, percutaneous arterial embolization or even nephrectomy may become necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gross hematuria is more likely among individuals with larger kidneys (particularly when &gt;15 cm in length), hypertension and higher plasma creatinine concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Frequent episodes of gross hematuria before the age of 30 may be associated with worse renal outcomes; this may possibly reflect accelerated cyst expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrolithiasis, which is described below, is another cause of hematuria, usually microscopic, in patients with ADPKD. The hematuria should resolve with passage or removal of the stone. Prolonged or recurrent hematuria, particularly in a man over the age of 50, raises the possibility of an underlying renal cell carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/2\">",
"     2",
"    </a>",
"    ] or of an unrelated problem such as bladder cancer or IgA nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Renal cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONCENTRATING DEFECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with autosomal dominant polycystic kidney disease have a mild concentrating defect. Patients with ADPKD most often complain of increased thirst, polyuria, nocturia, and urinary frequency. A decrease in urinary concentrating ability is one of the earliest manifestations of ADPKD. It is initially mild and worsens with increasing age and declining kidney function. The renal concentrating defect is closely related to the severity of anatomical deformities induced by the cysts independent of age and GFR. In a series of 53 children with a mean age of 12 years, nearly 60 percent had an abnormal response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/9\">",
"     9",
"    </a>",
"    ]. In one series of 177 adult patients with normal kidney function, all patients had a modest impairment in concentrating ability in response to overnight water deprivation, which worsened with age in parallel to the decline in concentrating ability of unaffected family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concentrating defect may not be clinically evident, except if a history of polydipsia or polyuria is elicited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/11\">",
"     11",
"    </a>",
"    ]. The underlying cause is not known, but disruption of tubular architecture, defect in principal cell function, or early tubulointerstitial disease are postulated factors. A central cause has been excluded since vasopressin levels are elevated in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/11\">",
"     11",
"    </a>",
"    ]. The increase in AVP concentrations may be a compensatory response that occurs early in the course of the disease in order to preserve water balance. This was suggested by a carefully performed water deprivation study of 30 individuals with and without ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/12\">",
"     12",
"    </a>",
"    ]. All subjects had an estimated GFR &ge;60",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73m2. After at least 14 hours of water deprivation, compared with age- and sex- matched healthy controls, the maximal urine osmolality was lower among ADPKD patients (915 versus 758",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    respectively). At the time at which the urinary concentrating capacity was at a plateau (implying maximal concentrating capacity), ADPKD patients had a higher mean plasma osmolality and higher mean plasma levels of AVP and an AVP precursor, copeptin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROTEINURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteinuria is not considered a major feature of ADPKD. In one study of 270 patients, for example, mean urinary protein excretion was 260",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/13\">",
"     13",
"    </a>",
"    ]. Only 48 (18 percent) excreted more than 300 mg of protein per day. Patients with more advanced renal dysfunction have more proteinuria (mean about 900",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Overall, secondary focal segmental glomerulosclerosis plays a relatively minor role in most patients in the progression of this disorder to renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30582?source=see_link\">",
"     \"Hypertension in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The nephrotic syndrome has rarely been reported and usually reflects a superimposed glomerular disease. One review found that focal segmental glomerulosclerosis was most common but minimal change disease, membranous nephropathy, IgA nephropathy, and membranoproliferative glomerulonephritis also occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/16\">",
"     16",
"    </a>",
"    ]. This report did not present sufficient information to distinguish primary from secondary glomerulosclerosis; as noted above, however, the latter seems to be extremely unusual in ADPKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NEPHROLITHIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kidney stones occur in up to 25 percent of patients with ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In contrast to the predominance of calcium oxalate in idiopathic stone formers, more than one-half of stones in ADPKD are composed of uric acid with most of the remainder being composed of calcium oxalate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased renal volume may be a risk factor for nephrolithiasis in patients with ADPKD. In one study, renal volume determined by unenhanced CT was greater in 35 patients with ADPKD and nephrolithiasis compared with those who had ADPKD but no nephrolithiasis (508 versus 220 mL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/19\">",
"     19",
"    </a>",
"    ]. However, in the CRISP study of 241 individuals, no association between nephrolithiasis and kidney volume could be established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/1\">",
"     1",
"    </a>",
"    ]. Other abnormalities that predispose to stone disease include low urinary volume, low urinary citrate and, less often, hyperuricosuria and hypercalciuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. The factors responsible for the hypocitraturia are not well understood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible presence of a kidney stone should be suspected in any ADPKD patient with acute flank pain (see below). However, establishing the diagnosis by ultrasonography is more difficult than in idiopathic stone formers because of the large cysts obscuring the view of the collecting system and of calcifications which may be present in the cyst walls. Most stones can be detected by intravenous pyelography, but CT scanning is more sensitive for the detection of small or radiolucent stones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/18\">",
"     18",
"    </a>",
"    ]. In the study cited above, among 125 patients with ADPKD, unenhanced CT detected calculi in 32 of 35 patients who had nephrolithiasis, including 20 patients in whom ultrasound failed to detect calculi [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of obstructing stones is more difficult than in patients with idiopathic stone disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/17\">",
"     17",
"    </a>",
"    ]. Dilation of the collecting system is often absent due to the presence of peri-pelvic cysts. Cystoscopy may be complicated by an infected cyst, while the large cysts may make percutaneous nephrostomy or extracorporeal shock-wave lithotripsy (ESWL) harder to perform. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27079?source=see_link\">",
"     \"Management of ureteral calculi\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these concerns, ESWL has been used successfully in patients with small stones (less than 2 cm in diameter) in the renal pelvis or calyces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/18\">",
"     18",
"    </a>",
"    ]. The frequency of residual fragments is higher in ADPKD than in other stone formers, a probable reflection of attempts to minimize the number of shock waves in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/18\">",
"     18",
"    </a>",
"    ]. Percutaneous nephrolithotomy has also been used in a limited number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FLANK AND ABDOMINAL PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flank and abdominal pain is a common problem in PKD and can be due to renal or extrarenal etiologies. Acute pain related to the kidney may be caused by infections (cystic or parenchymal), nephrolithiasis, or cyst hemorrhage. Pain may also be caused by cysts in the liver. An accurate diagnostic workup including a thorough clinical history, physical exam, urinalysis, urine cultures, and imaging studies usually identifies the cause of pain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link\">",
"     \"Urinary tract infection in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic kidney pain is more common in advanced disease in patients who have enlarged kidneys. It is often dull and persistent and is thought to reflect either stretching of the capsule or traction on the renal pedicle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the location of pain can vary and patients can have pain unrelated to the kidneys. In a review of 171 patients with PKD who filled out a questionnaire, the following order of frequency of pain was noted: low back pain, abdominal pain, headache, chest pain, and leg pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/23\">",
"     23",
"    </a>",
"    ]. The severity of pain was usually moderate (4 to 5 out of 10).",
"   </p>",
"   <p>",
"    Massive polycystic liver enlargement, although uncommon, may also cause pain. On the other hand, acute pain suggests a superimposed complication, such as hemorrhage into a cyst, torsion or infection of a cyst, or an obstructing stone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=see_link\">",
"     \"Urinary tract infection in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The great majority of patients require no specific therapy other than non-opioid analgesics (possibly including nonsteroidal antiinflammatory drugs for a limited duration). However, some patients have persistent pain that is severe enough to diminish the quality of life or to require opiates for pain control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In this setting, ultrasonography, CT-scan, or MR imaging should be performed to see if a large cyst is present in the area of pain. If so, invasive management (either CT-guided aspiration and sclerosis or surgical drainage) may be considered.",
"   </p>",
"   <p>",
"    The following table summarizes the differential diagnosis and treatment of renal pain in ADPKD patients (",
"    <a class=\"graphic graphic_table graphicRef67374 \" href=\"mobipreview.htm?24/13/24797\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RENAL CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal cell carcinoma is an infrequent complication of ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. It does not appear to occur with increased frequency when compared to the general population, but there are a number of different clinical characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients frequently present with fever (32 versus 7 percent in patients without ADPKD who develop renal cell carcinoma).",
"     </li>",
"     <li>",
"      The tumors are more often bilateral at presentation (12 versus 1 to 5 percent), multicentric (28 versus 6 percent), and sarcomatoid in type (33 versus 1 to 5 percent). These observations suggest the presence of multiple foci of cellular proliferation, although the absence of increased prevalence suggests a possible alteration in the biologic behavior of this tumor when it develops in ADPKD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of renal cell carcinoma is difficult to establish in ADPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/29\">",
"     29",
"    </a>",
"    ]. Findings such as hematuria, a flank mass, or, due in part to bleeding into cysts, a complex cyst (or cysts) on ultrasonography, CT scanning, or MR imaging are common in ADPKD in the absence of malignancy. Some clinical clues may be helpful. As an example, the possible presence of an underlying malignancy should be suspected if the patient complains of systemic signs and symptoms (fever, anorexia, fatigue, weight loss) that are out of proportion to the severity of the renal disease and unassociated with demonstrable renal infection or if there is rapid growth of a complex cyst. Percutaneous aspiration and cytologic examination can be performed on suspicious cysts. In addition, CT scanning, using thin slices in areas of interest, and MR imaging without and with gadolinium enhancement are often able to distinguish malignancy from a complex cyst [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/28\">",
"     28",
"    </a>",
"    ]. If present, evidence of metastatic disease to the local lymph nodes or inferior vena cava is also important diagnostically.",
"   </p>",
"   <p>",
"    The administration of gadolinium during MR imaging has been strongly linked to the often severe disease called nephrogenic systemic fibrosis among patients with moderate to severe renal disease, particularly those requiring dialysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .) As a result, it is recommended that gadolinium-based imaging be avoided, if possible, in patients with ESRD , kidney transplant with impaired kidney function, or an estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    In case of absolute necessity, the use of lower doses of a high-relaxivity linear gadolinium chelate such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/45/25301?source=see_link\">",
"     gadobenate dimeglumine",
"    </a>",
"    (Multihance) seems to be safer than standard dose of a linear dose chelate such as Omniscan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/31\">",
"     31",
"    </a>",
"    ]. There is no consensus among experts concerning the decision to administer gadolinium among patients with an estimated GFR between 30 and 60",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR NEPHRECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyst and total renal size increase progressively over time, even though cyst formation occurs in less than five to ten percent of nephrons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/32\">",
"     32",
"    </a>",
"    ]. Men over the age of 50 may have enormous kidneys that can reach 40 cm in length (three times normal volume) and 8 kg in weight, usually associated with significant renal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/2\">",
"     2",
"    </a>",
"    ]. In this setting, some patients will have disabling symptoms (including marked fatigue and anorexia due to pressure on intraabdominal organs) and can develop ventral (abdominal wall) hernias; these may be relieved by nephrectomy, which can be performed by an open procedure or, if possible, laparoscopically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrectomy may also be considered prior to renal transplantation in the presence of recurrent infection, suspected malignancy, or extension of the native polycystic kidney into the potential pelvic surgical site. However, there is no indication for routine pre-transplant nephrectomies among ADPKD patients.",
"   </p>",
"   <p>",
"    Severe renal hemorrhage is also a rare indication for nephrectomy, especially in case of contraindication or failure of embolization procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial cells adjacent to the walls of proximal-type cysts (those that have a sodium concentration similar to that in the plasma (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=see_link\">",
"     \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    )) also can produce erythropoietin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/34\">",
"     34",
"    </a>",
"    ]. This response, which may again be mediated by focal areas of ischemia, probably accounts in part for several observations that have been made in polycystic kidney disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with advanced renal insufficiency, plasma erythropoietin levels in polycystic kidney disease are roughly twice as high as those seen in other renal diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/34\">",
"       34",
"      </a>",
"      ]. Although previously reported to be associated with a modestly higher average hemoglobin concentration and hematocrit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/35\">",
"       35",
"      </a>",
"      ], ADPKD participants in the Modification of Diet in Renal Disease (MDRD) Study did not have higher hemoglobin levels. Many of these patients were treated with ACE inhibitors, which can reduce erythrocytosis.",
"     </li>",
"     <li>",
"      Increased erythropoietin production also may occur early in the course, as approximately 5 percent of nonazotemic men with ADPKD have a clearly elevated hemoglobin concentration (above 18",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30903/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/44/35523?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/24/38277?source=see_link\">",
"       \"Patient information: Polycystic kidney disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9123853\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal dominant polycystic kidney disease (ADPKD) often leads to progressive renal failure due in part to continued enlargement of the cysts. Other renal manifestations include hypertension, urinary tract infection, concentrating defects, hematuria, nephrolithiasis, and acute or chronic flank and abdominal pain; protein excretion is generally not a prominent feature. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematuria occurs in 35 to 50 percent of patients and may be the presenting symptom of the disease. Hematuria due to cyst rupture generally resolves with bed rest and hydration, although with unusual and severe bleeding, percutaneous arterial embolization or even nephrectomy may become necessary. Gross hematuria is more likely among individuals with larger kidneys, hypertension and higher plasma creatinine concentrations, and is associated with more rapid progression of kidney disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hematuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many patients have a mild concentrating defect which may not be clinically evident unless a history of polydipsia or polyuria is elicited. The underlying cause is not known. A central cause has been excluded since vasopressin levels are elevated in this disorder. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Concentrating defect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kidney stones occur in up to 20 percent of patients. More than one-half of stones in ADPKD are composed of uric acid with most of the remainder being composed of calcium oxalate. Increased renal volume may be a risk factor for nephrolithiasis. Other abnormalities that predispose to stone disease include low urinary volume, low urinary citrate and, less often, hyperuricosuria and hypercalciuria. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Nephrolithiasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flank and abdominal pain is common and may be caused by cystic or parenchymal infections, nephrolithiasis, or cyst hemorrhage. Chronic kidney pain is more common in advanced disease in patients who have enlarged kidneys and may reflect either stretching of the capsule or traction on the renal pedicle. Massive polycystic liver enlargement, although uncommon, may also cause pain. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Flank and abdominal pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal cell carcinoma is an infrequent complication of ADPKD. The diagnosis of renal cell carcinoma is more difficult to establish in ADPKD than in the general population since findings such as hematuria, a flank mass, or complex cysts on ultrasonography, CT scanning, or MR imaging are common in ADPKD in the absence of malignancy. Malignancy should be suspected if the patient complains of systemic signs and symptoms that are out of proportion to the severity of the renal disease, or if there is rapid growth of a complex cyst. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Renal cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for nephrectomy include disabling symptoms due to massively enlarged kidneys and development of ventral (abdominal wall) hernias. Nephrectomy may also be considered prior to renal transplantation in the presence of recurrent infection, suspected malignancy, or extension of the native polycystic kidney into the potential pelvic surgical site. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Indications for nephrectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/1\">",
"      Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/2\">",
"      Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/3\">",
"      Rizk D, Chapman AB. Cystic and inherited kidney diseases. Am J Kidney Dis 2003; 42:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/4\">",
"      Gabow PA, Duley I, Johnson AM. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1992; 20:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/5\">",
"      Ubara Y, Katori H, Tagami T, et al. Transcatheter renal arterial embolization therapy on a patient with polycystic kidney disease on hemodialysis. Am J Kidney Dis 1999; 34:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/6\">",
"      Milutinovic J, Fialkow PJ, Agodoa LY, et al. Clinical manifestations of autosomal dominant polycystic kidney disease in patients older than 50 years. Am J Kidney Dis 1990; 15:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/7\">",
"      Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 1997; 8:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/8\">",
"      Dedi R, Bhandari S, Turney JH, et al. Lesson of the week: Causes of haematuria in adult polycystic kidney disease. BMJ 2001; 323:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/9\">",
"      Seeman T, Dusek J, Vondr&aacute;k K, et al. Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 2004; 53:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/10\">",
"      Gabow PA, Kaehny WD, Johnson AM, et al. The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 1989; 35:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/11\">",
"      Torres VE. Vasopressin antagonists in polycystic kidney disease. Kidney Int 2005; 68:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/12\">",
"      Zittema D, Boertien WE, van Beek AP, et al. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol 2012; 7:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/13\">",
"      Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/14\">",
"      Jafar TH, Stark PC, Schmid CH, et al. The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005; 67:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/15\">",
"      Zeier M, Fehrenbach P, Geberth S, et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992; 42:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/16\">",
"      Contreras G, Mercado A, Pardo V, Vaamonde CA. Nephrotic syndrome in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995; 6:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/17\">",
"      Gabow PA. Autosomal dominant polycystic kidney disease--more than a renal disease. Am J Kidney Dis 1990; 16:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/18\">",
"      Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis 1993; 22:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/19\">",
"      Nishiura JL, Neves RF, Eloi SR, et al. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol 2009; 4:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/20\">",
"      Grampsas SA, Chandhoke PS, Fan J, et al. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 36:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/21\">",
"      Al-Kandari AM, Shoma AM, Eraky I, et al. Percutaneous nephrolithotomy for management of upper urinary tract calculi in patients with autosomal dominant polycystic kidney disease. Urology 2009; 74:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/22\">",
"      Umbreit EC, Childs MA, Patterson DE, et al. Percutaneous nephrolithotomy for large or multiple upper tract calculi and autosomal dominant polycystic kidney disease. J Urol 2010; 183:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/23\">",
"      Bajwa ZH, Sial KA, Malik AB, Steinman TI. Pain patterns in patients with polycystic kidney disease. Kidney Int 2004; 66:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/24\">",
"      Gibson P, Watson ML. Cyst infection in polycystic kidney disease: a clinical challenge. Nephrol Dial Transplant 1998; 13:2455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/25\">",
"      Elzinga LW, Barry JM, Torres VE, et al. Cyst decompression surgery for autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1992; 2:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/26\">",
"      Elzinga LW, Barry JM, Bennett WM. Surgical management of painful polycystic kidneys. Am J Kidney Dis 1993; 22:532.",
"     </a>",
"    </li>",
"    <li>",
"     Chapman, A, Rahbari-Oskoui, F. Renal cystic disorders. In: Therapy in Nephrology and Hypertension, 3rd, Wilcox, CS (Eds), Saunders, Philadelphia 2008..",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/28\">",
"      Kumar S, Cederbaum AI, Pletka PG. Renal cell carcinoma in polycystic kidneys: case report and review of literature. J Urol 1980; 124:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/29\">",
"      Keith DS, Torres VE, King BF, et al. Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 4:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/30\">",
"      Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/31\">",
"      Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010; 31:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/32\">",
"      Grantham JJ, Geiser JL, Evan AP. Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int 1987; 31:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/33\">",
"      Dunn MD, Portis AJ, Elbahnasy AM, et al. Laparoscopic nephrectomy in patients with end-stage renal disease and autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/34\">",
"      Eckardt KU, M&ouml;llmann M, Neumann R, et al. Erythropoietin in polycystic kidneys. J Clin Invest 1989; 84:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/35\">",
"      Milutinovic J, Fialkow PJ, Agodoa LY, et al. Autosomal dominant polycystic kidney disease: symptoms and clinical findings. Q J Med 1984; 53:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30903/abstract/36\">",
"      Gabow PA, Ikl&eacute; DW, Holmes JH. Polycystic kidney disease: prospective analysis of nonazotemic patients and family members. Ann Intern Med 1984; 101:238.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1680 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30903=[""].join("\n");
var outline_f30_11_30903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9123853\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEMATURIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONCENTRATING DEFECT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROTEINURIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NEPHROLITHIASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FLANK AND ABDOMINAL PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RENAL CANCER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATIONS FOR NEPHRECTOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9123853\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1680|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/13/24797\" title=\"table 1\">",
"      Kidney pain in ADPKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/55/30582?source=related_link\">",
"      Hypertension in autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27079?source=related_link\">",
"      Management of ureteral calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/24/38277?source=related_link\">",
"      Patient information: Polycystic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/44/35523?source=related_link\">",
"      Patient information: Polycystic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4807?source=related_link\">",
"      Urinary tract infection in autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_11_30904="Surgical and endovascular repair of ruptured abdominal aortic aneurysm";
var content_f30_11_30904=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical and endovascular repair of ruptured abdominal aortic aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30904/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30904/contributors\">",
"     Ellen D Dillavou, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30904/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30904/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30904/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30904/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30904/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/11/30904/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H108749055\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture is a fatal complication of abdominal aortic aneurysm. An aneurysm is defined as ruptured when bleeding is present outside of the wall of the aneurysm. Elective aneurysm repair is associated with low rates of morbidity and mortality in properly selected individuals, but in spite of advances in intensive care unit management and techniques for repair, mortality following repair of ruptured abdominal aortic aneurysm (ruptured AAA) remains high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/1\">",
"     1",
"    </a>",
"    ]. Surgical outcomes may be improved using endovascular aneurysm repair (EVAR), but aortic endografting under emergency circumstances presents many challenges. Increasing numbers of institutions have initiated protocols for endovascular repair of ruptured AAA with promising results in small series, but not all institutions are equipped to treat all ruptured AAAs using minimally-invasive technology.",
"   </p>",
"   <p>",
"    Specific considerations for the surgical and endovascular repair of emergent AAA repair will be reviewed here. General techniques for AAA repair are discussed elsewhere. The diagnosis and management of AAA and ruptured AAA are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link\">",
"     \"Endovascular repair of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=see_link&amp;anchor=H53322839#H53322839\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108751558\">",
"    <span class=\"h1\">",
"     OPEN SURGICAL VERSUS ENDOVASCULAR REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although significant differences in mortality rates for open compared with endovascular repair for ruptured aneurysm have not definitively been demonstrated, accumulating evidence from retrospective reviews and one randomized trial suggest that outcomes for endovascular aneurysm repair (EVAR) following ruptured AAA may be better than open AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. Thus, for patients with multiple risk factors for a poor prognosis following open surgical repair, we suggest endovascular repair. As promising as EVAR appears to be for the treatment of ruptured AAA, logistical and practical barriers need to be overcome to uniformly offer EVAR for repair of ruptured AAA. The issues involved in managing ruptured AAA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=see_link&amp;anchor=H933044413#H933044413\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Decision for patient transfer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endovascular repair may improve survival following repair of ruptured abdominal aortic aneurysm (ruptured AAA), but this has not been definitively established. In retrospective reviews, endovascular repair of ruptured AAA is associated with lower mortality rates (range 16 to 31 for EVAR versus 34 to 44 percent) compared with open repair of ruptured AAA, which may be due to decreased blood loss and decreased ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/1,2,9-14\">",
"     1,2,9-14",
"    </a>",
"    ]. The main criticism of these studies is that hemodynamically stable patients with ruptured AAA are more often selected for EVAR, and hemodynamically unstable patients tend to get treated with open repair. Some have suggested that such patient selection biases the comparison, and that the mortality rate for EVAR and open repair for ruptured AAA are actually similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/15\">",
"     15",
"    </a>",
"    ]. The only randomized trial comparing EVAR and open repair for ruptured AAA (n = 32) did not find a significant difference in mortality, which was 53 percent in each group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/3\">",
"     3",
"    </a>",
"    ]. Additional data are pending the results of The Immediate Management of the Patient with Rupture: Open versus Endovascular Repair (IMPROVE) Trial, which is underway in the United Kingdom and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although mortality rates following repair of ruptured AAA may be disputed, perioperative morbidity rates have been consistently and significantly lower for EVAR compared with open repair in randomized trials of elective AAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Extrapolating from these results, it seems that EVAR would be highly desirable in patients with ruptured AAA who have poor prognostic factors for open repair. The apparent advantage of EVAR in the setting of ruptured AAA likely relates to its minimally invasive nature, which minimizes physiologic stress and decreases the risk of subsequent cardiovascular, pulmonary, and renal morbidity.",
"   </p>",
"   <p>",
"    Although attempts have been made to quantify the risk of mortality with ruptured AAA, no variable or classification has proven reliable for predicting mortality with certainty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/20\">",
"     20",
"    </a>",
"    ]. Factors on admission that have been associated with increased mortality following",
"    <strong>",
"     open",
"    </strong>",
"    repair of ruptured AAA are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=see_link&amp;anchor=H933044043#H933044043\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273857002\">",
"    <span class=\"h1\">",
"     CRITERIA FOR ENDOVASCULAR REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several anatomic factors must be satisfied to undertake endovascular AAA repair under elective circumstances and also for ruptured AAA. Up to 50 percent of patients with ruptured AAA do not have anatomy suitable for endovascular aneurysm repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/5\">",
"     5",
"    </a>",
"    ]. Aortic anatomy, aortic measurements, and criteria for elective endovascular graft placement are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link&amp;anchor=H440175#H440175\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Anatomic suitability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the patient with ruptured AAA who is hemodynamically unstable or has a hostile abdomen (eg, multiple prior abdominal operations), some of the criteria for elective endovascular graft placement can be relaxed. Endograft placement that seals the rupture may serve as a temporizing measure allowing time for the patient to be resuscitated, delaying the need for open repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H273857034\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular repair is contraindicated in the circumstances listed below. These contraindications (absolute and relative) are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link&amp;anchor=H440175#H440175\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Anatomic suitability'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link&amp;anchor=H25900007#H25900007\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An aortic neck diameter more than 32 mm at the renal arteries should",
"      <strong>",
"       not",
"      </strong>",
"      be treated with endovascular aneurysm repair (elective or emergent). The largest available endograft is 36 mm in diameter (Zenith) (",
"      <a class=\"graphic graphic_table graphicRef67461 \" href=\"mobipreview.htm?4/16/4365\">",
"       table 1",
"      </a>",
"      ). With 10 percent over-sizing as recommended by most endograft manufacturers, an aortic neck diameter more than 32 mm will not have an adequate proximal seal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=see_link\">",
"       \"Endovascular devices for abdominal aortic repair\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An aortic neck length &lt;5 mm should",
"      <strong>",
"       not",
"      </strong>",
"      be treated with EVAR. More than 15 mm of undilated aorta (ie, aortic neck) below the renal arteries is ideal to achieve an adequate seal between the endograft and aortic neck; between 5 and 10 mm is the minimum for ruptured AAA depending upon the amount of aortic neck angulation that is present. When neck angulation is more than 30 degrees, a longer neck length should be present to provide an adequate proximal endograft seal. Adherence to these criteria may help reduce the incidence of endoleak. (See",
"      <a class=\"local\" href=\"#H108749287\">",
"       'Complications'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link&amp;anchor=H1191826906#H1191826906\">",
"       \"Complications of endovascular abdominal aortic repair\", section on 'Endoleak'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications to EVAR include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More than 40 percent of the aortic neck diameter occupied with thrombus",
"     </li>",
"     <li>",
"      Circumferential calcification at the level of the aortic neck",
"     </li>",
"     <li>",
"      Aortic neck angulation &gt;60 degrees",
"     </li>",
"     <li>",
"      Bilateral iliac arteries &lt;6.5 cm in diameter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749182\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard laboratory testing (basic metabolic panel, complete blood count, coagulation profile, and liver function tests), should be obtained in preparation for surgery. The patient should have at least 10 units of packed red blood cells (pRBCs), and fresh frozen plasma (FFP) available for transfusion. The blood bank should be alerted to the potential need for massive transfusion. Similar to trauma patients with severe ongoing hemorrhage, patients with ruptured AAA who require massive transfusion may benefit from a pRBC to FFP ratio &le;2:1 rather than higher ratios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=see_link&amp;anchor=H3986774#H3986774\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion for severe ongoing hemorrhage'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link&amp;anchor=H8#H8\">",
"     \"Massive blood transfusion\", section on 'FFP, platelets, and red cells in trauma patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During imaging and transfer to the operating room, the patient is allowed to have relatively low blood pressure (permissive hypotension), with a goal systolic blood pressure of 80 to 100 mmHg, which may prevent further tearing of the aorta and decrease blood loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. Pain control is an important part of management. It is important to keep the patient comfortable, but consciousness should be maintained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=see_link\">",
"     \"Pain control in the critically ill adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis is recommended prior to the placement of prosthetic material (",
"    <a class=\"graphic graphic_table graphicRef87206 \" href=\"mobipreview.htm?34/1/34844\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuraxial anesthesia is commonly used for elective open repair of abdominal aortic aneurysm, but the time needed to place a spinal or epidural catheter, and the hypotensive side effects of these techniques, prevents their use in patients with ruptured AAA. For patients undergoing endovascular repair, local anesthetic is generally adequate.",
"   </p>",
"   <p>",
"    Regardless of whether open or endovascular repair is performed, we prepare the patient from the chest to the knees. Access to the abdomen may be needed if EVAR becomes complicated or is unsuccessful, necessitating conversion to an open procedure. Access to the groin is necessary for EVAR, and may be needed for femoral thromboembolectomy during open surgery. The patient should be prepared and draped prior to induction of general anesthesia. The surgical team should be ready to make the abdominal incision immediately after induction in anticipation of hemodynamic collapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749217\">",
"    <span class=\"h1\">",
"     OPEN SURGICAL REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open surgical repair of ruptured AAA is similar to elective AAA repair with modifications in technique that reflect the urgency of the repair and the pathophysiology of rupture. The discussion below is focused on the essential differences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749224\">",
"    <span class=\"h2\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open surgical AAA repair can be performed through a midline abdominal or left retroperitoneal incision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/23\">",
"     23",
"    </a>",
"    ]. For infrarenal ruptured AAA, a midline approach is preferred because it is expedient and exposure of the right iliac artery is better, which is important if an iliac aneurysm is present or there are signs of thromboembolism on that side. In patients who are known to have a ruptured juxtarenal aneurysm, a retroperitoneal approach may provide better proximal exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749231\">",
"    <span class=\"h2\">",
"     Aortic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first priority after entering the abdomen should be control of hemorrhage. Bleeding from the rupture site can usually be controlled with direct pressure (manual or sponge stick) prior to aortic clamping. Direct pressure allows filling of the heart and facilitates resuscitative efforts by the anesthesia staff. The location of initial aortic clamping depends upon the location of the rupture and retroperitoneal hematoma. Opening a pararenal hematoma without adequate vascular control can result in hemorrhage that may be difficult to control, and although some surgeons may enter a pararenal retroperitoneal hematoma directly, we suggest controlling the aorta using a supraceliac aortic clamp prior to entering the hematoma. When the hematoma is located in the mid- to distal aorta, the infrarenal aorta can often be clamped without the need for supraceliac clamping. If there is any question, we suggest placing a suprarenal clamp, having it ready to clamp should it become necessary.",
"   </p>",
"   <p>",
"    To perform supraceliac clamping, the left triangular ligament attaching the left lobe of the liver to the diaphragm should be divided and the lesser sac can be entered by dividing the gastrohepatic ligament. Exposure of the supraceliac aorta is facilitated by retraction of the rib cage using a self-retraining retractor (eg, Thompson, Bookwalter, upper hand). The aorta is then palpated and the medial and lateral aspects of the aorta are cleared to the spine using finger dissection. The right crus of the diaphragm should be divided with electrocautery to aid exposure. A long aortic clamp is then placed on the aorta and closed to the degree that is needed to control bleeding from the aortic rupture site. Supraceliac aortic clamping can often be accomplished in less than five minutes, but may take longer. Once the supraceliac clamp is in place, it is usually necessary to adjust the retractors to facilitate exposure of the infrarenal aorta.",
"   </p>",
"   <p>",
"    In hemodynamically stable patients with an infrarenal rupture, it may be possible to open the retroperitoneum, dissect the infrarenal aorta, and obtain aortic control below the renal arteries without closing the supraceliac clamp. Once the aorta is controlled at the level of the renal arteries, the supraceliac clamp, if closed, can be opened to minimize visceral ischemia. Prolonged supraceliac aortic clamping &gt;30 minutes significantly increases morbidity due to hepatic, mesenteric, and renal ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H108749287\">",
"     'Complications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H108753418\">",
"     'Mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once vascular control is achieved, aortic replacement proceeds in a manner similar to elective open abdominal aortic aneurysm repair with a tube or bifurcated graft (",
"    <a class=\"graphic graphic_figure graphicRef56289 \" href=\"mobipreview.htm?32/11/32949\">",
"     figure 1",
"    </a>",
"    ). If the aortic neck is short, it may be necessary to perform the proximal anastomosis with the supraceliac clamp in place, releasing the supraceliac clamp after the proximal aortic graft has been clamped. Once the graft is in place, the aneurysm sac and retroperitoneal tissues should be reapproximated over the graft to cover the proximal and distal suture lines to minimize the potential for aortoenteric fistula.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749238\">",
"    <span class=\"h2\">",
"     Heparinization",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is commonly administered during the course of elective AAA repair, but we prefer to administer heparin on a case-by-case basis during repair of ruptured AAA.",
"   </p>",
"   <p>",
"    Once the infrarenal aorta has been clamped and hemorrhage is under control, we generally anticoagulate the patient. However, in patients with obvious coagulopathy, those at risk for coagulopathy (eg, massive transfusion), or in patients for whom supraceliac clamping was prolonged, proceeding without anticoagulation is an acceptable option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749245\">",
"    <span class=\"h2\">",
"     Handling the inferior mesenteric artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic ischemia is commonly observed following ruptured AAA with approximately 35 percent of ruptured AAA patients suffering some degree of ischemia, an incidence that is higher compared with elective AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. We prefer to reimplant the origin of the inferior mesenteric artery (IMA) into the distal aortic graft, whenever possible, to minimize the potential for colonic ischemia, unless backbleeding from the IMA orifice within the aneurysm sac is vigorous, indicating adequate collateral flow, or the vessel is occluded (no backbleeding). However, because reimplantation of the IMA prolongs the operation, the IMA is reimplanted less frequently for ruptured AAA than with elective AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/20,27\">",
"     20,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749252\">",
"    <span class=\"h2\">",
"     Thromboembolectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our experience, thromboembolism is also a more common sequela of ruptured AAA compared with elective aneurysm repair. All aortic aneurysms have some degree of mural thrombus and cholesterol plaque, which have the potential to dislodge and embolize during the course of aortic dissection and clamping. Fresh thrombus can also form in situ in the iliac and femoral arteries in patients who have not been anticoagulated. Diminished backbleeding from the iliac arteries just prior to the completion of the distal anastomosis should prompt Fogarty catheter embolectomy. &nbsp;",
"   </p>",
"   <p>",
"    Distal perfusion should be assessed by palpating the pedal vessels or by using a handheld Doppler prior to removing the surgical drapes and comparing the quality of the pulse or Doppler signal with the preoperative examination. If the distal pulses are diminished by comparison, embolization to the infrainguinal vessels may have occurred and embolectomy is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749259\">",
"    <span class=\"h1\">",
"     ENDOVASCULAR REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular repair of ruptured AAA is limited to endovascular centers with a defined program for emergency endovascular surgery. Some centers have adapted an &ldquo;EVAR first&rdquo; approach to ruptured AAA, in which endovascular repair is attempted first and conversion to an open repair is made if the attempted EVAR is not successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/9,28,29\">",
"     9,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519610139\">",
"    <span class=\"h2\">",
"     Aortic control and graft placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular repair is largely limited to patients who remain hemodynamically stable, most of whom will have undergone computed tomography (CT) of the abdomen and pelvis prior to consideration for EVAR to determine the anatomic suitability of EVAR. The anatomic requirements for endovascular repair are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H273857002\">",
"     'Criteria for endovascular repair'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link&amp;anchor=H440175#H440175\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Anatomic suitability'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    For hemodynamically unstable patients, anatomic feasibility for EVAR can be determined intraoperatively. Bleeding from the aortic rupture site can be controlled using an aortic occlusion balloon that is advanced through the femoral access site to the area of aortic rupture and stabilized with a long sheath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/30\">",
"     30",
"    </a>",
"    ]. Once the balloon is inflated, the patient should be fluid-resuscitated by the anesthesia staff.",
"   </p>",
"   <p>",
"    An aortogram below the level of the aortic occlusion balloon should be performed to evaluate the diameter, length and morphology of the aorta to determine if endovascular repair is possible. Alternatively, the aorta can be imaged using intravascular ultrasound (IVUS), if available. Once it has been determined that endovascular repair is appropriate, endograft positioning and deployment proceed in a manner that is similar to elective endovascular aneurysm repair. For infrarenal aortic rupture, the balloon should be repositioned just distal to the renal arteries to preserve renal blood flow while the device is positioned and deployed. Intermittent deflation of the balloon may be required during the course of endograft placement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link&amp;anchor=H2369876151#H2369876151\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Endograft placement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A completion aortogram should be obtained to evaluate for endoleak (",
"    <a class=\"graphic graphic_figure graphicRef64707 \" href=\"mobipreview.htm?36/13/37074\">",
"     figure 2",
"    </a>",
"    ). Although reasonable efforts should be made to minimize the volume of contrast used during the procedure, it is important to get an adequate final study demonstrating that",
"    <strong>",
"     no",
"    </strong>",
"    endoleaks are present. As with elective repair, type I and type III endoleaks are repaired when identified. During elective EVAR, type II endoleak (backbleeding into the aneurysm sac) can be observed initially since the majority will resolve over time. However, following endovascular repair for ruptured AAA, type II endoleak will",
"    <strong>",
"     not",
"    </strong>",
"    tamponade spontaneously, and thus, when type II endoleak is identified, open surgical ligation of the backbleeding vessel is necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link&amp;anchor=H1191826906#H1191826906\">",
"     \"Complications of endovascular abdominal aortic repair\", section on 'Endoleak'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749266\">",
"    <span class=\"h2\">",
"     Conversion to open surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;During elective AAA repair, conversion from EVAR to open repair is uncommon, and early conversion (at the time of EVAR) was reported in 1.5 percent of procedures in one review study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/31\">",
"     31",
"    </a>",
"    ]. Conversion rates for ruptured AAA may be higher compared with elective repair because of unanticipated anatomic features or device-related issues.",
"   </p>",
"   <p>",
"    Early conversion from EVAR to open repair may be needed following EVAR for ruptured AAA for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bleeding cannot be controlled with endovascular balloon occlusion",
"     </li>",
"     <li>",
"      The graft cannot be positioned or deployed",
"     </li>",
"     <li>",
"      Large endoleaks or continued bleeding are evident after graft deployment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When EVAR cannot be accomplished, open repair is performed in the manner described above. (See",
"    <a class=\"local\" href=\"#H108749217\">",
"     'Open surgical repair'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1133144472\">",
"    <span class=\"h1\">",
"     FOLLOW-UP IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following aortic repair, imaging of the aorta should be tailored to the clinical needs of the patient. It is common to have some degree of postoperative renal dysfunction following ruptured AAA, and thus, imaging in the immediate postoperative period using intravenous contrast should be limited to concerns for bleeding or other ongoing abdominal pathology such as intraabdominal infection or suspected ischemic bowel. Following EVAR, computed tomography should be performed to evaluate the endograft once renal function has stabilized. Thereafter, follow-up is similar to elective aneurysm repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=see_link&amp;anchor=H436613#H436613\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Postoperative care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749287\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of ruptured AAA repair are similar to those of elective aneurysm repair, but there is a higher incidence of complications such as myocardial infarction, respiratory failure, and acute kidney injury compared with elective AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/28,32,33\">",
"     28,32,33",
"    </a>",
"    ]. Late complications such as aortic graft infection, aortoenteric fistula, and graft occlusion do not appear to be significantly different between ruptured and elective aneurysm repair. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link\">",
"     \"Complications of endovascular abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged operating time, increased blood loss, increased fluid administration, and intraoperative hypotension are predictive of postoperative bowel ischemia, which has a nearly 60 percent mortality rate in patients undergoing open ruptured AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/27\">",
"     27",
"    </a>",
"    ]. Intestinal ischemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42313?source=see_link\">",
"     \"Colonic ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversion from EVAR to open repair is uncommon for elective AAA repair and is, as yet, undefined with ruptured AAA. Conversion of EVAR to open repair is generally associated with higher mortality rates compared with primary open repair. There are no comparable studies for ruptured AAA. In one study of elective EVAR, early conversion to open surgery was associated with a mortality rate of 12.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/31\">",
"     31",
"    </a>",
"    ], which contrasts to the approximately 3 percent mortality for the initial AAA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/1\">",
"     1",
"    </a>",
"    ]. Late conversions had a 10 percent mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=see_link&amp;anchor=H1191825949#H1191825949\">",
"     \"Complications of endovascular abdominal aortic repair\", section on 'Conversion to open repair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of abdominal compartment syndrome (ACS) is also increased in patients with ruptured AAA due to the magnitude of the fluid resuscitation, and the volume effect of the retroperitoneal hematoma. ACS can occur as a sequela of open or endovascular repair of ruptured AAA, and we routinely measure bladder pressure and peak inspiratory pressures following repair of ruptured AAA. The diagnosis and management of ACS and the open abdomen are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20761?source=see_link&amp;anchor=H20#H20\">",
"     \"Abdominal compartment syndrome\", section on 'Measurement of intraabdominal pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108753418\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of improvements in prehospital care, cardiovascular anesthesia, and critical care, postoperative mortality following repair of ruptured AAA remains about 40 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/11,34-39\">",
"     11,34-39",
"    </a>",
"    ]. The mortality associated with ruptured AAA may be as high as 90 percent when patients who die at home or upon arrival to the hospital are taken into account [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that worsen survival during open surgical repair of ruptured AAA include supraceliac aortic clamping &gt;30 minutes, volume of blood administered &gt;3500 mL, intraoperative urine output &lt;200 mL, thrombosis of other vascular beds, and intraoperative hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/24\">",
"     24",
"    </a>",
"    ]. Endovascular aneurysm repair (EVAR) has the potential to minimize these variable complications and may improve survival following ruptured AAA, but this has not been definitively established. &nbsp;(See",
"    <a class=\"local\" href=\"#H108751558\">",
"     'Open surgical versus endovascular repair'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Long-term (five-year) survival following repair of ruptured AAA is 53 to 64 percent, in contrast to survival rates following elective repair, which range from 69 to 74 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30904/abstract/24,40,41\">",
"     24,40,41",
"    </a>",
"    ]. Factors associated with poor long-term survival include advancing age, renal dysfunction, respiratory failure, and myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108749294\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rupture is a fatal complication of abdominal aortic aneurysm (AAA). In spite of improvements in prehospital, operative and postoperative care, mortality following repair of ruptured AAA has not improved. Of patients who survive long enough to be treated, about 40 to 50 percent survive their repair, resulting in an overall survival of less than 25 percent. (See",
"      <a class=\"local\" href=\"#H108749055\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H108753418\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ruptured AAA, where appropriate facilities, personnel, equipment, and expertise are available for endovascular aneurysm repair (EVAR), we suggest EVAR rather than open AAA repair, provided it is anatomically feasible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although significant differences in mortality rates for open compared with endovascular repair for ruptured aneurysm have not been demonstrated in randomized trials, perioperative morbidity for endovascular aneurysm repair (EVAR) appears to be lower compared with open repair, though there may be a selection bias in the available studies. (See",
"      <a class=\"local\" href=\"#H108751558\">",
"       'Open surgical versus endovascular repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As promising as EVAR appears to be for the treatment of ruptured AAA, logistical and practical barriers need to be overcome to uniformly offer EVAR for repair of ruptured AAA. Thus, ruptured AAA is often repaired with open surgical techniques, particularly in smaller hospitals, due to the limited number of centers capable of performing urgent or emergent EVAR. For hemodynamically stable patients with ruptured AAA who are poor candidates for open surgical repair, transfer to a vascular center is appropriate for possible EVAR, and for the recognized benefits of repair of ruptured AAA when performed at a tertiary center. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=see_link&amp;anchor=H933044413#H933044413\">",
"       \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Decision for patient transfer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Repair of ruptured AAA using an open or endovascular approach is similar to elective AAA repair with modifications in technique that reflect the urgency of the repair and the pathophysiology of rupture. Endovascular repair is largely limited to patients with ruptured AAA who remain hemodynamically stable, most of whom will have undergone computed tomography (CT) of the abdomen and pelvis to determine the anatomic suitability for EVAR. However, feasibility for EVAR can be determined intraoperatively in hemodynamically unstable patients. An aortic neck diameter more than 32 mm at the renal arteries, or an aortic neck length less than 5 mm contraindicate endovascular repair. If endovascular repair is feasible, endograft positioning and deployment proceeds in a manner that is similar to elective endovascular aneurysm repair. If not, an abdominal incision is made and open surgical repair is undertaken. (See",
"      <a class=\"local\" href=\"#H108749217\">",
"       'Open surgical repair'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H108749259\">",
"       'Endovascular repair'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H273857034\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During open repair of ruptured AAA in patients with retroperitoneal hematoma that obscures the proximal infrarenal aorta, we suggest placement of a supraceliac clamp rather than opening the hematoma to place an infrarenal clamp (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Opening the hematoma without adequate vascular control can result in hemorrhage that may be difficult to control. (See",
"      <a class=\"local\" href=\"#H108749231\">",
"       'Aortic control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of ruptured AAA repair are similar to those occurring after elective aneurysm repair, but there is a higher incidence of complications such as myocardial infarction, respiratory failure, bowel ischemia, peripheral ischemia, and acute kidney injury. (See",
"      <a class=\"local\" href=\"#H108749287\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/1\">",
"      Dillavou ED, Muluk SC, Makaroun MS. A decade of change in abdominal aortic aneurysm repair in the United States: Have we improved outcomes equally between men and women? J Vasc Surg 2006; 43:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/2\">",
"      Veith FJ, Lachat M, Mayer D, et al. Collected world and single center experience with endovascular treatment of ruptured abdominal aortic aneurysms. Ann Surg 2009; 250:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/3\">",
"      Hinchliffe RJ, Bruijstens L, MacSweeney ST, Braithwaite BD. A randomised trial of endovascular and open surgery for ruptured abdominal aortic aneurysm - results of a pilot study and lessons learned for future studies. Eur J Vasc Endovasc Surg 2006; 32:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/4\">",
"      IMPROVE Trial, Powell JT, Thompson SG, et al. The Immediate Management of the Patient with Rupture: Open Versus Endovascular repair (IMPROVE) aneurysm trial--ISRCTN 48334791 IMPROVE trialists. Acta Chir Belg 2009; 109:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/5\">",
"      Ten Bosch JA, Teijink JA, Willigendael EM, Prins MH. Endovascular aneurysm repair is superior to open surgery for ruptured abdominal aortic aneurysms in EVAR-suitable patients. J Vasc Surg 2010; 52:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/6\">",
"      Ricotta JJ 2nd, Malgor RD, Oderich GS. Ruptured endovascular abdominal aortic aneurysm repair: part II. Ann Vasc Surg 2010; 24:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/7\">",
"      Coppi G, Gennai S, Saitta G, et al. Treatment of ruptured abdominal aortic aneurysm after endovascular abdominal aortic repair: A comparison with patients without prior treatment. J Vasc Surg 2009; 49:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/8\">",
"      Hinchliffe RJ, Powell JT, Cheshire NJ, Thompson MM. Endovascular repair of ruptured abdominal aortic aneurysm: A strategy in need of definitive evidence. J Vasc Surg 2009; 49:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/9\">",
"      Starnes BW, Quiroga E, Hutter C, et al. Management of ruptured abdominal aortic aneurysm in the endovascular era. J Vasc Surg 2010; 51:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/10\">",
"      McPhee J, Eslami MH, Arous EJ, et al. Endovascular treatment of ruptured abdominal aortic aneurysms in the United States (2001-2006): a significant survival benefit over open repair is independently associated with increased institutional volume. J Vasc Surg 2009; 49:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/11\">",
"      Chagpar RB, Harris JR, Lawlor DK, et al. Early mortality following endovascular versus open repair of ruptured abdominal aortic aneurysms. Vasc Endovascular Surg 2010; 44:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/12\">",
"      Lesperance K, Andersen C, Singh N, et al. Expanding use of emergency endovascular repair for ruptured abdominal aortic aneurysms: disparities in outcomes from a nationwide perspective. J Vasc Surg 2008; 47:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/13\">",
"      Mureebe L, Egorova N, Giacovelli JK, et al. National trends in the repair of ruptured abdominal aortic aneurysms. J Vasc Surg 2008; 48:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/14\">",
"      Davenport DL, O'Keeffe SD, Minion DJ, et al. Thirty-day NSQIP database outcomes of open versus endoluminal repair of ruptured abdominal aortic aneurysms. J Vasc Surg 2010; 51:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/15\">",
"      Takagi H, Kawai N, Umemoto T. Regarding \"Endovascular repair of ruptured abdominal aortic aneurysms\". J Vasc Surg 2008; 48:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/16\">",
"      Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med 2004; 351:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/17\">",
"      EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet 2005; 365:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/18\">",
"      Lederle FA, Freischlag JA, Kyriakides TC, et al. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA 2009; 302:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/19\">",
"      Becquemin JP, Pillet JC, Lescalie F, et al. A randomized controlled trial of endovascular aneurysm repair versus open surgery for abdominal aortic aneurysms in low- to moderate-risk patients. J Vasc Surg 2011; 53:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/20\">",
"      Tambyraja AL, Murie JA, Chalmers RT. Prediction of outcome after abdominal aortic aneurysm rupture. J Vasc Surg 2008; 47:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/21\">",
"      Mell MW, O'Neil AS, Callcut RA, et al. Effect of early plasma transfusion on mortality in patients with ruptured abdominal aortic aneurysm. Surgery 2010; 148:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/22\">",
"      Reimerink JJ, Hoornweg LL, Vahl AC, et al. Controlled hypotension in patients suspected of a ruptured abdominal aortic aneurysm: feasibility during transport by ambulance services and possible harm. Eur J Vasc Endovasc Surg 2010; 40:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/23\">",
"      Chang BB, Shah DM, Paty PS, et al. Can the retroperitoneal approach be used for ruptured abdominal aortic aneurysms? J Vasc Surg 1990; 11:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/24\">",
"      Johnston KW. Ruptured abdominal aortic aneurysm: six-year follow-up results of a multicenter prospective study. Canadian Society for Vascular Surgery Aneurysm Study Group. J Vasc Surg 1994; 19:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/25\">",
"      Piotrowski JJ, Ripepi AJ, Yuhas JP, et al. Colonic ischemia: the Achilles heel of ruptured aortic aneurysm repair. Am Surg 1996; 62:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/26\">",
"      Eliason JL, Wainess RM, Dimick JB, et al. The effect of secondary operations on mortality following abdominal aortic aneurysm repair in the United States: 1988-2001. Vasc Endovascular Surg 2005; 39:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/27\">",
"      Cho JS, Kim JY, Rhee RY, et al. Contemporary results of open repair of ruptured abdominal aortoiliac aneurysms: effect of surgeon volume on mortality. J Vasc Surg 2008; 48:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/28\">",
"      Mehta M, Taggert J, Darling RC 3rd, et al. Establishing a protocol for endovascular treatment of ruptured abdominal aortic aneurysms: outcomes of a prospective analysis. J Vasc Surg 2006; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/29\">",
"      Setacci F, Sirignano P, De Donato G, et al. Endovascular approach for ruptured abdominal aortic aneursyms. J Cardiovasc Surg (Torino) 2010; 51:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/30\">",
"      Malina M, Veith F, Ivancev K, Sonesson B. Balloon occlusion of the aorta during endovascular repair of ruptured abdominal aortic aneurysm. J Endovasc Ther 2005; 12:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/31\">",
"      Moulakakis KG, Dalainas I, Mylonas S, et al. Conversion to open repair after endografting for abdominal aortic aneurysm: a review of causes, incidence, results, and surgical techniques of reconstruction. J Endovasc Ther 2010; 17:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/32\">",
"      Drury D, Michaels JA, Jones L, Ayiku L. Systematic review of recent evidence for the safety and efficacy of elective endovascular repair in the management of infrarenal abdominal aortic aneurysm. Br J Surg 2005; 92:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/33\">",
"      Alonso-P&eacute;rez M, Segura RJ, S&aacute;nchez J, et al. Factors increasing the mortality rate for patients with ruptured abdominal aortic aneurysms. Ann Vasc Surg 2001; 15:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/34\">",
"      Bown MJ, Sutton AJ, Bell PR, Sayers RD. A meta-analysis of 50 years of ruptured abdominal aortic aneurysm repair. Br J Surg 2002; 89:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/35\">",
"      Hoornweg LL, Storm-Versloot MN, Ubbink DT, et al. Meta analysis on mortality of ruptured abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2008; 35:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/36\">",
"      Bengtsson H, Bergqvist D. Ruptured abdominal aortic aneurysm: a population-based study. J Vasc Surg 1993; 18:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/37\">",
"      Cho JS, Park T, Kim JY, et al. Prior endovascular abdominal aortic aneurysm repair provides no survival benefits when the aneurysm ruptures. J Vasc Surg 2010; 52:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/38\">",
"      Schl&ouml;sser FJ, Vaartjes I, van der Heijden GJ, et al. Mortality after hospital admission for ruptured abdominal aortic aneurysm. Ann Vasc Surg 2010; 24:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/39\">",
"      Biancari F, Mazziotti MA, Paone R, et al. Outcome after open repair of ruptured abdominal aortic aneurysm in patients&gt;80 years old: a systematic review and meta-analysis. World J Surg 2011; 35:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/40\">",
"      Cho JS, Gloviczki P, Martelli E, et al. Long-term survival and late complications after repair of ruptured abdominal aortic aneurysms. J Vasc Surg 1998; 27:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30904/abstract/41\">",
"      Kazmers A, Perkins AJ, Jacobs LA. Aneurysm rupture is independently associated with increased late mortality in those surviving abdominal aortic aneurysm repair. J Surg Res 2001; 95:50.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16843 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30904=[""].join("\n");
var outline_f30_11_30904=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H108749294\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108749055\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108751558\">",
"      OPEN SURGICAL VERSUS ENDOVASCULAR REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H273857002\">",
"      CRITERIA FOR ENDOVASCULAR REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H273857034\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108749182\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108749217\">",
"      OPEN SURGICAL REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108749224\">",
"      Incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108749231\">",
"      Aortic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108749238\">",
"      Heparinization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108749245\">",
"      Handling the inferior mesenteric artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108749252\">",
"      Thromboembolectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108749259\">",
"      ENDOVASCULAR REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519610139\">",
"      Aortic control and graft placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H108749266\">",
"      Conversion to open surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1133144472\">",
"      FOLLOW-UP IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108749287\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108753418\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H108749294\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/16843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16843|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/11/32949\" title=\"figure 1\">",
"      Abdominal aortic aneurysm repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/13/37074\" title=\"figure 2\">",
"      Types of endoleak after endovascular repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16843|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/16/4365\" title=\"table 1\">",
"      Characteristics of abdominal endovascular devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/1/34844\" title=\"table 2\">",
"      Antimicrobial prophylaxis for vascular surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/20/42313?source=related_link\">",
"      Colonic ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25626?source=related_link\">",
"      Complications of endovascular abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/29/9689?source=related_link\">",
"      Endovascular devices for abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31162?source=related_link\">",
"      Endovascular repair of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11225?source=related_link\">",
"      Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_11_30905="Management of an adnexal mass";
var content_f30_11_30905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of an adnexal mass",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30905/contributors\">",
"     Michael G Muto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30905/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30905/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30905/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30905/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/11/30905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25411714\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adnexal mass (mass of the ovary, fallopian tube, or surrounding connective tissues) is a common gynecologic problem. In the United States, it is estimated that there is a 5 to 10 percent lifetime risk for women undergoing surgery for a suspected ovarian neoplasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/1\">",
"     1",
"    </a>",
"    ]. Adnexal masses may be found in females of all ages, fetuses to the elderly, and there is a wide variety of types of masses (",
"    <a class=\"graphic graphic_table graphicRef69013 \" href=\"mobipreview.htm?20/40/21131\">",
"     table 1",
"    </a>",
"    ). The management of an adnexal mass depends upon the type of mass, urgency of the presentation (eg, ectopic pregnancy or ovarian torsion require immediate intervention), and degree of suspicion that the mass is malignant.",
"   </p>",
"   <p>",
"    The management of patients with an adnexal mass is reviewed here. The initial approach to, and an overview of, the evaluation of patients with an adnexal mass and other topics related to the management of an adnexal mass are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link\">",
"       \"Approach to the patient with an adnexal mass\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23690?source=see_link\">",
"       \"Ovarian and fallopian tube torsion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9863?source=see_link\">",
"       \"Evaluation and management of ruptured ovarian cyst\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/34/21033?source=see_link\">",
"       \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25409875\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of an adnexal mass depends upon the location and etiology of the mass (",
"    <a class=\"graphic graphic_table graphicRef69013 \" href=\"mobipreview.htm?20/40/21131\">",
"     table 1",
"    </a>",
"    ) and the characteristics of the patient. In general, there are three options for managing an adnexal mass:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery &ndash; Surgery is performed for the following indications: malignancy is suspected; there are other risks associated with the mass (eg, torsion, infection), or the mass is symptomatic. For ovarian masses, an oophorectomy or ovarian cystectomy may be performed. For other adnexal masses, the mass may be biopsied or resected.",
"     </li>",
"     <li>",
"      Continued surveillance &ndash; Continued surveillance is indicated if the suspicion of malignancy is low, but it has not been completely excluded. Surveillance usually includes serial pelvic ultrasounds",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      measurement of serum tumor markers.",
"     </li>",
"     <li>",
"      Expectant management &ndash; If the apparent etiology of the mass is benign and there are no other indications for surgery or surveillance, no further follow-up is needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice between these management options for different adult patient populations is discussed in the sections that follow. Management of an adnexal mass in a child or adolescent is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/34/21033?source=see_link\">",
"     \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15996796\">",
"    <span class=\"h1\">",
"     CLINICAL SCENARIOS FOR OVARIAN MASSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of an ovarian mass according to the clinical presentation and potential for malignancy is discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079233\">",
"    <span class=\"h2\">",
"     Suspected malignancy or uncertain etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excluding malignancy is a principal goal of the evaluation of an adnexal mass. For women with a mass that is suspicious for malignancy after an initial evaluation, surgical exploration is required.",
"   </p>",
"   <p>",
"    Surgical evaluation is the standard approach to the evaluation of an adnexal mass because there is no noninvasive technique for the diagnosis of ovarian cancer. Unfortunately, this approach results in many women undergoing surgery for a benign mass. As an example, in a large ovarian cancer screening randomized trial, among 570 women who underwent surgical evaluation for suspected ovarian cancer, 20 cases of malignancy were found (3.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the prognosis of ovarian cancer is poor unless the disease is treated at an early stage and the risk of failing to diagnose a life-threatening condition, no matter how small, must be weighed against the potential morbidity associated with surgical intervention.",
"   </p>",
"   <p>",
"    In some cases, if malignancy seems unlikely but has not been fully excluded, continued surveillance is warranted. (See",
"    <a class=\"local\" href=\"#H10104063\">",
"     'Surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The information used to evaluate an adnexal mass is briefly reviewed here, and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link&amp;anchor=H3884375#H3884375\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Evaluation for malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1591534\">",
"    <span class=\"h3\">",
"     Assessing risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important factor used to determine the clinical suspicion of malignancy of an adnexal mass is the appearance of the mass on imaging; transvaginal ultrasound is the preferred study. The sensitivity of pelvic ultrasound for the diagnosis of ovarian cancer ranged from 86 to 91 percent and the specificity ranged from 68 to 83 percent in a large meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound morphology associated with malignancy includes (",
"    <a class=\"graphic graphic_table graphicRef79259 \" href=\"mobipreview.htm?1/0/1035\">",
"     table 2",
"    </a>",
"    ): (1) a solid component or nodularity, particularly with color or power Doppler demonstration of flow in the solid component; (2) thick septations (&gt;2 to 3 mm). Based upon the ultrasound morphology, in our practice, we categorize masses into the following risk groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk &ndash; Features of malignancy, ie, solid, nodular, thick septations (",
"      <a class=\"graphic graphic_table graphicRef79259 \" href=\"mobipreview.htm?1/0/1035\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intermediate risk &ndash; Not anechoic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unilocular, but no features of malignancy (eg, a mass with thin septations or low level echoes)",
"     </li>",
"     <li>",
"      Low risk &ndash; Anechoic unilocular fluid filled cysts with thin walls",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other characteristics of the mass that contribute to the suspicion of malignancy, but are less important, are size and bilaterality. Observational series have generally found the average size of malignant adnexal masses to be &gt;10 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. There are no data regarding an increased risk of malignancy with bilateral ovarian masses. While benign masses may be bilateral, in our experience, this is a finding that increases the suspicion of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34440?source=see_link&amp;anchor=H7#H7\">",
"     \"Sonographic differentiation of benign versus malignant adnexal masses\", section on 'Characteristics suggestive of a malignant mass'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If imaging findings suggestive of metastatic disease are present, even in the absence of malignant features in the mass itself, surgical exploration is required. These features include: ascites or evidence of metastatic disease (eg, peritoneal masses, enlarged lymph nodes). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link&amp;anchor=H13733571#H13733571\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Assessing for metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors, such as menopausal status, an elevated tumor marker, symptoms, or risk factors (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"mobipreview.htm?11/59/12221\">",
"     table 3",
"    </a>",
"    ) may add to the degree of suspicion.",
"   </p>",
"   <p>",
"    This discussion is intended to provide a general framework of the indications for surgery. The management of an individual patient depends upon the clinical features of that patient and upon clinical judgement. If there is uncertainty about the appropriate management decision, a gynecologic oncologist should be consulted. (See",
"    <a class=\"local\" href=\"#H15998736\">",
"     'Referral to a specialist'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Women with a hereditary ovarian cancer syndrome (",
"    <em>",
"     BRCA",
"    </em>",
"    mutation or Lynch syndrome) are managed differently than the general population. In these women, the presence of almost any adnexal mass is an indication for surgical exploration. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34202?source=see_link\">",
"     \"Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10103830\">",
"    <span class=\"h3\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of clinical suspicion of ovarian cancer is significantly higher for postmenopausal than for premenopausal women; thus, surgical exploration is required for many postmenopausal women with an ovarian mass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link&amp;anchor=H2727399#H2727399\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Age and reproductive status'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is evidence on imaging studies of metastatic disease, surgical exploration is required, even in the absence of malignant features in the mass itself.",
"   </p>",
"   <p>",
"    Based upon the ultrasound morphology risk categories described above, we manage postmenopausal patients as follows (see",
"    <a class=\"local\" href=\"#H1591534\">",
"     'Assessing risk'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk &ndash; Women with a high risk mass require surgical exploration (",
"      <a class=\"graphic graphic_table graphicRef79259 \" href=\"mobipreview.htm?1/0/1035\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Intermediate risk &ndash; Women with an intermediate risk mass are managed based upon coexisting tumor marker levels, risk factors (",
"      <a class=\"graphic graphic_table graphicRef59585 \" href=\"mobipreview.htm?11/59/12221\">",
"       table 3",
"      </a>",
"      ), and symptoms (",
"      <a class=\"graphic graphic_table graphicRef78148 \" href=\"mobipreview.htm?6/6/6251\">",
"       table 4",
"      </a>",
"      ). Many women may be managed with surveillance, but surgical exploration should be performed if clinically significant risk factors or symptoms are present.",
"     </li>",
"     <li>",
"      Low risk &ndash; For most women with an anechoic ovarian cyst and no other, we suggest surveillance rather than surgery because the risk of malignancy is less than the risk of complications associated with surgical exploration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For postmenopausal women with a mass with an intermediate or low risk appearance, surgical exploration is required if a serum tumor marker is elevated. CA 125 is the tumor marker used most commonly for the detection of epithelial ovarian cancer. CA 125 &gt;35",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    has a sensitivity of 69 to 97 percent and a specificity of 81 to 93 percent for the diagnosis of ovarian cancer, based upon data from a meta-analysis of six studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/3\">",
"     3",
"    </a>",
"    ]. The markers OVA1 and ROMA may be used to decide whether to refer a patient to a gynecologic oncologist. Other serum markers are used to evaluate women for less common histologic types, germ cell and sex cord-stromal tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33033?source=see_link&amp;anchor=H12758113#H12758113\">",
"     \"Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum\", section on 'Referral to a gynecologic oncologist'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link&amp;anchor=H5378980#H5378980\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Serum markers for other histologic types'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Size of the mass must also be considered. We suggest surgical exploration rather than surveillance for postmenopausal women with a mass that is &ge;10 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. In addition, in our practice, we proceed with surgical exploration for women with a 5 to 10 cm mass who also have symptoms suggestive of ovarian cancer (",
"    <a class=\"graphic graphic_table graphicRef78148 \" href=\"mobipreview.htm?6/6/6251\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Risk factors (other than a hereditary ovarian cancer syndrome) or symptoms alone are not typically an indication for surgery in a woman with a mass with an intermediate or low risk appearance. The absence of risk factors and symptoms helps to support a decision to manage the patient with surveillance.",
"   </p>",
"   <p>",
"    In some cases, an adnexal mass in a postmenopausal woman was noted on imaging prior to menopause and is unchanged; this information is reassuring and surveillance is typically appropriate for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535724\">",
"    <span class=\"h3\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ovarian mass in a premenopausal woman is often a diagnostic dilemma. The risk of ovarian, fallopian tubal, or peritoneal cancer is low in this age group, but the possibility of malignancy should be considered in all patients with an adnexal mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/8\">",
"     8",
"    </a>",
"    ]. The incidence of ovarian cancer increases with age (1.8 to 2.2 per 100,000 women for ages 20 to 29 years; 3.1 to 5.1 for ages 30 to 39 years; and 9.0 to 15.2 for ages 40 to 49 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For premenopausal women with an adnexal mass, the decision whether to proceed with surgical evaluation depends upon the characteristics of the mass and the patient. If there is evidence on imaging studies of metastatic disease, surgical exploration is required, even in the absence of malignant features in the mass itself. As with postmenopausal women, we categorize patients according to risk of malignancy based upon ultrasound morphology (see",
"    <a class=\"local\" href=\"#H1591534\">",
"     'Assessing risk'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk &ndash; Similar to postmenopausal women, surgery is required for women with a mass with features associated with malignancy or any adnexal mass combined with ascites",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evidence of metastatic disease consistent with ovarian cancer (",
"      <a class=\"graphic graphic_table graphicRef79259 \" href=\"mobipreview.htm?1/0/1035\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Intermediate/low",
"      </span>",
"      risk &ndash; Many masses related to reproductive function occur in premenopausal women, and thus, there is likely to be a greater proportion of patients with a mass with an intermediate or low risk appearance. For most premenopausal women with a mass with an intermediate or low risk appearance, we suggest surveillance rather than surgery. The exceptions to this are women with a very elevated serum CA 125 or those in whom a germ cell or sex cord-stromal tumor is suspected. These neoplasms are uncommon, but often occur in younger women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link&amp;anchor=H6#H6\">",
"       \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Diagnosis overview'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16087?source=see_link&amp;anchor=H727968#H727968\">",
"       \"Overview of sex cord-stromal tumors of the ovary\", section on 'Diagnosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In premenopausal women, we measure a serum CA 125",
"      <strong>",
"       only",
"      </strong>",
"      if the ultrasound appearance of a mass raises sufficient suspicion of malignancy to warrant a repeat ultrasound or surgical evaluation. In this population, a CA 125 value of &gt;35",
"      <span class=\"nowrap\">",
"       U/mL",
"      </span>",
"      has a sensitivity and specificity of less than 80 percent, and possibly as low as 50 to 60 percent, based upon data from a meta-analysis of six studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/3\">",
"       3",
"      </a>",
"      ]. The low specificity in premenopausal women is because an elevated CA 125 is also associated with many conditions other than ovarian cancer, and many of these are found in reproductive age patients (",
"      <a class=\"graphic graphic_table graphicRef81621 \" href=\"mobipreview.htm?12/48/13069\">",
"       table 5",
"      </a>",
"      ). Based upon the poor diagnostic performance of CA 125 in premenopausal women, there has been some discussion of using a higher CA 125 level (&gt;200",
"      <span class=\"nowrap\">",
"       U/mL),",
"      </span>",
"      but this has been evaluated in few studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/10\">",
"       10",
"      </a>",
"      ]. The markers OVA1 and ROMA may be used to decide whether to refer a patient to a gynecologic oncologist. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link&amp;anchor=H5379592#H5379592\">",
"       \"Approach to the patient with an adnexal mass\", section on 'Serum markers for epithelial ovarian carcinoma'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H15998736\">",
"       'Referral to a specialist'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors (other than a hereditary ovarian cancer syndrome) or symptoms may increase the degree of suspicion of malignancy, but are not typically the sole indication for surgery in a woman with a mass with an intermediate or low risk appearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535940\">",
"    <span class=\"h3\">",
"     Management options",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10104048\">",
"    <span class=\"h4\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical exploration for an adnexal mass may be performed laparoscopically (conventional or robotic) or via a laparotomy. The choice of surgical approach depends upon the degree of suspicion of malignancy and surgeon and patient preference. Ovarian cancer staging can be performed using either approach, although the majority of surgeons in current practice prefer laparotomy if there is a high degree of suspicion of malignancy. However, if there is a low or moderate suspicion of malignancy, a laparoscopic approach is typically used. Laparoscopy is associated with a shorter recovery and decreased perioperative morbidity compared with laparotomy.",
"   </p>",
"   <p>",
"    If malignancy is suspected, oophorectomy is required rather than ovarian cystectomy. Patients with early stage ovarian cancer (ie, no malignant cells in ascites or peritoneal cytology) benefit from removal of the adnexal mass intact, since opening the mass results in a more advanced stage and adversely affects prognosis (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"mobipreview.htm?14/43/15038\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60565 \" href=\"mobipreview.htm?14/11/14526\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For premenopausal women, ovarian cystectomy is reasonable if the preoperative suspicion of malignancy is low, the mass appears benign intraoperatively, and there is no evidence of metastatic disease. Every safeguard against intraoperative rupture of the mass should be taken.",
"   </p>",
"   <p>",
"    Aspiration of cyst contents is not advisable because no tissue is obtained for histopathology and cytology of cyst fluid is not reliable for exclusion of malignancy, and there is a high rate of recurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12393?source=see_link&amp;anchor=H3#H3\">",
"     \"Oophorectomy and ovarian cystectomy\", section on 'Aspiration and fenestration versus cystectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10104063\">",
"    <span class=\"h4\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women for whom the likelihood of ovarian cancer appears low, but has not been fully excluded, should be managed with continued surveillance with serial pelvic ultrasound, and, if appropriate, a serum tumor marker. There is no evidence to establish the best approach to surveillance of an ovarian mass. The approach we use in our practice is presented here.",
"   </p>",
"   <p>",
"    For postmenopausal women with a simple ovarian cyst, several studies have examined the role of pelvic examination, ultrasound, and tumor marker measurement (particularly CA 125) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/13-19\">",
"     13-19",
"    </a>",
"    ]. In the largest of these studies, 2763 postmenopausal women were diagnosed with 3259 simple cysts up to 10 cm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/18\">",
"     18",
"    </a>",
"    ]. Serial follow-up ultrasounds were performed every three to six months. Spontaneous resolution of the simple cysts occurred in 2261 women (69 percent) over a mean follow-up of six years. Ten patients were subsequently diagnosed with ovarian cancer:",
"    <span class=\"nowrap\">",
"     7/10",
"    </span>",
"    had additional abnormal areas which were identified on an interval ultrasound examination,",
"    <span class=\"nowrap\">",
"     2/10",
"    </span>",
"    developed ovarian cancer after the cyst in question had resolved on sonographic follow-up, and",
"    <span class=\"nowrap\">",
"     1/10",
"    </span>",
"    developed cancer in the ovary opposite the cyst being followed.",
"   </p>",
"   <p>",
"    In premenopausal women, 70 percent of adnexal masses will resolve over the course of several menstrual cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When patients with an adnexal mass are managed with surveillance, it is important to counsel the patient about what morphologic or size changes would prompt surgical exploration and when surveillance will be stopped if there are no significant changes. During surveillance, if the mass develops features of malignancy, increases in size to &ge;10 cm, or the CA 125 increases to &gt;35",
"    <span class=\"nowrap\">",
"     U/mL,",
"    </span>",
"    we proceed with surgery. If the mass resolves, we discontinue surveillance. If the mass remains unchanged or decreases in size and the CA 125 remains &lt;35",
"    <span class=\"nowrap\">",
"     U/mL,",
"    </span>",
"    surveillance continues until the planned stopping point is reached.",
"   </p>",
"   <p>",
"    For",
"    <strong>",
"     postmenopausal",
"    </strong>",
"    women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermediate risk mass &ndash; We repeat a transvaginal ultrasound and CA 125 in six weeks and then again six weeks later. We then repeat the ultrasound and CA 125 every three to six months for a year. We do a final ultrasound and CA 125 one year later.",
"     </li>",
"     <li>",
"      For low risk masses, we repeat an ultrasound and CA 125 at three months then six months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For",
"    <strong>",
"     premenopausal",
"    </strong>",
"    women:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intermediate risk masses &ndash; We repeat a transvaginal ultrasound in six weeks. This allows visualization of the mass at a different point of the menstrual cycle. We then repeat an ultrasound in three months and then six more months. We then do a final ultrasound one year later.",
"     </li>",
"     <li>",
"      Low risk masses &ndash; We repeat an ultrasound in three months and then six more months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do not routinely follow with CA 125 in premenopausal women. If an initial level was drawn and was very elevated, we proceed with surgery. If the initial level was &lt;35",
"    <span class=\"nowrap\">",
"     U/mL,",
"    </span>",
"    we do not repeat it. If it was moderately elevated (35 to &lt;200",
"    <span class=\"nowrap\">",
"     U/mL),",
"    </span>",
"    we draw it with each ultrasound until a pattern emerges. If it is consistently low or moderately elevated, we discontinue CA 125 testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7610682\">",
"    <span class=\"h2\">",
"     Benign mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some benign ovarian masses have characteristic sonographic features and the diagnosis is fairly certain without surgical exploration, including: follicular or corpus luteal cysts, endometriomas, and mature teratomas (dermoid). Surgery is not required for follicular or corpus luteal cysts. Surgical treatment of endometriomas depends upon whether the patient is symptomatic. Most mature teratomas are benign, but surgery is indicated to exclude malignancy and prevent malignant transformation (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link&amp;anchor=H10#H10\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Mature cystic teratoma (dermoid cyst)'",
"    </a>",
"    ). For any ovarian mass, however, if the diagnosis is uncertain, further evaluation is required. (See",
"    <a class=\"local\" href=\"#H5079233\">",
"     'Suspected malignancy or uncertain etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2499557\">",
"    <span class=\"h2\">",
"     Acute pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who present with acute pain and an ovarian mass should be evaluated without delay and may require urgent intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link&amp;anchor=H3884018#H3884018\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Evaluation for urgent conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the conditions listed below, an ectopic pregnancy is a common gynecologic emergency, but ectopic gestations are usually located in the fallopian tube, and are discussed below. Rarely, an ovarian pregnancy is present. (See",
"    <a class=\"local\" href=\"#H5079870\">",
"     'Ectopic pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2499567\">",
"    <span class=\"h3\">",
"     Ovarian torsion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Torsion of the ovary or fallopian tube requires urgent surgical treatment to avoid ischemic injury. The evaluation and management of adnexal torsion are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23690?source=see_link\">",
"     \"Ovarian and fallopian tube torsion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link&amp;anchor=H3884034#H3884034\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Adnexal torsion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2499575\">",
"    <span class=\"h3\">",
"     Ruptured or hemorrhagic ovarian cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian masses may rupture or become hemorrhagic. This occurs most commonly in physiologic cysts that are associated with the menstrual cycle (follicular cysts, corpus luteal cysts).",
"   </p>",
"   <p>",
"    A ruptured or hemorrhagic ovarian cyst is occasionally accompanied by significant bleeding. Women with uncomplicated cyst rupture (hemodynamically stable, no evidence ongoing blood loss on laboratory evaluation or pelvic imaging) can be managed expectantly. Women with complicated cyst rupture require hospital admission for close monitoring, with a possible need for surgical intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood product replacement. &nbsp;",
"   </p>",
"   <p>",
"    The evaluation and management of a ruptured ovarian cyst are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9863?source=see_link\">",
"     \"Evaluation and management of ruptured ovarian cyst\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link&amp;anchor=H3884042#H3884042\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Ruptured or hemorrhagic ovarian cyst'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15998490\">",
"    <span class=\"h2\">",
"     Persistent pain or pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian cysts may cause pain or pressure symptoms. Since many cysts are transient and the pain will resolve with the cyst, these symptoms are best managed with analgesics in the short term while the patient is evaluated and it is determined whether surgery is needed for another indication (eg, suspicion of malignancy, infertility).",
"   </p>",
"   <p>",
"    A particular type of ovarian mass, an endometrioma, may be associated with dysmenorrhea, pelvic pain, or dyspareunia. These masses are usually recognized by their characteristic appearance on ultrasound. They are also often associated with endometriosis at other sites within the pelvis. Surgical removal is the usual treatment of a symptomatic endometrioma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and management of ovarian endometriomas\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some women will have an ovarian mass with an indeterminate appearance on ultrasound, but with no features of malignancy. In such cases, other sources of pelvic pain should be investigated. However, if no other etiology of the pain is identified and the pain is persistent and not relieved by analgesics, we suggest ovarian cystectomy or oophorectomy.",
"   </p>",
"   <p>",
"    Some patients with a history of recurrent painful ovarian cysts are managed with hormonal contraceptives to inhibit ovulation. This prevents the formation of new physiologic ovarian cysts. Oral contraceptives (OCs) do not decrease the size of existing cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/20\">",
"     20",
"    </a>",
"    ]. Numerous studies have investigated the effects of OCs on follicular cyst development and ovulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/21-28\">",
"     21-28",
"    </a>",
"    ]. In general, current OCs with a dose of &le;35 mcg ethinyl estradiol resulted in the development of fewer follicular cysts, but to a lesser extent than higher dose formulations (50 mcg ethinyl estradiol). There was no difference in the suppression of cyst development between monophasic and multiphasic OCs.",
"   </p>",
"   <p>",
"    The typical regimen is an OC once daily; this can be continued for as long as the patient desires to remain on an OC. Other types of estrogen-progestin contraceptives (eg, patch, ring) have not been studied for this indication, but are likely to have the same effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15998498\">",
"    <span class=\"h2\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriomas are a type of ovarian mass that is associated with infertility, and these should be removed in infertile patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and management of ovarian endometriomas\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other types of ovarian masses are not typically removed for the indication of treating infertility. However, an ovarian mass may adversely affect fertility if it undergoes torsion or ruptures. &nbsp;",
"   </p>",
"   <p>",
"    On the other hand, removal of an adnexal mass in a premenopausal woman may lead to adhesion formation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduce ovarian reserve, potentially adversely impacting fertility.",
"   </p>",
"   <p>",
"    A hydrosalpinx is another type of adnexal mass that is associated with infertility. &nbsp;(See",
"    <a class=\"local\" href=\"#H15996861\">",
"     'Hydrosalpinx'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15995958\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian or other adnexal masses in pregnant women are managed by the same principles as in other patients, although the choice of treatment depends upon issues of maternal and fetal safety.",
"   </p>",
"   <p>",
"    Most adnexal masses discovered during pregnancy are an incidental finding on a routine prenatal ultrasound. The vast majority are physiologic cysts or benign masses that can be managed expectantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/8,29-34\">",
"     8,29-34",
"    </a>",
"    ]. In patients managed expectantly, 51 to 70 percent of adnexal masses resolved during pregnancy; risk factors for persistence were size greater than 5 cm and complex morphology on transvaginal ultrasonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/30,35-39\">",
"     30,35-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Operative intervention is indicated in three situations: (1) a malignancy is suspected, (2) an acute complication (eg, torsion or rupture) develops, or (3) the size of the tumor is likely to cause obstetric or other difficulty.",
"   </p>",
"   <p>",
"    Approximately 10 percent of adnexal masses that persist during pregnancy are malignant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/29,40,41\">",
"     29,40,41",
"    </a>",
"    ]. A substantial portion of these are epithelial low malignant potential tumors or germ cell tumors, both tumors with a typically favorable prognosis.",
"   </p>",
"   <p>",
"    The reported rate of complications with expectant management was less than 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/42\">",
"     42",
"    </a>",
"    ]. Most persistent adnexal masses are pushed well out of the pelvis as pregnancy progresses by the enlarging uterus. Occasionally, however, an ovarian tumor may be located in the posterior cul-de sac, even at term. A tumor in the posterior cul-de-sac can obstruct delivery or may rupture.",
"   </p>",
"   <p>",
"    Some ovarian tumors are so large that they appear to be incompatible with an advancing pregnancy. Such a tumor may accommodate in shape and become less problematic, as it is gradually pushed into the upper abdomen. Management of large or impacted benign appearing adnexal tumors during pregnancy must be individualized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/29-34,43\">",
"     29-34,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When nonurgent removal of an adnexal mass is determined to be necessary during pregnancy, it is generally preferable to postpone surgery until after the first trimester. This is based on the greater potential for pregnancy loss or teratogenicity during the first trimester. In addition, waiting for the second trimester is generally acceptable given the high likelihood of a corpus luteum cyst and the low likelihood of an invasive malignancy.",
"   </p>",
"   <p>",
"    However, as pregnancy progresses beyond the first trimester, surgery poses other problems: operative exposure diminishes and the need to manipulate the pregnant uterus increases. Elective surgery for an adnexal mass any time prior to term increases the risk of pregnancy loss and the likelihood of intrauterine growth retardation and preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/41,44,45\">",
"     41,44,45",
"    </a>",
"    ]. Adnexal surgery during the late second or early third trimester may pose the greatest risk. The conventional wisdom is to electively operate for an adnexal mass during the early to mid-second trimester. Operating at this point in pregnancy still affords some pelvic exposure without the need for significant uterine manipulation and has been associated with a lower risk of pregnancy complications. The other window for operation is at the time of cesarean section.",
"   </p>",
"   <p>",
"    The data on laparoscopy during the first and second trimesters of pregnancy indicate that it is as safe as laparotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/45\">",
"     45",
"    </a>",
"    ]. Small series of laparoscopic procedures to manage an adnexal mass during pregnancy suggest that this approach is most applicable during the first (for highly selected emergent cases) or early second trimester to manage masses less than 10 cm in diameter, particularly when adnexectomy is planned. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8727?source=see_link\">",
"     \"Laparoscopic surgery in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15996804\">",
"    <span class=\"h1\">",
"     OTHER ADNEXAL MASSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adnexal mass may involve the fallopian tube or the connective tissue surrounding the ovary and tube.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412408\">",
"    <span class=\"h2\">",
"     Fallopian tubal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;High grade serous epithelial ovarian carcinoma, fallopian tubal, and peritoneal carcinomas are considered a single clinical entity due to their shared clinical behavior and treatment. There is also accumulating evidence of a common pathogenesis for these carcinomas. Fallopian tubal cancer rarely presents as a tubal mass alone; ovarian involvement is typically also present at time of diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of fallopian tubal cancer is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=see_link\">",
"     \"Epithelial ovarian cancer: Initial surgical management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5079870\">",
"    <span class=\"h2\">",
"     Ectopic pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic pregnancy is a potentially life-threatening condition; the fallopian tube is the most common site of an ectopic pregnancy, although ovarian or cervical pregnancy may also occur.",
"   </p>",
"   <p>",
"    The management of ectopic pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/24/34184?source=see_link\">",
"     \"Ultrasonography of pregnancy of unknown location\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15998066\">",
"    <span class=\"h2\">",
"     Tuboovarian abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic presentation of a tuboovarian abscess includes acute lower abdominal pain, fever, chills, vaginal discharge, and an adnexal mass. Pelvic imaging typically shows a complex multilocular mass that obliterates normal adnexal architecture. Timely diagnosis and management are required to diagnose or avoid sepsis and to prevent further damage to the ovary and fallopian tubes. &nbsp;",
"   </p>",
"   <p>",
"    The diagnosis and management of a tuboovarian abscess are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36823?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=see_link\">",
"     \"Management and complications of tuboovarian abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15996812\">",
"    <span class=\"h2\">",
"     Paratubal or paraovarian cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paratubal or paraovarian cyst arises from the broad ligament in the area of the fallopian tube or ovary. The most common findings in this area are simple cysts that originate from the remnants of paramesonephric (M&uuml;llerian) or mesonephric (Wolffian) ducts that are present during urogenital embryologic development. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19352?source=see_link&amp;anchor=H14#H14\">",
"     \"Differential diagnosis of the adnexal mass\", section on 'Paraovarian/paratubal cysts and other tubal and broad ligament neoplasms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A simple, asymptomatic paratubal or paraovarian cyst can be managed expectantly without further follow-up. Surgical removal is indicated for these lesions if they undergo torsion, cause persistent pain or pressure symptoms, or appear neoplastic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23690?source=see_link&amp;anchor=H426499#H426499\">",
"     \"Ovarian and fallopian tube torsion\", section on 'Paratubal or paraovarian cyst torsion'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15996861\">",
"    <span class=\"h2\">",
"     Hydrosalpinx",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hydrosalpinx is an edematous fallopian tube, typically caused by an infection. A hydrosalpinx may be asymptomatic or may result in chronic pelvic pain or infertility and sometimes be the source of chronic pelvic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/46\">",
"     46",
"    </a>",
"    ]. Other etiologies of chronic pelvic pain should be excluded before salpingectomy is performed. An asymptomatic hydrosalpinx does not generally need to be removed or followed with imaging. The exception to this is women undergoing in vitro fertilization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/18/9513?source=see_link&amp;anchor=H11#H11\">",
"     \"Reproductive surgery for female infertility\", section on 'Salpingectomy before in vitro fertilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15996820\">",
"    <span class=\"h2\">",
"     Broad ligament leiomyoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A broad ligament leiomyoma may be located proximal to the ovary and fallopian tube. These are usually diagnosed with pelvic ultrasound and are managed in the same manner as other leiomyomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15998736\">",
"    <span class=\"h1\">",
"     REFERRAL TO A SPECIALIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;For masses that are highly suspicious for ovarian, fallopian tubal, or peritoneal cancer, referral to a gynecologic oncologist is advised, since outcomes of staging and cytoreduction have been shown to be better than when the procedure is performed by other surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. This was illustrated in a systematic review of observational studies that found that, in patients with advanced disease, there was a six- to nine-month median survival benefit for patients operated on by gynecologic oncologists and that, in patients with early stage disease, gynecologic oncologists were significantly more likely to perform optimal staging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists (ACOG) and the Society of Gynecologic Oncologists (SGO) have published a joint guideline about referral of women with an adnexal mass to a gynecologic oncologist (",
"    <a class=\"graphic graphic_table graphicRef55063 \" href=\"mobipreview.htm?7/38/7787\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/47\">",
"     47",
"    </a>",
"    ]. For premenopausal women, the guideline advises referral for those with a &ldquo;very elevated&rdquo; CA 125, but a specific value is not given. A version of the guideline published in 2002 used a value of &gt;200",
"    <span class=\"nowrap\">",
"     U/mL,",
"    </span>",
"    but this was removed in the 2011 guideline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have evaluated the performance of this guideline for the diagnosis of ovarian cancer, and found the following: premenopausal women (sensitivity 70 to 79 percent and specificity 70 percent) and postmenopausal women (sensitivity 93 to 94 percent and specificity 60 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30905/abstract/10,53\">",
"     10,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/1/11283?source=see_link\">",
"       \"Patient information: Ovarian cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/27/39346?source=see_link\">",
"       \"Patient information: Ovarian cysts (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/20/2371?source=see_link\">",
"       \"Patient information: Ovarian cysts (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11252?source=see_link\">",
"       \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25409988\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An adnexal mass (mass of the ovary, fallopian tube, or surrounding connective tissues) is a common gynecologic problem. The management of an adnexal mass depends upon the type of mass, urgency of the presentation, and degree of suspicion that the mass is malignant. (See",
"      <a class=\"local\" href=\"#H25411714\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Excluding malignancy is a principal goal of the evaluation of an adnexal mass. The most important factor used to determine the clinical suspicion of malignancy of an adnexal mass is the sonographic appearance of the mass. Other factors, such as menopausal status, an elevated tumor marker, symptoms, or risk factors (",
"      <a class=\"graphic graphic_table graphicRef59585 \" href=\"mobipreview.htm?11/59/12221\">",
"       table 3",
"      </a>",
"      ) may add to the degree of suspicion. (See",
"      <a class=\"local\" href=\"#H5079233\">",
"       'Suspected malignancy or uncertain etiology'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Based upon the ultrasound morphology, in our practice, we categorize masses as high (features of malignancy, ie, solid, nodular, thick septations (",
"      <a class=\"graphic graphic_table graphicRef79259 \" href=\"mobipreview.htm?1/0/1035\">",
"       table 2",
"      </a>",
"      )), intermediate (not anechoic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unilocular, but no features of malignancy, eg, a mass with thin septations or low level echoes), or low risk (anechoic unilocular fluid filled cysts with thin walls). (See",
"      <a class=\"local\" href=\"#H5079233\">",
"       'Suspected malignancy or uncertain etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If malignancy has not been excluded, we manage patients according to these risk categories (see",
"      <a class=\"local\" href=\"#H10103830\">",
"       'Postmenopausal women'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H535724\">",
"       'Premenopausal women'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Women with a high risk mass require surgical exploration. In addition, surgical exploration is required if imaging findings suggestive of metastatic disease are present, even in the absence of malignant features in the mass itself.",
"     </li>",
"     <li>",
"      For most women with an intermediate risk mass, we suggest surveillance rather than surgical exploration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For postmenopausal women with an intermediate risk mass, we suggest surgical exploration if clinically significant risk factors or symptoms are present or if the patient places a higher value on a definitive diagnosis than on avoiding surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For premenopausal women, risk factors or symptoms do not typically determine management.",
"     </li>",
"     <li>",
"      Size of the mass is an important factor. We suggest surgical exploration rather than surveillance for women with a mass that is &ge;10 cm in diameter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In addition, in our practice, we proceed with surgical exploration for postmenopausal women with a 5 to 10 cm mass who also have symptoms suggestive of ovarian cancer (",
"      <a class=\"graphic graphic_table graphicRef78148 \" href=\"mobipreview.htm?6/6/6251\">",
"       table 4",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      For most women with a low risk mass, we suggest surveillance rather than surgical exploration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tumor markers influence the management of women with an intermediate or low risk mass. Surgical exploration is required if a serum tumor marker is elevated in a postmenopausal woman. For premenopausal women, surgical exploration is reasonable if a serum CA 125 is very elevated or if a germ cell or sex cord stromal tumor is suspected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oophorectomy rather than ovarian cystectomy is required for women with an ovarian mass that is suspicious for malignancy. For premenopausal women, ovarian cystectomy is reasonable if the preoperative suspicion of malignancy is low, the mass appears benign intraoperatively, and there is no evidence of metastatic disease. (See",
"      <a class=\"local\" href=\"#H10104048\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who present with acute pain and an ovarian mass should be evaluated without delay and may require urgent intervention. Etiologies that present in this manner include ovarian torsion and rupture of an ovarian mass. (See",
"      <a class=\"local\" href=\"#H2499557\">",
"       'Acute pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with an ovarian mass with no clinical features of malignancy who have persistent pain, analgesics are first line therapy. For those with persistent pain despite analgesics, we suggest surgical treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15998490\">",
"       'Persistent pain or pressure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical treatment of some types of adnexal masses (eg, endometrioma, hydrosalpinx) may be therapeutic in women with infertility. (See",
"      <a class=\"local\" href=\"#H15998498\">",
"       'Infertility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5813190\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to acknowledge Dr. Mitchel S Hoffman, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/1\">",
"      National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994; 55:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/2\">",
"      Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193:1630.",
"     </a>",
"    </li>",
"    <li>",
"     Myers ER, Bastian LA, Havrilesky LJ, et al. Management of Adnexal Mass. Evidence Report/Technology Assessment No.130 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025). AHRQ Publication No. 06-E004, Agency for Healthcare Research and Quality, Rockville, MD February 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/4\">",
"      Roman LD, Muderspach LI, Stein SM, et al. Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer. Obstet Gynecol 1997; 89:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/5\">",
"      Curtin JP. Management of the adnexal mass. Gynecol Oncol 1994; 55:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/6\">",
"      Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989; 74:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/7\">",
"      Saunders BA, Podzielinski I, Ware RA, et al. Risk of malignancy in sonographically confirmed septated cystic ovarian tumors. Gynecol Oncol 2010; 118:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/8\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Management of adnexal masses. Obstet Gynecol 2007; 110:201.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/ (Accessed on September 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/10\">",
"      Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005; 105:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/11\">",
"      Webb MJ, Decker DG, Mussey E, Williams TJ. Factor influencing survival in Stage I ovarian cancer. Am J Obstet Gynecol 1973; 116:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/12\">",
"      Sainz de la Cuesta R, Goff BA, Fuller AF Jr, et al. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/13\">",
"      Strigini FA, Gadducci A, Del Bravo B, et al. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Gynecol Oncol 1996; 61:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/14\">",
"      Maggino T, Gadducci A, D'Addario V, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol 1994; 54:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/15\">",
"      Schutter EM, Kenemans P, Sohn C, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer 1994; 74:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/16\">",
"      Bailey CL, Ueland FR, Land GL, et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol 1998; 69:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/17\">",
"      Nardo LG, Kroon ND, Reginald PW. Persistent unilocular ovarian cysts in a general population of postmenopausal women: is there a place for expectant management? Obstet Gynecol 2003; 102:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/18\">",
"      Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003; 102:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/19\">",
"      Castillo G, Alc&aacute;zar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 2004; 92:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/20\">",
"      Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev 2006; :CD006134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/21\">",
"      Spanos WJ. Preoperative hormonal therapy of cystic adnexal masses. Am J Obstet Gynecol 1973; 116:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/22\">",
"      Functional ovarian cysts and oral contraceptives. Negative association confirmed surgically. A cooperative study. JAMA 1974; 228:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/23\">",
"      Caillouette JC, Koehler AL. Phasic contraceptive pills and functional ovarian cysts. Am J Obstet Gynecol 1987; 156:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/24\">",
"      Holt VL, Daling JR, McKnight B, et al. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 1992; 79:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/25\">",
"      Mishell DR Jr. Noncontraceptive benefits of oral contraceptives. J Reprod Med 1993; 38:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/26\">",
"      Grimes DA, Godwin AJ, Rubin A, et al. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol 1994; 83:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/27\">",
"      Egarter C, Putz M, Strohmer H, et al. Ovarian function during low-dose oral contraceptive use. Contraception 1995; 51:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/28\">",
"      Holt VL, Cushing-Haugen KL, Daling JR. Oral contraceptives, tubal sterilization, and functional ovarian cyst risk. Obstet Gynecol 2003; 102:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/29\">",
"      Hoffman, MS, Sayer, RA. Adnexal masses in pregnancy. OBG Management 2007; 19:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/30\">",
"      Zanetta G, Mariani E, Lissoni A, et al. A prospective study of the role of ultrasound in the management of adnexal masses in pregnancy. BJOG 2003; 110:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/31\">",
"      Sherard GB 3rd, Hodson CA, Williams HJ, et al. Adnexal masses and pregnancy: a 12-year experience. Am J Obstet Gynecol 2003; 189:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/32\">",
"      Agarwal N, Kriplani A, Bhatla N, et al. Management and outcome of pregnancies complicated with adnexal masses. Arch Gynecol Obstet 2003; 267:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/33\">",
"      Schmeler KM, Mayo-Smith WW, Peipert JF, et al. Adnexal masses in pregnancy: surgery compared with observation. Obstet Gynecol 2005; 105:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/34\">",
"      Caspi B, Levi R, Appelman Z, et al. Conservative management of ovarian cystic teratoma during pregnancy and labor. Am J Obstet Gynecol 2000; 182:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/35\">",
"      Bernhard LM, Klebba PK, Gray DL, Mutch DG. Predictors of persistence of adnexal masses in pregnancy. Obstet Gynecol 1999; 93:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/36\">",
"      Platek DN, Henderson CE, Goldberg GL. The management of a persistent adnexal mass in pregnancy. Am J Obstet Gynecol 1995; 173:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/37\">",
"      Bromley B, Benacerraf B. Adnexal masses during pregnancy: accuracy of sonographic diagnosis and outcome. J Ultrasound Med 1997; 16:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/38\">",
"      Sunoo CS, Terada KY, Kamemoto LE, Hale RW. Adnexal masses in pregnancy: occurrence by ethnic group. Obstet Gynecol 1990; 75:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/39\">",
"      Spitzer M, Kaushal N, Benjamin F. Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 1998; 43:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/40\">",
"      Hoffman, MS. Primary ovarian carcinoma during pregnancy. Clin Consul Obstet Gynecol 1995; 7:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/41\">",
"      Leiserowitz GS, Xing G, Cress R, et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/42\">",
"      Whitecar MP, Turner S, Higby MK. Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management. Am J Obstet Gynecol 1999; 181:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/43\">",
"      Caspi B, Ben-Arie A, Appelman Z, et al. Aspiration of simple pelvic cysts during pregnancy. Gynecol Obstet Invest 2000; 49:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/44\">",
"      Mazze RI, K&auml;ll&eacute;n B. Reproductive outcome after anesthesia and operation during pregnancy: a registry study of 5405 cases. Am J Obstet Gynecol 1989; 161:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/45\">",
"      Reedy MB, K&auml;ll&eacute;n B, Kuehl TJ. Laparoscopy during pregnancy: a study of five fetal outcome parameters with use of the Swedish Health Registry. Am J Obstet Gynecol 1997; 177:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/46\">",
"      Okaro E, Condous G, Khalid A, et al. The use of ultrasound-based 'soft markers' for the prediction of pelvic pathology in women with chronic pelvic pain--can we reduce the need for laparoscopy? BJOG 2006; 113:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/47\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/48\">",
"      Chan JK, Kapp DS, Shin JY, et al. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obstet Gynecol 2007; 109:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/49\">",
"      Engelen MJ, Kos HE, Willemse PH, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006; 106:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/50\">",
"      Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005; 99:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/51\">",
"      Earle CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006; 98:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/52\">",
"      American College of Obstetricians anf Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30905/abstract/53\">",
"      Dearking AC, Aletti GD, McGree ME, et al. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol 2007; 110:841.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83704 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30905=[""].join("\n");
var outline_f30_11_30905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25409988\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25411714\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25409875\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15996796\">",
"      CLINICAL SCENARIOS FOR OVARIAN MASSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079233\">",
"      Suspected malignancy or uncertain etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1591534\">",
"      - Assessing risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10103830\">",
"      - Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H535724\">",
"      - Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H535940\">",
"      - Management options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10104048\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10104063\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7610682\">",
"      Benign mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2499557\">",
"      Acute pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2499567\">",
"      - Ovarian torsion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2499575\">",
"      - Ruptured or hemorrhagic ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15998490\">",
"      Persistent pain or pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15998498\">",
"      Infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15995958\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15996804\">",
"      OTHER ADNEXAL MASSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H412408\">",
"      Fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5079870\">",
"      Ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15998066\">",
"      Tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15996812\">",
"      Paratubal or paraovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15996861\">",
"      Hydrosalpinx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15996820\">",
"      Broad ligament leiomyoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15998736\">",
"      REFERRAL TO A SPECIALIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25409988\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5813190\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/83704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/83704|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/40/21131\" title=\"table 1\">",
"      Differential dx adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/0/1035\" title=\"table 2\">",
"      Sonographic findings ovarian CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/59/12221\" title=\"table 3\">",
"      Risk factors ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/6/6251\" title=\"table 4\">",
"      Ovarian cancer symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/48/13069\" title=\"table 5\">",
"      Causes of an elevated CA 125",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/43/15038\" title=\"table 6\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/11/14526\" title=\"table 7\">",
"      Staging fallopian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/38/7787\" title=\"table 8\">",
"      Referral to gyn oncologist",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19352?source=related_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36823?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/48/36618?source=related_link\">",
"      Epithelial ovarian cancer: Initial surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9863?source=related_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/33/8727?source=related_link\">",
"      Laparoscopic surgery in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/34/43560?source=related_link\">",
"      Management and complications of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12393?source=related_link\">",
"      Oophorectomy and ovarian cystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/8/23690?source=related_link\">",
"      Ovarian and fallopian tube torsion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/34/21033?source=related_link\">",
"      Ovarian cysts and neoplasms in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16087?source=related_link\">",
"      Overview of sex cord-stromal tumors of the ovary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/1/11283?source=related_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/63/11252?source=related_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/20/2371?source=related_link\">",
"      Patient information: Ovarian cysts (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/27/39346?source=related_link\">",
"      Patient information: Ovarian cysts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/18/9513?source=related_link\">",
"      Reproductive surgery for female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34202?source=related_link\">",
"      Risk-reducing bilateral salpingo-oophorectomy in women at high risk of epithelial ovarian and fallopian tubal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33033?source=related_link\">",
"      Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/40/34440?source=related_link\">",
"      Sonographic differentiation of benign versus malignant adnexal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/24/34184?source=related_link\">",
"      Ultrasonography of pregnancy of unknown location",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_11_30906="Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy";
var content_f30_11_30906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Vinod Ravi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Shreyaskumar R Patel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Chandrajit P Raut, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/11/30906/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/11/30906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors (also called aggressive fibromatosis, deep musculoaponeurotic fibromatosis, and also formerly termed fibrosarcoma grade I of the desmoid type) are locally aggressive tumors with no known potential for metastasis or dedifferentiation. The term \"desmoid\" originates from the Greek word \"desmos\", meaning band or tendon-like, and was first applied in the 1800s to describe tumors with a tendon-like consistency.",
"   </p>",
"   <p>",
"    Although they lack the capacity to establish metastases, desmoids are locally aggressive and have a high rate of recurrence even after complete resection. Tumor-related destruction of vital structures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    organs can be fatal, particularly when these tumors arise in patients with familial adenomatous polyposis (FAP, Gardner's syndrome).",
"   </p>",
"   <p>",
"    This topic review will discuss the epidemiology, risk factors, molecular pathogenesis, clinical presentation, and local treatment options for desmoid tumors. Systemic therapy is discussed elsewhere, as are other miscellaneous benign diseases affecting soft tissue and bone, such as Gorham's disease, desmoplastic fibroma of bone, pigmented villonodular synovitis, keloids and ganglia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=see_link\">",
"     \"Desmoid tumors: Systemic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42150?source=see_link\">",
"     \"Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1847?source=see_link\">",
"     \"Keloids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=see_link\">",
"     \"Ganglia and nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors are rare; they account for about 0.03 percent of all neoplasms and less than 3 percent of all soft tissue tumors. The estimated incidence in the general population is two to four per million population per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals between the ages of 15 and 60 are most commonly affected; desmoids are rare in the young and in the elderly. They are slightly more common in women than in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/2\">",
"     2",
"    </a>",
"    ], and there is no significant racial or ethnic predilection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gardner's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most desmoids arise sporadically, although approximately 2 percent are associated with familial adenomatous polyposis (FAP). Desmoid tumors affect between 10 to 20 percent of patients with FAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. The risk of developing a desmoid in a patient with FAP is 852 times that of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of desmoid tumors in patients with FAP was first described by Gardner in 1951 and is now designated Gardner's syndrome (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54879 \" href=\"mobipreview.htm?1/23/1392\">",
"     image 1",
"    </a>",
"    ). Although extremity desmoids can also occur, most of these patients develop abdominal tumors, one-half of which are intraabdominal, the remainder involving the abdominal wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/11\">",
"     11",
"    </a>",
"    ]. Other prominent extraintestinal lesions in these patients include osteomas and cysts. Families have been described who exhibit desmoids as the only manifestation of an APC mutation.",
"   </p>",
"   <p>",
"    Until early elective colectomy became routine in patients with FAP, the dominant cause of death in these patients was carcinoma of the colon at a relatively young age. With the increasing use of prophylactic colectomy, desmoid tumors have become an important cause of morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/12-17\">",
"     12-17",
"    </a>",
"    ]. Desmoids are the cause of death in up to 11 percent of patients with FAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. However, progression is often gradual and approximately 60 percent are still alive 10 years after the diagnosis, some with advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/3,4,17,19\">",
"     3,4,17,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7352?source=see_link&amp;anchor=H6#H6\">",
"     \"Gardner syndrome\", section on 'Desmoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prognosis varies according to disease extent, although there is no consensus on the best way to quantify disease extent. (See",
"    <a class=\"local\" href=\"#H106560989\">",
"     'Mortality associated with desmoids'",
"    </a>",
"    below.) The desmoids that arise in patients with FAP have a particular predilection for surgical sites (eg, the mesentery or abdominal wall following colectomy, the site of an ileal pouch-anal anastomosis), and prior surgery is a risk factor for the development of desmoids in these families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/11-14,20-22\">",
"     11-14,20-22",
"    </a>",
"    ]. In one series, prior abdominal surgery had been performed in 68 percent of patients with FAP and abdominal desmoid tumors; lesions developed within five years after surgery in approximately one-half [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/21\">",
"     21",
"    </a>",
"    ]. One patient in particular dramatically demonstrated this association with surgery. She had been treated, apparently successfully, with chemotherapy for an intraabdominal desmoid tumor. To confirm the response, laparoscopy was performed. Within months, desmoid tumors began developing in each of the three trocar sites; the tumors became massive and inoperable and led to the death of the patient.",
"   </p>",
"   <p>",
"    The only other described risk factors in these kindreds are a family history of desmoid tumor and an APC mutation 3&rsquo; of codon 1444 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'APC mutations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The intraabdominal desmoids that develop in patients with FAP are often unresectable because they diffusely infiltrate the mesentery. Furthermore, recurrences tend to become more frequent and aggressive with each surgical intervention. For these reasons, a multidisciplinary approach that includes systemic therapy is typically required to achieve optimal outcomes for these patients. (See",
"    <a class=\"local\" href=\"#H958380\">",
"     'Issues specific to intraabdominal desmoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors have been associated with high estrogen states. Extraabdominal and abdominal desmoids tend to occur in women during or following pregnancy. The classic presentation is that of an abdominal mass that is separate from the uterus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/23\">",
"     23",
"    </a>",
"    ]. Trauma related to the pregnancy (including a scar from a prior Cesarean section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/24\">",
"     24",
"    </a>",
"    ]) and exposure to elevated hormone levels may both be contributory, although the evidence linking high estrogen levels and desmoid tumors is largely based on anecdotal and retrospective reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/25\">",
"     25",
"    </a>",
"    ]. Subsequent pregnancy is not necessarily a risk factor for recurrence or development of new disease in a woman with a pregnancy-related desmoid, although the data are quite limited (three cases described in which there was no recurrence with subsequent pregnancy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antecedent trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors have also been associated with episodes of antecedent trauma. Up to 30 percent of patients with desmoid tumors have a history that involves antecedent trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], particularly, as noted above, surgical trauma in patients with FAP. A similar relationship has been observed in some sporadically occurring desmoid tumors. In one series, an antecedent history of trauma at the tumor site was elicited in 28 percent of 32 primary desmoid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between antecedent trauma and the development of desmoids is particularly compelling in view of emerging data implicating a molecular connection between wound healing processes and fibroproliferative disorders of mesenchymal tissue. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Etiology and molecular pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of desmoid tumors is unknown. However, the identification of clonal chromosomal changes in a significant fraction of cases supports the neoplastic nature of these tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, as noted above, emerging evidence implicates dysregulated wound healing in the pathogenesis of these and other fibroblastic lesions.",
"   </p>",
"   <p>",
"    Understanding molecular pathogenesis is of considerable interest in this disease given its highly variable clinical course. Lesions can range from stable or spontaneously regressing to slow growing to rapidly progressive with varying propensity to recur after definitive therapy. Identifying the molecular aberrations that predict the clinical course can be very useful from a therapeutic standpoint and is a subject of active investigation.",
"   </p>",
"   <p>",
"    Molecular aberrations in desmoid tumors can be broadly classified into two categories: aberrations involving the",
"    <span class=\"nowrap\">",
"     Wnt/beta-catenin",
"    </span>",
"    pathway and aberrations involving other genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Wnt/beta-catenin pathway and its role in desmoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     Wnt/beta-catenin",
"    </span>",
"    signaling pathway is thought to play a key role in the molecular pathogenesis of desmoid tumors. The basic features of the Wnt signaling pathway are depicted in the figure (",
"    <a class=\"graphic graphic_figure graphicRef72022 \" href=\"mobipreview.htm?31/17/32019\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Beta-catenin plays an active role in transcription within mesenchymal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/32\">",
"     32",
"    </a>",
"    ]. The adenomatous polyposis coli (APC) complex tightly regulates levels of beta-catenin in the cell by phosphorylation, which results in destruction of beta-catenin in the proteosome. Activation of the Wnt pathway initiated by binding of an external ligand causes inhibition of the kinase activity of the APC complex resulting in greater levels of beta-catenin in the cell. This non-phosphorylated beta-catenin translocates to the nucleus where it acts with other proteins to activate the transcription of genes such as CYCD1 and MYC, thereby promoting proliferation and enhanced survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/33\">",
"     33",
"    </a>",
"    ]. Mutations in either the APC gene or the beta-catenin gene (CTNNB1) can result in dysregulation of the levels of beta-catenin in the cell that leads to its accumulation in the nucleus.",
"   </p>",
"   <p>",
"    The importance of the Wnt signaling pathway (APC and beta-catenin) to the molecular pathogenesis of fibroblastic tumors such as desmoids is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatic APC mutations as well as activating mutations of the beta-catenin gene (both of which result in accumulation of beta-catenin) have been discovered in the majority of sporadic desmoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/34-38\">",
"       34-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta-catenin protein levels and tcf transcriptional activity are elevated in fibroblasts during the proliferative phase of wound healing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/36,39,40\">",
"       36,39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In preclinical models, stabilization of intracellular beta-catenin leads to dysregulation of mesenchymal cell proliferation, motility and invasiveness, and in transgenic mice, induces the development of desmoid tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is hoped that the elucidation of the central role of beta-catenin in the pathogenesis of desmoid tumors will lead to future therapeutic advances targeting this molecule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     APC mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal APC protein prevents the accumulation of beta-catenin, a cytosolic and nuclear protein, by mediating its phosphorylation and resultant degradation. The majority of germline as well as sporadic mutations in the APC gene lead to premature truncation of the APC protein and loss of the beta-catenin regulatory domain. This allows beta catenin to accumulate, bind to, and activate the transcription factor tcf-4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=see_link&amp;anchor=H547090028#H547090028\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, between 10 and 20 percent of patients with FAP develop a desmoid tumor. Mutations of the APC gene on chromosome 5q are responsible for FAP. More than 300 mutations have been described, most of which lead to frame shifts or premature stop codons, resulting in a truncated APC gene product. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have attempted to correlate specific APC mutations with the clinical phenotype. APC gene mutations 3' of codon 1444 may be important for the risk of developing a desmoid tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/11,22,43\">",
"     11,22,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7352?source=see_link&amp;anchor=H6#H6\">",
"     \"Gardner syndrome\", section on 'Desmoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    How the abnormal gene that is responsible for FAP promotes the formation of tumors such as desmoids is incompletely understood. However, increasing evidence points to involvement of the APC gene and beta-catenin (both components of the Wnt signaling pathway) in the molecular pathogenesis of inherited desmoids (Gardner's syndrome) as well as in sporadic cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Sex hormones may also be actively involved in this process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Mutations in the beta-catenin gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in CTNNB1 have been found in sporadic desmoid tumors with variable prevalence (39 to 87 percent); however, larger and more recent studies place the prevalence estimate at around 85 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/33\">",
"     33",
"    </a>",
"    ]. CTNNB1 gene mutations are therefore the most common route of Wnt pathway activation in desmoids. Phosphorylation of beta-catenin is mediated by a portion of the protein encoded by exon 3 of CTNNB1 gene. Three specific mutations are encountered in desmoid tumors: T41A, S45F and S45P. At least some data suggest that S45F mutations are associated with a higher rate of recurrence after surgical resection of a primary desmoid tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sporadic tumors and trisomy 8 and 20",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonrandom clonal chromosomal changes, particularly trisomy 8",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    20, occur in one-third or more of sporadic desmoid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. Similar nonrandom genetic aberrations have been found in benign fibrous bone lesions (such as fibrous dysplasia), suggesting a similar pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/50\">",
"     50",
"    </a>",
"    ]. Although the clinical relevance of these genetic abnormalities is unclear, their presence has been associated with a higher risk of local recurrence in some reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of individual trisomies and their association in the same cell is rare in solid tumors, particularly mesenchymal tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. However, these aberrations are known to occur in related benign, fibrous lesions arising in both soft tissue and bone tumors (eg, Dupuytren's contracture, plantar fibrosis, Peyronie's disease, carpal tunnel syndrome and infantile fibrosarcoma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Trisomy 8 is also a frequent finding in hematologic malignancies but is remarkably infrequent in nonfibrous solid tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most desmoid tumors present as a deeply seated painless or minimally painful mass with a history of slow growth. Intraabdominal desmoids can present with intestinal obstruction, bowel ischemia, or functional deterioration in an ileoanal anastomosis (typically in a patient who has undergone colectomy for FAP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Desmoid tumors can develop at virtually any body site, but three main anatomic sites are described:",
"    <span class=\"nowrap\">",
"     trunk/extremity,",
"    </span>",
"    abdominal wall, and intraabdominal (bowel and mesentery). In patients with FAP, intraabdominal desmoids predominate. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Gardner's syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In non-FAP-associated cases, the most commonly involved areas are the shoulder girdle, hip-buttock region and the extremities, where the location is usually deep in the muscles or along fascial planes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/28\">",
"     28",
"    </a>",
"    ]. Desmoid tumors may be multifocal at one site (typically the extremity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/53\">",
"     53",
"    </a>",
"    ]), but they rarely occur at different regions in the same patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Breast desmoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors are an unusual cause of a breast mass, and they may be mistaken for a primary or recurrent breast cancer. Many patients have a history of breast cancer or breast surgery. In a series of 32 patients with a breast desmoid, eight (25 percent) had a previous history of breast cancer, and 14 (44 percent) had prior breast surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/54\">",
"     54",
"    </a>",
"    ]. All patients had a palpable mass, which was seen on mammography in six of 16 and MRI in all eight patients who had the test. Following resection, eight (29 percent) had a recurrence at a median of 15 months, and there was a trend toward more local recurrences in the setting of positive margins (5 of 9 versus 3 of 19 with negative margins) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Local recurrence and the importance of resection margins'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The spectrum of molecular abnormalities seen in breast desmoids is similar to that described for desmoid tumors of the abdomen, trunk and extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional imaging of the affected area with CT or MRI is needed to define the relationship of the tumor to adjacent structures in order to assess resectability and the need for treatment. There are no radiographic characteristics that can reliably distinguish desmoids from malignant soft tissue tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H12227142#H12227142\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Radiographic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although desmoids can be adequately evaluated by CT (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54879 \" href=\"mobipreview.htm?1/23/1392\">",
"     image 1",
"    </a>",
"    ), we prefer MRI, especially for truncal and extremity tumors. MRI characteristics of desmoid tumors are variable and relate to their cellularity and fibrous content. Desmoids may be hypointense or isointense to muscle on T1-weighted images; they are predominantly hyperintense on T2-weighted images, but hypointense bands may be seen that represent dense collections of collagen bundles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/55\">",
"     55",
"    </a>",
"    ]. T2 hyperintensity may diminish over time as tumor cellularity decreases and collagen deposition increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/56\">",
"     56",
"    </a>",
"    ]. With the administration of gadolinium, desmoids typically show moderate to marked enhancement, and the hypointense bands may become more apparent because collagen bundles are not enhanced by contrast material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Histologic diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a desmoid tumor can only be established by histological examination of a biopsy specimen. Incisional biopsy generally yields more tissue than a core needle biopsy to help distinguish between a benign and malignant process. However, in the hands of experienced pathologists, tissue from a core biopsy may be sufficient to make the diagnosis.",
"   </p>",
"   <p>",
"    Histologically, desmoids are characterized by a monoclonal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/58\">",
"     58",
"    </a>",
"    ] fibroblastic proliferation appearing as small bundles of spindle cells in an abundant fibrous stroma. The fibroblasts have a propensity to concentrate at the periphery of the lesion, and the cellularity is low. The infiltrative connective tissue process may resemble that of a low-grade fibrosarcoma, but the cells lack nuclear and cytoplasmic features of malignancy. There are usually few mitotic figures and necrosis is absent. Histologically, sporadic and FAP-associated desmoids are indistinguishable.",
"   </p>",
"   <p>",
"    Immunohistochemistry may aid the histologic diagnosis. The spindle cells usually stain for vimentin and smooth muscle actin and nuclear beta-catenin but are generally negative for desmin, cytokeratins, and S-100. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'APC mutations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Mutations in the beta-catenin gene'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nuclear beta-catenin immunoreactivity supports the diagnosis of a desmoid tumor; positive staining was identified in 80 and 67 percent of sporadic and FAP-associated desmoids in one large series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/59\">",
"     59",
"    </a>",
"    ]. However, it is not definitive because other entities (superficial fibromatoses, low grade myofibroblastic sarcomas, solitary fibrous tumors) also stain for nuclear beta-catenin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/59\">",
"     59",
"    </a>",
"    ]. Furthermore, beta-catenin negativity does not preclude the diagnosis of fibromatosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no need to obtain staging radiographic studies of any other site because desmoids lack the propensity for regional or distant spread.",
"   </p>",
"   <p>",
"    There is no commonly used or agreed upon staging system for desmoids. The 7th edition of the American Joint Committee on Cancer (AJCC) TNM staging system for soft tissue sarcomas specifically excludes desmoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=see_link&amp;anchor=H351701269#H351701269\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A novel classification for staging intraabdominal desmoids in patients with FAP has been developed, but is not in widespread use. Its prognostic utility is unclear. (See",
"    <a class=\"local\" href=\"#H106560989\">",
"     'Mortality associated with desmoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1416296943\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the association of desmoids and FAP, it is important to obtain an accurate family history, particularly of colon cancer, during the initial evaluation. At some institutions, colonoscopy is recommended for all patients diagnosed with a desmoid tumor, particularly an intraabdominal desmoid. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Gardner's syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoids are characterized by variable clinical behavior. Although most grow progressively larger over time, growth is indolent, and periods of growth arrest are not uncommon. The following data are available regarding the natural history of untreated desmoids:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 54 patients with a primary or recurrent desmoid who were not treated initially with surgery, radiotherapy (RT), or systemic therapy, the five-year progression-free survival rate was 50 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report, 27 patients with newly diagnosed sporadic desmoids underwent initial attentive medical surveillance rather than active therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/61\">",
"       61",
"      </a>",
"      ]. Patients were chosen for this approach according to the site of progression, which could not be life-threatening or at risk for mutilation (adjacent nerves or vessels). At a median follow-up of 52 months, only six progressed (22 percent). Sixteen patients had stable disease and five had spontaneous tumor regression. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that an initial &ldquo;wait and see&rdquo; approach to therapy is a reasonable option for some patients, although the features that identify those patients at low risk of disease progression are not established. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The factors suggested to influence disease recurrence rate are anatomic site of disease (tumors of the extremity have the worst prognosis, particularly in distal locations;",
"    <span class=\"nowrap\">",
"     trunk/abdominal",
"    </span>",
"    wall tumors have a lower rate of recurrence than either intraabdominal and extraabdominal disease sites), size (particularly &gt;7 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/61\">",
"     61",
"    </a>",
"    ]), gender (women have a higher rate of local recurrence than men), and age (younger patients [under age 37 in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/61\">",
"     61",
"    </a>",
"    ]] have a higher recurrence rate than older individuals) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/2,61,62\">",
"     2,61,62",
"    </a>",
"    ]. The influence of positive resection margins is controversial and discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Local recurrence and the importance of resection margins'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    How these factors should be used to select treatment is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106560930\">",
"    <span class=\"h2\">",
"     Molecular markers of biologic behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging data suggest that specific molecular factors (such as specific mutations within the beta-catenin gene) may correlate with recurrence risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/47,63,64\">",
"     47,63,64",
"    </a>",
"    ]. In a study of gene expression profiles of 14 patients with sporadic desmoids, expression of the midkine gene was correlated with a higher likelihood of recurrence and shorter time to recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/65\">",
"     65",
"    </a>",
"    ]. However, this work is in its infancy, and validation in a prospective clinical trial will be necessary prior to clinical application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106560989\">",
"    <span class=\"h2\">",
"     Mortality associated with desmoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite being histologically benign and neither associated with the capacity for metastatic spread nor malignant degeneration into a fibrosarcoma, desmoids are locally infiltrative and can cause death via destruction of adjacent vital structures and organs. Most centers report a cause-specific mortality rate of 1 percent or less in patients with desmoid tumors at other than intraabdominal sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. As an example, in a report of 189 patients treated for a desmoid tumor at M. D. Anderson from 1995 to 2005 and followed for a median 63 months, only five died, four of non-desmoid causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Desmoids are more often fatal in patients with intraabdominal tumors, particularly in the setting of FAP. As noted above, desmoids are the cause of death in up to 11 percent of patients with this syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors that influence survival have not been well characterized, particularly for sporadic tumors. A prognostic stratification system for FAP-associated desmoids has been proposed that was derived from a series of 154 such patients seen at the Cleveland Clinic; five-year survival rates according to stage were as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I (asymptomatic, &lt;10 cm maximum diameter and not growing) &ndash; 95 percent",
"     </li>",
"     <li>",
"      Stage II (mildly symptomatic [sensation of mass or pain but no restriction], &lt;10 cm in maximum diameter, and not growing) &ndash; 100 percent",
"     </li>",
"     <li>",
"      Stage III (moderately symptomatic [sensation of mass, pain, restrictive but not hospitalized], or",
"      <span class=\"nowrap\">",
"       bowel/ureteric",
"      </span>",
"      obstruction, or 10 to 20 cm or slowly growing) &ndash; 89 percent",
"     </li>",
"     <li>",
"      Stage IV (severely symptomatic [sensation of mass, pain, restrictive and hospitalized], septic complications such as fistula and abscess, or &gt;20 cm and rapidly growing) &ndash; 76 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic value of this proposed staging system has not been independently validated. Treatment was variable within each group. With median follow-up ranging from 44 to 81 months depending on the group, there were no deaths among patients with stage I or II disease, while four patients with stage III disease (15 percent) and eight of those with stage IV disease (44 percent) died from their desmoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The locally aggressive nature of desmoid tumors renders anatomic site the major factor in treatment planning and overall management strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H958084\">",
"    <span class=\"h2\">",
"     Initial observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoids have an unpredictable clinical course, and close observation is an acceptable strategy for stable, asymptomatic primary or recurrent desmoids, particularly if resection would entail major morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/25,60,61,69\">",
"     25,60,61,69",
"    </a>",
"    ]. In one series of 142 patients presenting with a primary (n = 74) or recurrent (n = 68), 83 were treated with observation only, while 59 were initially offered medical therapy (hormone therapy or chemotherapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/60\">",
"     60",
"    </a>",
"    ]. The five-year progression-free survival rate was 50 versus 41 percent for the observation and medically-treated patients, respectively. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) suggest that patients with desmoid tumors can be followed carefully if the tumors are small and not located on the trunk, and if surgery would lead to excessive morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of an extraabdominal desmoid is indicated for symptomatic patients, and patients with progressively enlarging tumors irrespective of symptoms, if there is imminent risk to adjacent structures or if the tumor creates cosmetic concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;When medically and technically feasible, desmoid tumors are treated by surgical resection with a negative margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/66,71\">",
"     66,71",
"    </a>",
"    ]. Complete resection of the tumor with negative microscopic margins is the standard surgical goal but is often constrained by anatomic boundaries and the infiltrative nature of desmoids.",
"   </p>",
"   <p>",
"    Due to the size and infiltrative nature of extraabdominal desmoids, resection may require skin grafting or flap reconstruction. Resection of abdominal wall desmoids may require reconstruction of the abdominal wall to close the defect and minimize the risk of hernias. Intraabdominal desmoid tumors typically involve the mesentery, and resection generally requires concomitant bowel resection. During resection, the surgeon must take care not to compromise the superior mesenteric artery or vein.",
"   </p>",
"   <p>",
"    Desmoid tumors have a high rate of recurrence following even complete surgical removal, and the contribution of incomplete resection to local recurrence rates is unclear. Furthermore, resection does not appear to affect survival, which is not surprising in view of the histologically benign nature of desmoids. Given these issues, the overall surgical strategy should be an attempt at complete removal using function-preserving surgical approaches to minimize major morbidity (functional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cosmetic).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Local recurrence and the importance of resection margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;All desmoid tumors have a high rate of recurrence following even complete resection, and the contribution of margin status to recurrence rates is unclear , as evidenced by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Even patients who undergo aggressive resection with widely negative margins have recurrence rates of 16 to 39 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/62,66,68,72-76\">",
"       62,66,68,72-76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While some series show higher recurrence rates with close or positive resection margins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/20,62,66,73,75-77\">",
"       20,62,66,73,75-77",
"      </a>",
"      ], many report that the risk of recurrence is independent of margin status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/40,68,78-81\">",
"       40,68,78-81",
"      </a>",
"      ]. In one of the largest series of 426 newly diagnosed desmoid tumors, 370 had initial surgical resection, and 252 had histologic assessment of surgical margins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/61\">",
"       61",
"      </a>",
"      ]. The two and five-year progression-free survival rates for the 110 patients with microscopically complete (R0) resection (77 and 63 percent) were not significantly different from those of the 107 patients with a microscopically positive (R1) resection margin (74 and 61 percent), but they were markedly lower among the 37 patients with a macroscopically positive (R2) resection margin (43 and 22 percent). Similar findings have been noted in other large series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/68,78\">",
"       68,78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data, combined with the fact that recurrence only develops in fewer of one-half of those with positive margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/76\">",
"     76",
"    </a>",
"    ], have led some to conclude that aggressive attempts to achieve negative resection margins are not warranted if they result in excessive morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/25,40,76,82\">",
"     25,40,76,82",
"    </a>",
"    ]. Moreover, uncertainty as to the importance of positive resection margins has led to controversy with regard to the utility of postoperative RT for patients with incompletely resected disease. These data are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is an effective primary therapeutic option for desmoid tumors in patients who are not good surgical candidates, those who decline surgery, and those for whom surgical morbidity would be excessive. The time to regression after RT alone is often quite long and several years may elapse before regression is complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a number of reports, RT alone (50 to 60 Gy) or combined with surgery in patients with incomplete resection achieves long-term control in approximately 70 to 80 percent of desmoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/72,73,80,84-91\">",
"     72,73,80,84-91",
"    </a>",
"    ]. The volume of disease does not appear to influence the probability of local control.",
"   </p>",
"   <p>",
"    The contribution of primary RT to the management of desmoid tumors can be illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report included 107 patients with desmoid tumors who were treated with surgery alone (n = 51), RT alone (n = 15), or surgery followed by RT (n = 41) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/73\">",
"       73",
"      </a>",
"      ]. The five-year actuarial local control rates were 69, 93, and 72 percent in the three groups, respectively. The five-year rate of local control with surgery alone was 50 percent (three of six) if gross residual disease was left behind, 56 percent for microscopically positive margins, and 77 percent for negative margins. In contrast, local control was achieved in all five patients treated with RT alone for a primary tumor and in 9 of 10 treated at the time of recurrence.",
"     </li>",
"     <li>",
"      Similar conclusions were reached in a comparative review of published experience with treatment of desmoid tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/72\">",
"       72",
"      </a>",
"      ]. Local control rates after surgery alone (n = 381) were 61 percent overall, and they were 72 and 41 percent for those with negative or positive margins, respectively. For patients undergoing surgery plus RT (n = 297), the local control rate was 75 percent overall, and it was 94 and 75 percent for cases with negative and positive margins, respectively. The overall local control rate for RT alone (n = 102) was 78 percent, and it was 83 and 73 percent for those treated for primary or recurrent tumors, respectively.",
"     </li>",
"     <li>",
"      Remarkably similar local control rates (80 to 81 percent) were noted in a German patterns of care study of 345 patients from 19 institutions who were followed for a median of 43 months after either definitive RT or surgery followed by RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It can be concluded from these data that despite their non-metastatic nature, desmoids are radiosensitive tumors. Although RT is an option for nonsurgical definitive therapy of desmoids, its use must be balanced against the potential for late radiation effects such as secondary malignancies, particularly in younger patients, and RT-related fibrosis. In general, primary RT could be considered an appropriate option for patients who are symptomatic or otherwise in need of treatment, who are not good surgical candidates, or decline surgery, and those for whom surgical morbidity would be excessive.",
"   </p>",
"   <p>",
"    The recommended dose of RT for definitive therapy is 50 to 60 Gy in five to seven weeks at 1.8 to 2 Gy per fraction. Local recurrence rates do not appear to be reduced by the use of higher doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/80\">",
"     80",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Postoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data to support the use of RT in the adjuvant setting after complete surgical resection, and it is generally not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/73,92\">",
"     73,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of postoperative RT for patients with positive resection margins is controversial for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While improved recurrence-free survival in patients with irradiated microscopically margin-positive tumors was shown in an early report from M. D. Anderson [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/66\">",
"       66",
"      </a>",
"      ], a large series from Massachusetts General Hospital [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/73\">",
"       73",
"      </a>",
"      ], and a comparative review of published experience with treatment of desmoid tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/72\">",
"       72",
"      </a>",
"      ], at least three other large series (including a later cohort of patients treated at M. D. Anderson) have failed to demonstrate benefit from RT in this setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/40,68,78\">",
"       40,68,78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As noted previously, the status of the resection margins has not consistently been shown to correlate with the risk of recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/40,68,78-81,93\">",
"       40,68,78-81,93",
"      </a>",
"      ]. Even in those series that did show a higher rate of recurrence in patients with positive margins in the absence of RT, recurrence is not inevitable in patients with positive resection margins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/73,94\">",
"       73,94",
"      </a>",
"      ]. Furthermore, successful salvage therapy at the time of recurrence has been possible in the majority of patients, particularly those with extremity or truncal tumors. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Management of recurrent disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The potential for late radiation effects such as secondary malignancies is of concern, particularly in younger patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From these data, many clinicians conclude that deferring RT is an acceptable option for patients with microscopically positive margins as long as local progression, if it occurred, would not risk significant morbidity. However, we and others recommend postoperative RT for patients with gross or macroscopic residual disease after initial resection, as well as for those with microscopically positive margins after resection of recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Management of recurrent disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Others disagree with this approach, advocating postoperative RT regardless of the surgical margins (or RT alone) because of the importance of local control to cure of this nonmetastatic condition. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/72\">",
"     72",
"    </a>",
"    ]. Guidelines from the NCCN suggest that postoperative RT be considered in patients with a large tumor, although they provide no definition for what constitutes a \"large\" tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Neoadjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach to increasing resectability and reducing rates of local recurrence in extraabdominal desmoids is the use of neoadjuvant (preoperative) radiotherapy. Experience with this approach is limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest report, 58 patients underwent preoperative RT and were followed for a median of 69 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/96\">",
"       96",
"      </a>",
"      ]. There were 11 local recurrences (19 percent), and two patients had major wound complications (3.4 percent). This wound complication rate was lower than the authors' historical experience with a similar preoperative RT dose and schedule for soft tissue sarcomas, leading them to speculate that patients with fibromatosis might have an inherent wound healing advantage over those with soft tissue sarcoma.",
"     </li>",
"     <li>",
"      In two other small series from the same institution, a total of 43 patients with potentially resectable desmoid tumors received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      30 mg by continuous infusion daily for three days concurrent with RT (10 x 3 Gy fractions); resection was performed four to eight weeks later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/97\">",
"       97",
"      </a>",
"      ]. In the later study, 16 of 30 patients received one year of postoperative therapy with high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      and an NSAID [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/98\">",
"       98",
"      </a>",
"      ]. With a median follow-up of 71 and 45 months in the two studies, respectively, there were only five local recurrences (11 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these results are promising, confirmation with larger, prospective, randomized trials is needed before this approach can be considered standard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Neoadjuvant systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of using systemic therapy with or without RT to reduce tumor",
"    <span class=\"nowrap\">",
"     size/bulk",
"    </span>",
"    prior to an attempt at surgical resection of desmoid tumors is relatively new, and there are few data on the utility of this approach. However, interest in multimodality approaches to avoid debilitating local therapy is increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/98\">",
"     98",
"    </a>",
"    ], particularly in view of the demonstration that several chemotherapy regimens are active, at least in the setting of advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=see_link\">",
"     \"Desmoid tumors: Systemic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least some data suggest that the improved outcomes seen in contemporary series of patients treated for desmoid tumors might be at least partly attributable to the increased use of multimodality therapy applied both in the neoadjuvant and adjuvant setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/68\">",
"     68",
"    </a>",
"    ]. However, no prospective data are available. Further experience with neoadjuvant systemic therapy is needed in order to address optimal patient selection criteria and the best way to sequence surgery, systemic therapy, and RT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H958380\">",
"    <span class=\"h2\">",
"     Issues specific to intraabdominal desmoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraabdominal desmoids are less often resectable than are extraabdominal and abdominal wall desmoids. Surgery may be difficult and even impossible for intraabdominal desmoids, particularly when they arise in the setting of FAP, although it is an important option for selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/3,99,100\">",
"     3,99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The intraabdominal desmoids that develop in patients with FAP are often unresectable because they diffusely infiltrate the mesentery and are often multiple. Morbidity after attempted resection, which often necessitates removal of part of the small intestine, is substantial and includes bowel ischemia, adhesions and resultant obstruction, and fistula formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/101\">",
"     101",
"    </a>",
"    ]. Moreover, the rate of recurrence is high after attempted resection, and the recurrent disease is often more aggressive than the initial desmoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/15,19,67\">",
"     15,19,67",
"    </a>",
"    ]. In one report, as an example, tumor debulking led to aggressive progression of desmoids in four of six patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations have led the American Society of Colon and Rectal Surgeons and a joint task force of the American Society of Clinical",
"    <span class=\"nowrap\">",
"     Oncology/Society",
"    </span>",
"    of Surgical Oncology to advocate conservative management rather than initial resection for patients with Gardner's syndrome and intraabdominal desmoid tumors that are large, slow-growing, involve the mesentery, or encase vessels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    organs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At many institutions, a multimodality approach that includes initial medical therapy is preferred for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. Options for systemic therapy include noncytotoxic therapy (a nonsteroidal antiinflammatory agent [NSAID],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ), radiation therapy, targeted therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , or cytotoxic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=see_link&amp;anchor=H4#H4\">",
"     \"Desmoid tumors: Systemic therapy\", section on 'Management of desmoid tumors in FAP patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no evidence-based protocols for surveillance following treatment. We typically follow patients by clinical examination and radiographic studies (where appropriate) every six months for the first three years, every 12 months to year 6, and then every other year. Consensus-based guidelines from the NCCN suggest a history and physical examination with appropriate imaging every three to six months for two to three years, then annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful salvage therapy is possible in the majority of patients who have a local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/66,72,84,106\">",
"     66,72,84,106",
"    </a>",
"    ]. If it is feasible and can be carried out using a function-preserving approach, surgical resection is preferred for a recurrent extraabdominal desmoid tumor. We recommend postoperative RT if the margins are positive.",
"   </p>",
"   <p>",
"    However, RT alone is a reasonable alternative due to the higher morbidity of repeat operation and the increased probability of positive margins. In a comparative review of the literature, the overall local control rate for RT alone (n = 102) was 78 percent, and it was 83 and 73 percent for those treated for primary or recurrent tumors, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/72\">",
"     72",
"    </a>",
"    ]. In one series, local control was achieved in all 9 of 10 patients receiving RT for recurrent desmoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who develop a recurrence in a previously irradiated area where successful surgical salvage is not possible can be treated with systemic therapy. Cytotoxic and non-cytotoxic agents can be considered for treatment based upon the clinical setting and symptoms experienced by the patient (",
"    <a class=\"graphic graphic_algorithm graphicRef67503 \" href=\"mobipreview.htm?0/5/91\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=see_link\">",
"     \"Desmoid tumors: Systemic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     FAP patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to proceed with surgery in patients with recurrent intraabdominal desmoid in the setting of FAP is more difficult. Recurrences can become more frequent and aggressive with each surgical intervention. Optimal management must be individualized depending on symptomatology and the clinical circumstances. For most of these patients, initial medical therapy is a reasonable approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=see_link\">",
"     \"Desmoid tumors: Systemic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoid tumors (also called aggressive fibromatosis) are benign, slowly growing fibroblastic neoplasms with no metastatic potential but a propensity for local recurrence, even after complete surgical resection. Despite being histologically benign, they are locally infiltrative and can cause death through destruction of adjacent vital structures and organs. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risk of desmoids is increased in patients with familial adenomatous polyposis (FAP). The occurrence of desmoid tumors in the setting of FAP is designated Gardner's syndrome. Given the association with FAP, at some institutions, colonoscopy is recommended for all patients with desmoid tumors, particularly intraabdominal. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Gardner's syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment of desmoids is a clinical challenge, particularly in patients with FAP who tend to develop intraabdominal desmoids at sites of prior surgery. Because of their locally aggressive behavior and tendency to relapse with more aggressive disease, multimodality treatment is often required for these benign lesions and is best delivered within the context of a multidisciplinary team specializing in sarcoma treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of desmoid tumors is prolonged, variable, and unpredictable, and it is not clear that any intervention improves survival. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Extraabdominal and abdominal wall tumors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observation is an appropriate option in asymptomatic patients who may be reliably followed. If desmoids remain unchanged or shrink, observation may be continued. If the tumor increases in size or becomes symptomatic, if there is imminent risk to adjacent structures, or if the desmoid creates cosmetic concerns, treatment should be pursued. (See",
"      <a class=\"local\" href=\"#H958084\">",
"       'Initial observation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest complete surgical excision as the treatment of choice for a potentially resectable extraabdominal (extremity, trunk, breast) or abdominal wall desmoids in a patient who is medically able to tolerate surgery and if resection can be accomplished without major functional or cosmetic deficit (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Controversy remains as a number of patients will fare well without surgical intervention, so a more conservative approach appears rational for relatively static lesions. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary radiation therapy (RT) is an appropriate option for patients who need treatment but are not good surgical candidates, those who decline surgery, and those for whom surgical morbidity would be excessive. An alternative approach is initiation of systemic treatment in these patients, especially if they are young and there are concerns about the potential for late toxicity from RT. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not pursuing adjuvant RT in patients with microscopically negative surgical margins, regardless of tumor size (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest not pursuing adjunctive RT following resection of a primary desmoid tumor with microscopically positive margins (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Since fewer than 50 percent of these patients will develop a recurrence, patients who remain progression-free will be spared the long-term sequelae of RT. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Postoperative RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For gross residual disease of a primary desmoid, we suggest observation or RT rather than more radical resection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Due to the very high local control rates with RT, additional surgery is warranted only if there is strong confidence in obtaining clear margins, and functional loss is minimal and acceptable.",
"     </li>",
"     <li>",
"      For a recurrent desmoid tumor, our preference is observation or surgical resection. However, systemic therapy or RT alone are reasonable alternative treatments in selected patients who are thought to have a higher morbidity from repeat operation and an increased probability of positive margins. For patients who undergo surgery for a recurrent desmoid, we suggest observation or postoperative RT if the margins are positive (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Management of recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Intraabdominal desmoid, Gardner's syndrome",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have large intraabdominal desmoid tumors, particularly in the setting of Gardner's syndrome, surgery is still a standard approach for resectable tumors. However, the infiltrative nature of the desmoid in this situation often precludes surgery, and the surgical margins are often positive. Medical therapy in lieu of surgery is a viable option for patients with more difficult tumors such as those involving the mesentery, major vessels, or other critical structures. (See",
"      <a class=\"local\" href=\"#H958380\">",
"       'Issues specific to intraabdominal desmoids'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=see_link\">",
"       \"Desmoid tumors: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgery with or without RT is an appropriate option if there is no response to medical therapy. In this situation, consideration should be given to use of intraoperative electron beam therapy as a component of the treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/11/30906/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Management of recurrence of an intraabdominal tumor in patients with Gardner's syndrome is challenging because recurrences tend to become more frequent and aggressive with each surgical intervention. Most of these patients are managed with systemic therapy rather than additional local measures. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Management of recurrent disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=see_link\">",
"       \"Desmoid tumors: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Posttreatment surveillance",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no standard protocol for follow-up of patients with desmoid tumors. However, we typically follow patients by clinical examination and radiographic studies (where appropriate) every six months for the first three years, every 12 months to year 6, and then biannually. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/1\">",
"      Reitamo JJ, H&auml;yry P, Nykyri E, Sax&eacute;n E. The desmoid tumor. I. Incidence, sex-, age- and anatomical distribution in the Finnish population. Am J Clin Pathol 1982; 77:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/2\">",
"      Mankin HJ, Hornicek FJ, Springfield DS. Extra-abdominal desmoid tumors: a report of 234 cases. J Surg Oncol 2010; 102:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/3\">",
"      Clark SK, Neale KF, Landgrebe JC, Phillips RK. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg 1999; 86:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/4\">",
"      Heiskanen I, J&auml;rvinen HJ. Occurrence of desmoid tumours in familial adenomatous polyposis and results of treatment. Int J Colorectal Dis 1996; 11:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/5\">",
"      Gurbuz AK, Giardiello FM, Petersen GM, et al. Desmoid tumours in familial adenomatous polyposis. Gut 1994; 35:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/6\">",
"      Hizawa K, Iida M, Mibu R, et al. Desmoid tumors in familial adenomatous polyposis/Gardner's syndrome. J Clin Gastroenterol 1997; 25:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/7\">",
"      Griffioen G, Bus PJ, Vasen HF, et al. Extracolonic manifestations of familial adenomatous polyposis: desmoid tumours, and upper gastrointestinal adenomas and carcinomas. Scand J Gastroenterol Suppl 1998; 225:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/8\">",
"      Tsukada K, Church JM, Jagelman DG, et al. Noncytotoxic drug therapy for intra-abdominal desmoid tumor in patients with familial adenomatous polyposis. Dis Colon Rectum 1992; 35:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/9\">",
"      Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 2001; 95:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/10\">",
"      Koh PK, Loi C, Cao X, et al. Mesenteric desmoid tumors in Singapore familial adenomatous polyposis patients: clinical course and genetic profile in a predominantly Chinese population. Dis Colon Rectum 2007; 50:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/11\">",
"      Nieuwenhuis MH, Lefevre JH, B&uuml;low S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 2011; 54:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/12\">",
"      Church JM. Mucosal ischemia caused by desmoid tumors in patients with familial adenomatous polyposis: report of four cases. Dis Colon Rectum 1998; 41:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/13\">",
"      Sagar PM, M&ouml;slein G, Dozois RR. Management of desmoid tumors in patients after ileal pouch-anal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 1998; 41:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/14\">",
"      Penna C, Tiret E, Parc R, et al. Operation and abdominal desmoid tumors in familial adenomatous polyposis. Surg Gynecol Obstet 1993; 177:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/15\">",
"      Kadmon M, M&ouml;slein G, Buhr HJ, Herfarth C. [Desmoid tumors in patients with familial adenomatous polyposis (FAP). Clinical and therapeutic observations from the Heidelberg polyposis register]. Chirurg 1995; 66:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/16\">",
"      Arvanitis ML, Jagelman DG, Fazio VW, et al. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 1990; 33:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/17\">",
"      Quintini C, Ward G, Shatnawei A, et al. Mortality of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis: a single center review of 154 patients. Ann Surg 2012; 255:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/18\">",
"      Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 1993; 36:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/19\">",
"      Soravia C, Berk T, McLeod RS, Cohen Z. Desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum 2000; 43:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/20\">",
"      Goy BW, Lee SP, Eilber F, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys 1997; 39:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/21\">",
"      Lynch HT, Fitzgibbons R Jr. Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review. Am J Gastroenterol 1996; 91:2598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/22\">",
"      Lefevre JH, Parc Y, Kern&eacute;is S, et al. Risk factors for development of desmoid tumours in familial adenomatous polyposis. Br J Surg 2008; 95:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/23\">",
"      Gansar GF, Markowitz IP, Cerise EJ. Thirty years of experience with desmoid tumors at Charity Hospital. Am Surg 1987; 53:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/24\">",
"      De Cian F, Delay E, Rudigoz RC, et al. Desmoid tumor arising in a cesarean section scar during pregnancy: monitoring and management. Gynecol Oncol 1999; 75:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/25\">",
"      Lewis JJ, Boland PJ, Leung DH, et al. The enigma of desmoid tumors. Ann Surg 1999; 229:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/26\">",
"      Way JC, Culham BA. Desmoid tumour. The risk of recurrent or new disease with subsequent pregnancy: a case report. Can J Surg 1999; 42:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/27\">",
"      Johner A, Tiwari P, Zetler P, Wiseman SM. Abdominal wall desmoid tumors associated with pregnancy: current concepts. Expert Rev Anticancer Ther 2009; 9:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/28\">",
"      Schlemmer M. Desmoid tumors and deep fibromatoses. Hematol Oncol Clin North Am 2005; 19:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/29\">",
"      Lopez R, Kemalyan N, Moseley HS, et al. Problems in diagnosis and management of desmoid tumors. Am J Surg 1990; 159:450.",
"     </a>",
"    </li>",
"    <li>",
"     Enzinger FM, Weiss SW. Enzinger, FM, Weiss, SW, 3rd, Mosby-Yearbook, Inc, St. Louis 1995. p.201.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/31\">",
"      De Wever I, Dal Cin P, Fletcher CD, et al. Cytogenetic, clinical, and morphologic correlations in 78 cases of fibromatosis: a report from the CHAMP Study Group. CHromosomes And Morphology. Mod Pathol 2000; 13:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/32\">",
"      Barker N. The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol 2008; 468:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/33\">",
"      Lazar AJ, Hajibashi S, Lev D. Desmoid tumor: from surgical extirpation to molecular dissection. Curr Opin Oncol 2009; 21:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/34\">",
"      Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999; 18:6615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/35\">",
"      Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/36\">",
"      Cheon SS, Cheah AY, Turley S, et al. beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A 2002; 99:6973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/37\">",
"      Abraham SC, Reynolds C, Lee JH, et al. Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol 2002; 33:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/38\">",
"      Signoroni S, Frattini M, Negri T, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res 2007; 13:5034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/39\">",
"      Cheon S, Poon R, Yu C, et al. Prolonged beta-catenin stabilization and tcf-dependent transcriptional activation in hyperplastic cutaneous wounds. Lab Invest 2005; 85:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/40\">",
"      Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 1999; 86:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/41\">",
"      Kotiligam D, Lazar AJ, Pollock RE, Lev D. Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol 2008; 23:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/42\">",
"      Li C, Bapat B, Alman BA. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor). Am J Pathol 1998; 153:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/43\">",
"      Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 2007; 61:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/44\">",
"      Halling KC, Lazzaro CR, Honchel R, et al. Hereditary desmoid disease in a family with a germline Alu I repeat mutation of the APC gene. Hum Hered 1999; 49:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/45\">",
"      Giarola M, Wells D, Mondini P, et al. Mutations of adenomatous polyposis coli (APC) gene are uncommon in sporadic desmoid tumours. Br J Cancer 1998; 78:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/46\">",
"      Hong H, Nadesan P, Poon R, Alman BA. Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumour). Br J Cancer 2011; 104:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/47\">",
"      Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008; 173:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/48\">",
"      Fletcher JA, Naeem R, Xiao S, Corson JM. Chromosome aberrations in desmoid tumors. Trisomy 8 may be a predictor of recurrence. Cancer Genet Cytogenet 1995; 79:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/49\">",
"      Kouho H, Aoki T, Hisaoka M, Hashimoto H. Clinicopathological and interphase cytogenetic analysis of desmoid tumours. Histopathology 1997; 31:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/50\">",
"      Bridge JA, Swarts SJ, Buresh C, et al. Trisomies 8 and 20 characterize a subgroup of benign fibrous lesions arising in both soft tissue and bone. Am J Pathol 1999; 154:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/51\">",
"      Qi H, Dal Cin P, Hern&aacute;ndez JM, et al. Trisomies 8 and 20 in desmoid tumors. Cancer Genet Cytogenet 1996; 92:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/52\">",
"      Mertens F, Will&eacute;n H, Rydholm A, et al. Trisomy 20 is a primary chromosome aberration in desmoid tumors. Int J Cancer 1995; 63:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/53\">",
"      Fong Y, Rosen PP, Brennan MF. Multifocal desmoids. Surgery 1993; 114:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/54\">",
"      Neuman HB, Brogi E, Ebrahim A, et al. Desmoid tumors (fibromatoses) of the breast: a 25-year experience. Ann Surg Oncol 2008; 15:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/55\">",
"      Azizi L, Balu M, Belkacem A, et al. MRI features of mesenteric desmoid tumors in familial adenomatous polyposis. AJR Am J Roentgenol 2005; 184:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/56\">",
"      Vandevenne JE, De Schepper AM, De Beuckeleer L, et al. New concepts in understanding evolution of desmoid tumors: MR imaging of 30 lesions. Eur Radiol 1997; 7:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/57\">",
"      Lee JC, Thomas JM, Phillips S, et al. Aggressive fibromatosis: MRI features with pathologic correlation. AJR Am J Roentgenol 2006; 186:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/58\">",
"      Li M, Cordon-Cardo C, Gerald WL, Rosai J. Desmoid fibromatosis is a clonal process. Hum Pathol 1996; 27:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/59\">",
"      Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007; 51:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/60\">",
"      Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/61\">",
"      Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011; 29:3553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/62\">",
"      Huang K, Fu H, Shi YQ, et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol 2009; 100:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/63\">",
"      Gebert C, Hardes J, Kersting C, et al. Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology 2007; 50:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/64\">",
"      D&ocirc;mont J, Salas S, Lacroix L, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 2010; 102:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/65\">",
"      Colombo C, Creighton CJ, Ghadimi MP, et al. Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target. J Pathol 2011; 225:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/66\">",
"      Ballo MT, Zagars GK, Pollack A, et al. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999; 17:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/67\">",
"      Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/68\">",
"      Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/69\">",
"      Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 34:462.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/71\">",
"      Abbas AE, Deschamps C, Cassivi SD, et al. Chest-wall desmoid tumors: results of surgical intervention. Ann Thorac Surg 2004; 78:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/72\">",
"      Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer 2000; 88:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/73\">",
"      Spear MA, Jennings LC, Mankin HJ, et al. Individualizing management of aggressive fibromatoses. Int J Radiat Oncol Biol Phys 1998; 40:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/74\">",
"      Karakousis CP, Mayordomo J, Zografos GC, Driscoll DL. Desmoid tumors of the trunk and extremity. Cancer 1993; 72:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/75\">",
"      Meazza C, Bisogno G, Gronchi A, et al. Aggressive fibromatosis in children and adolescents: the Italian experience. Cancer 2010; 116:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/76\">",
"      Mullen JT, Delaney TF, Kobayashi WK, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol 2012; 19:4028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/77\">",
"      Peng PD, Hyder O, Mavros MN, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol 2012; 19:4036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/78\">",
"      Gronchi A, Casali PG, Mariani L, et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003; 21:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/79\">",
"      Pignatti G, Barbanti-Br&ograve;dano G, Ferrari D, et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res 2000; :207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/80\">",
"      Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys 1998; 42:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/81\">",
"      Reitamo JJ. The desmoid tumor. IV. Choice of treatment, results, and complications. Arch Surg 1983; 118:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/82\">",
"      Hansmann A, Adolph C, Vogel T, et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004; 100:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/83\">",
"      Acker JC, Bossen EH, Halperin EC. The management of desmoid tumors. Int J Radiat Oncol Biol Phys 1993; 26:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/84\">",
"      Zlotecki RA, Scarborough MT, Morris CG, et al. External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 2002; 54:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/85\">",
"      Plukker JT, van Oort I, Vermey A, et al. Aggressive fibromatosis (non-familial desmoid tumour): therapeutic problems and the role of adjuvant radiotherapy. Br J Surg 1995; 82:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/86\">",
"      Micke O, Seegenschmiedt MH, German Cooperative Group on Radiotherapy for Benign Diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national Patterns of Care Study. Int J Radiat Oncol Biol Phys 2005; 61:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/87\">",
"      Bataini JP, Belloir C, Mazabraud A, et al. Desmoid tumors in adults: the role of radiotherapy in their management. Am J Surg 1988; 155:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/88\">",
"      McCollough WM, Parsons JT, van der Griend R, et al. Radiation therapy for aggressive fibromatosis. The Experience at the University of Florida. J Bone Joint Surg Am 1991; 73:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/89\">",
"      Leibel SA, Wara WM, Hill DR, et al. Desmoid tumors: local control and patterns of relapse following radiation therapy. Int J Radiat Oncol Biol Phys 1983; 9:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/90\">",
"      Sherman NE, Romsdahl M, Evans H, et al. Desmoid tumors: a 20-year radiotherapy experience. Int J Radiat Oncol Biol Phys 1990; 19:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/91\">",
"      R&uuml;diger HA, Ngan SY, Ng M, et al. Radiation therapy in the treatment of desmoid tumours reduces surgical indications. Eur J Surg Oncol 2010; 36:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/92\">",
"      Wong SL. Diagnosis and management of desmoid tumors and fibrosarcoma. J Surg Oncol 2008; 97:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/93\">",
"      Miralbell R, Suit HD, Mankin HJ, et al. Fibromatoses: from postsurgical surveillance to combined surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1990; 18:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/94\">",
"      Jenkins NH, Freedman LS, McKibbin B. Spontaneous regression of a desmoid tumour. J Bone Joint Surg Br 1986; 68:780.",
"     </a>",
"    </li>",
"    <li>",
"     Serber W, Bracy LW, Zhang M, Hoppe RT. Radiation treatment of benign disease. In: Principles and Practice of Radiation Oncology, 4th, Perez CA, Brady LW, Halperin EG, Schmidt-Ullrich R (Eds), Lippincott, Williams and Wilkins, Philadelphia 2004. p.2340.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/96\">",
"      O'Dea FJ, Wunder J, Bell RS, et al. Preoperative radiotherapy is effective in the treatment of fibromatosis. Clin Orthop Relat Res 2003; :19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/97\">",
"      Baliski CR, Temple WJ, Arthur K, Schachar NS. Desmoid tumors: a novel approach for local control. J Surg Oncol 2002; 80:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/98\">",
"      Francis WP, Zippel D, Mack LA, et al. Desmoids: a revelation in biology and treatment. Ann Surg Oncol 2009; 16:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/99\">",
"      Rodriguez-Bigas MA, Mahoney MC, Karakousis CP, Petrelli NJ. Desmoid tumors in patients with familial adenomatous polyposis. Cancer 1994; 74:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/100\">",
"      Middleton SB, Phillips RK. Surgery for large intra-abdominal desmoid tumors: report of four cases. Dis Colon Rectum 2000; 43:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/101\">",
"      Smith AJ, Lewis JJ, Merchant NB, et al. Surgical management of intra-abdominal desmoid tumours. Br J Surg 2000; 87:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/102\">",
"      Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006; 24:4642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/103\">",
"      Church J, Simmang C, Standards Task Force, et al. Practice parameters for the treatment of patients with dominantly inherited colorectal cancer (familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer). Dis Colon Rectum 2003; 46:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/104\">",
"      Patel SR, Benjamin RS. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. J Clin Oncol 2006; 24:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/105\">",
"      Bertagnolli MM, Morgan JA, Fletcher CD, et al. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer 2008; 44:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/106\">",
"      Posner MC, Shiu MH, Newsome JL, et al. The desmoid tumor. Not a benign disease. Arch Surg 1989; 124:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/11/30906/abstract/107\">",
"      Roeder F, Timke C, Oertel S, et al. Intraoperative electron radiotherapy for the management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 2010; 76:1154.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7746 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30906=[""].join("\n");
var outline_f30_11_30906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gardner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antecedent trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY AND MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Wnt/beta-catenin pathway and its role in desmoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - APC mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Mutations in the beta-catenin gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sporadic tumors and trisomy 8 and 20",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Breast desmoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Histologic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1416296943\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106560930\">",
"      Molecular markers of biologic behavior",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106560989\">",
"      Mortality associated with desmoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H958084\">",
"      Initial observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Local recurrence and the importance of resection margins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Postoperative RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Neoadjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Neoadjuvant systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H958380\">",
"      Issues specific to intraabdominal desmoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MANAGEMENT OF RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      FAP patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Extraabdominal and abdominal wall tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Intraabdominal desmoid, Gardner's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7746\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7746|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?0/5/91\" title=\"algorithm 1\">",
"      Algorithm Syst Rx desmoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7746|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/23/1392\" title=\"diagnostic image 1\">",
"      Intraabdominal desmoid tumor in familial polyposis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7746|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/17/32019\" title=\"figure 1\">",
"      APC and wnt signaling pathway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/10/42150?source=related_link\">",
"      Antineoplastic therapy for miscellaneous benign diseases affecting soft tissue and bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11881?source=related_link\">",
"      Desmoid tumors: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=related_link\">",
"      Ganglia and nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7352?source=related_link\">",
"      Gardner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1847?source=related_link\">",
"      Keloids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_11_30907="Analysis of ascitic fluid";
var content_f30_11_30907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tests performed on ascitic fluid",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Routine tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cell count and differential",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Albumin concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total protein concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Culture in blood culture bottles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Optional tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucose concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lactate dehydrogenase concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gram stain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amylase concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Unusual tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tuberculosis smear and culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adenosine deaminase activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Triglyceride concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bilirubin concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum pro-brain natriuretic peptide",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30907=[""].join("\n");
var outline_f30_11_30907=null;
var title_f30_11_30908="Subcutaneous sliding scale sample";
var content_f30_11_30908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F83834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F83834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sample subcutaneous sliding scale using short-acting insulin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Insulin sensitive",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Usual",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Insulin resistant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Glucose values (mg/dL/mmol/L)",
"       </td>",
"       <td class=\"subtitle2\">",
"        AC",
"       </td>",
"       <td class=\"subtitle2\">",
"        HS",
"       </td>",
"       <td class=\"subtitle2\">",
"        AC",
"       </td>",
"       <td class=\"subtitle2\">",
"        HS",
"       </td>",
"       <td class=\"subtitle2\">",
"        AC",
"       </td>",
"       <td class=\"subtitle2\">",
"        HS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;150/8.3",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        151 to 200/8.4 to 11.1",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        201 to 250/11.2 to 13.9",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        251 to 300/13.9 to 16.6",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        301 to 350/16.7 to 19.4",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        16",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        351 to 400/19.5 to 22.2",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        20",
"       </td>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AC: before meals; HS: bedtime.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30908=[""].join("\n");
var outline_f30_11_30908=null;
var title_f30_11_30909="Contents: Genodermatoses";
var content_f30_11_30909=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Genodermatoses",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Genodermatoses",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/12/24776\">",
"           Darier disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/21/39255\">",
"           Diagnosis of epidermolysis bullosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/28/28106\">",
"           Epidemiology, pathogenesis, and clinical features of epidermolysis bullosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/40/11912\">",
"           Hailey-Hailey disease (benign familial pemphigus)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/5/44121\">",
"           Nevoid basal cell carcinoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/63/3066\">",
"           Overview of the management of epidermolysis bullosa",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/0/24586\">",
"           The genodermatoses",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-EC71F2A67A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f30_11_30909=[""].join("\n");
var outline_f30_11_30909=null;
var title_f30_11_30910="Adherence to safety measures";
var content_f30_11_30910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 638px\">",
"   <div class=\"ttl\">",
"    Adherence to safety measures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 618px; height: 371px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adherence to six selected safety measures at baseline and after checklist implementation (p&lt;0.0001 for all measures).",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weiser T, Haynes A, Dziekan G, et al. Effect of a 19-item surgical safety checklist during urgent operations in a global patient population. Ann Surg 2010; 251:976. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30910=[""].join("\n");
var outline_f30_11_30910=null;
var title_f30_11_30911="Small bowel polyp";
var content_f30_11_30911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Small bowel polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel polyp detected during double balloon enteroscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Hiroto Kita, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_11_30911=[""].join("\n");
var outline_f30_11_30911=null;
